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African horse sickness (AHS) is a viral disease with high mortality rates, vectored by 
the Culicoides midge and affecting members of the Equidae family. AHS is endemic to 
South Africa, and, as a result, affects export and international competitiveness in 
equine trade, and impacts significantly on the South African racehorse and 
performance horse industries. AHS also has devastating consequences for rural and 
subsistence equine ownership. The protocol developed in this dissertation has the 
potential to serotype and confirm the AHS virus within a few hours at significantly less 
cost than current methods. It will ease the financial and time constraints of studying an 
outbreak in real time and has the potential to solve many of the unknown factors 
surrounding AHS, particularly and most importantly, the role that each serotype plays in 
outbreaks and the form of the disease contracted by horses.  
 
This dissertation focuses on preliminary investigations into the development of an 
assay, and provides a brief analysis of a preliminary set of melt curves from the nine 
serotypes. The AHS virus was propagated in both embryonated chicken eggs and Vero 
cell culture. The latter resulted in the most reliable viral RNA extraction. Of the two 
genome segments that provide divergence among the nine serotypes of AHS, 
Segment 2 was found to be less suitable in a bioinformatic analysis for primer design. 
Segment 10 is more conserved and was selected for primer design for reverse 
transcription-PCR of AHS viral RNA. Primers were designed using GenBank, 
ClustalX2, Primaclade, TreeView and POLAND and successfully amplify the 10-190 bp 
region of Segment 10 of all nine AHS viral serotypes. High Resolution Melt (HRM) 
analysis was performed on the amplified products using the Corbett Rotor-Gene® 6000. 
HRM is based on the release of an intercalating fluorescent dye that is released from 
DNA as it is denatured with increasing temperature immediately following PCR. The 
melt curves were grouped into three distinct „bins‟, which correspond to the groupings 
of a dendrogram based on the sequenced products. This constitutes proof of concept 
for a protocol for the molecular serotyping of the AHS virus. This provides a strong 
platform for the validation of a rapid diagnostic assay for informing vaccine programs, 
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Chapter 1: INTRODUCTION AND PROPOSAL 
 
African horse sickness (AHS) is a viscerotropic, non-contagious, vector-borne disease 
with high mortality and morbidity that primarily affects members of the Equidae taxon 
(OIE, 2007). There are nearly 300,000 horses and approximately 160,000 donkeys that 
make up the South African national herd (Gerdes, 2006). According to data from South 
African National Parks and KZN Wildlife, there were over 30,000 zebra in protected 
areas around the country. Worldwide, it is estimated that there may be up to 100 million 
working equines, the majority in developing countries (El Idrissi & Lubroth, 2006). Due 
to climate change, the vector appears to be spreading, increasing the number of 
equines at risk (Mellor & Hamblin, 2004). Thousands of horses are lost every year in 
South Africa due to AHS. AHS influences export and international competitiveness in 
equine trade, and impacts significantly on the South African racehorse and 
performance horse industry (Agüero et al., 2008).  The current vaccine produced by 
Onderstepoort Biological Products (OBP) remains the best and most practical means 
of protection. However, the vaccine cannot be relied upon for full protection from 
infection. The individual response may vary; there may be some interference between 
the serotypes in the polyvalent vaccine or over-attenuation of some of the vaccine 
strains, leading to weakly immunogenic vaccine strains (Coetzer & Erasmus, 1994). As 
an alternative, inactive, monovalent vaccines have been proposed, which many 
researchers acknowledge are far safer and more effective (Mellor & Hamblin, 2004). 
New generation monovalent vaccines have also been developed (Guthrie et al., 2009).  
 
An accurate and rapid diagnosis of equine infectious diseases is an important goal for 
researchers and veterinarians alike. Early detection of causative agents and 
identification of strain/serotype has immediate benefits that include applying the correct 
treatment regime for the animal, notifying authorities in the case of notifiable diseases 
and implementing suitable control measures to prevent further spread of the disease. 
The development of rapid assay methods to identify AHS serotypes is imperative in the 
study of the disease, in order that control (including vaccination) might augment the 
conventional prophylactic strategies currently employed. The ability to serotype an AHS 
outbreak rapidly, combined with the increasing development of monovalent vaccines, 
makes a rapid serotyping assay even more important (Koekemoer et al., 2000). As a 
result, the national equine population could be protected far more effectively against 





rapid classification of future outbreaks for taxonomic and epidemiological purposes. A 
rapid assay may also promote future exportation of South African equine athletes and 
improve the livelihood of rural people who depend on equines as working animals for 
subsistence.  
 
African horse sickness (AHS) accounts for large numbers of equine deaths per year, 
although many go undetected and unreported (AHS-Trust, 2008).  There are a great 
number of rural horses and other equids used for subsistence agriculture and other 
tasks in previously disadvantaged communities that contract the disease and die 
without ever being reported to the authorities, due to a lack of education or intervention 
by the authorities (AHS-Trust, 2009, Personal Communication). Furthermore, the sero-
prevalence of the virus and the vaccination coverage in the South African equid 
population are unknown (Lord et al., 1997a) and remain so to this day. These problems 
are compounded by the lack of research funding for AHS. Expensive tests are required 
to understand the disease thoroughly and are therefore not performed, with many 
owners unwilling to pay for tests on a dead horse. Tests to determine the serotype are 
undertaken only at Onderstepoort Veterinary Institute, take up to two weeks to achieve 
a result and cost in excess of R1000. All of these factors compound the minimal 
number of epidemiological studies being undertaken which lead to often grossly 
misunderstood aspects of the disease. A rapid assay will go some way to easing the 
financial and time constraints of studying an outbreak in real time. This has the 
potential to solve many of the unknowns surrounding AHS, particularly and most 
importantly, the role that each serotype plays in outbreaks and the form of the disease 
contracted by horses. In addition, the strain is not usually classified until sometime after 
the initial outbreak, as no system to rapidly classify the virus involved in the outbreak 
exists. Early identification of the serotype will benefit overall investigations and our 
understanding of the clinical disease (Abdalla et al., 2002). The last two decades have 
seen a shift in the pursuit for rapid diagnostics from classical microbiology to molecular 
biology based techniques, such as nucleic acid detection, particularly the polymerase 
chain reaction (PCR). The applicability of PCR has increased dramatically with the 
advent of real-time or quantitative PCR  (Pusterla et al., 2006). The system that is 
proposed is based on DNA amplification and High Resolution Melt (HRM) analysis that 
will detect the AHS virus and serotype it in a single test in a few hours and could 






The significance of this research lies within the advantages of PCR combined with High 
Resolution Melt analysis (HRMA) for detecting the AHS virus in the blood or other 
biological samples from infected equids. Noteworthy advantages exist in using PCR 
and HRMA in clinical situations where conventional microbiology is inadequate, time-
consuming or labour-intensive (e.g. cell culture), or difficult and hazardous (Abdalla et 
al., 2002). The rapid nature of PCR also has important consequences for limiting the 
spread of highly contagious pathogens in an epidemic. Results are available in less 
than 24 hours as opposed to 4-5 days for virus isolation (Stone-Marschat et al., 1994). 
 
High resolution melting (HRM) was introduced in 2002 through the collaborative efforts 
of academia (University of Utah) and industry (Idaho Technology) (Reed et al., 2007). 
A variety of methods had previously been developed to detect the DNA sequence 
variation of PCR products, however, these involve extra processing and separation 
steps subsequent to the PCR run, include additional apparatuses and are time-
consuming. Gundry et al. (2003) described the ability of melt temperatures to 
distinguish unique variants in a homogenous, closed-tube procedure performed 
automatically after PCR. Reed et al. (2007) considers HRM the simplest method of 
determining sequence variation. 
 
HRM requires normal PCR reagents, a fluorescing double-stranded DNA (dsDNA)-
binding dye and a short period of closed-tube, post-PCR analysis (Reed & Wittwer, 
2004). In its simplest form, HRM involves the release of an intercalating fluorescent dye 
from dsDNA as it is denatured or dissociated into single-stranded DNA (ssDNA) with 
increasing temperature. The melt curve is generated from heating the sample through 
a range of temperatures, as fluorescence data is continuously collected. As the 
temperature is increased, the fluorescence drops rapidly at a characteristic point, 
indicating the dissociation of the dsDNA into single strands and the release of the 
bound dye. This point, the melting temperature of the DNA (Tm), is dependent on GC 
content, length and sequence. This behaviour results in a characteristic melt profile for 
each individual amplicon (Reed et al., 2007). The decrease in fluorescence is analysed 
in silico (Corbett, 2006). HRM has a number of applications including mutation 
detection, genotyping and species identification (Gundry et al., 2003; Corbett, 2006). 
HRM is simple, cost-effective and requires no post-PCR processing, such as agarose 
gel electrophoresis. It also compares favourably with other similar, expensive 





smallest genetic change such as single base changes (single nucleotide 
polymorphisms) (White & Potts, 2006). In general, the greater the number of changes, 
the easier they are to detect using HRM. Developing technically simple and reliable 
methods for detecting sequence variations in related genes has become an important 
goal of molecular diagnostics. Although DNA sequencing still remains the “gold 
standard”, it is too labour- and time-intensive for clinical, routine use (Highsmith, 2004).   
 
A review of the literature pertaining to HRM reveals that most applications have sought 
the detection of single point mutations. However, in 2006, HRM analysis successfully 
and repeatedly differentiated between species of the amoebaflagellate genus Naegleria 
using a single primer set (Robinson et al., 2006). The amplified sequences were almost 
invariant in individual species, but divergent among species. The melt curves that 
resulted were distinguishable and unique for each species, due to the differences seen 
in the positions and relative heights of the peaks on the melt curves. Feline 
caliciviruses, Plasmodium species and Cryptosporidium species have also all been 
successfully species-differentiated using HRM analysis (Helps et al., 2002; Tanriverdi 
et al., 2002; Mangold et al., 2005). HRM analysis was also used to detect and identify 
clinically important bacteria and used to distinguish Bacillus anthracis species (Cheng 
et al., 2006; Fortini et al., 2007). Most recently, HRM was used to successfully 
distinguish Chlamydophila psittaci genotypes and fowl adenovirus serotypes (Mitchell 
et al., 2009; Steer et al., 2009). 
 
The African horse sickness virus has nine serotypes, each with ten common double-
stranded RNA segments making up the genome (Grubman & Lewis, 1992). Two of the 
segments are responsible for the genetic diversity amongst the serotypes (Roy et al., 
1994; Venter et al., 2000) and it these segments that will be investigated and used to 
distinguish the different serotypes using HRM. Segment 2 (encoding for the VP2 
protein) and Segment 10 (encoding for the NS3 protein) have been selected as 
possible targets for the development of this assay. VP5, an additional outer capsid 
protein may also be involved in serotype determination (Koekemoer et al., 2000). 
Segment 10 is being investigated in this dissertation as it is more conserved than 
Segment 2. In addition, there is more sequence “depth” on current, available databases 






In the future, rapid serotyping assays, such as the one proposed, will gain increasing 
significance as new-age vaccines are developed. These vaccines are likely to be 
monovalent (Mellor & Hamblin, 2004) and as such, the serotype of the infecting virus 
must be determined before the correct monovalent vaccine can be used. “Since 
protection against African horsesickness (AHS) is serotype-specific, rapid serotyping of 
AHSV is crucial to identify the correct vaccine serotype for efficient control of the 
spread of AHS outbreaks, especially when they occur in non-endemic regions” 
(Koekemoer & van Dijk, 2004). The South African national equine herd will enjoy 
enhanced protection from each annual outbreak as the serotype and classification of 
the virus will be determined rapidly and the correct vaccine program can immediately 
be undertaken.  
 
Internationally, in non-endemic zones, it will become crucial to serotype the virus as 
rapidly as possible so that the correct monovalent vaccine can be distributed to protect 
equines in the surrounding areas. In the past, delays in determining the serotype saw 
the rapid spread of the disease to unprotected equines and a decrease in the ability to 
control the outbreak. “The amount of damage that a foreign animal disease will cause 
is directly proportional to the time between introduction and accurate diagnosis” 
(Brown, 2002). In the case of African horse sickness, which has nine distinct serotypes, 
control of the disease depends on a roll-out of the correct monovalent vaccine. Rapid 
serotyping is therefore imperative. Additionally, the use of HRMA combined with PCR 
adds a new dimension to classification and the use of taxonomic keys. In a sense, the 
melt curve generated provides the taxonomic key to enable researchers to correctly 
classify the virus. This combination of techniques has the potential to be expanded to 
other organisms and possibly provides an additional dimension to taxonomic keys in 
biological systems. 
 
Use of PCR and HRM analysis will make epidemiological studies into African horse 
sickness more thorough. Indeed, the modern nucleic-acid based assays have 
revolutionised the diagnosis of disease and its related epidemiological studies. These 
molecular systems have made the isolation of pathogens secondary. The 
characterisation of pathogens will follow this lead and other isolation steps may 
become obsolete (Eaton & White, 2004). This study represents the future in that 
regard. The cost and analysis time for serotyping will be drastically reduced. Blood 





strategies and interventions to be employed. These include early quarantining of viral 
„hot spots‟; subunit, recombinant, vectored vaccination (Guthrie et al., 2009; Young, 
2009, Personal Communication) and prophylaxis measures can be extrapolated to 
vector control and husbandry measures (Jenkins, 2008; Simpkin, 2008). Furthermore, 
the possibility of real-time simulation modelling on AHS becomes a very real possibility 
as the role that different serotypes play in the epidemiology of the disease will lead to a 
comprehensive modelling strategy that will predict future outbreaks and so permit a 
more effective, monovalent vaccination program. 
 
It is expected that with the advent of new-age vaccines that are easier to administer, 
with far fewer side effects and complications, and a rapid serotyping program at the 
beginning of localised outbreaks, all segments of the local horse population will be far 
better protected. The impact of this research could also be extended to taxonomic and 
classification systems of all organisms as a „rapid confirmation‟ of field samples. It has 
already been noted that comprehensive molecular databases should be established in 
order to monitor the spread of the virus during an outbreak and increase movement 
controls (Gerdes, 2006). A database of melt curves would augment this. 
 
However, some caveats do exist. Knowledge of the molecular systems of pathogenesis 
and virulence and the nucleic acid based approach to serotype determination is 
rudimentary and this must be borne in mind when attempting to rapidly detect, identify 
and characterise viral RNA. Live viral cell culture will still be necessary. Despite the 
rapidity and multiplexing abilities of PCR and related technologies, they are unable to 
detect actual, live viral particles (Eaton & White, 2004). 
 
The overall approach to the development of this protocol will be to test a variety of 
primer pairs on a culture of each serotype of the virus, to determine which portion of 
the sequence will give the most divergent melt curves, whilst using the least number of 
primer pairs to achieve that purpose. Presently, only one primer pair has been tested to 
provide proof of concept. Segment 2 will be analysed at a later stage and the results 
from all primer pairs will be compared to determine which will give the most reliable 
identification of a particular serotype. 
 
This work has already been acknowledged as intellectual property and a provisional 












Chapter 2: LITERATURE REVIEW 
 
2.1 Introduction 
African horse sickness (AHS) is a viscerotropic, non-contagious, viral disease with high 
mortality and morbidity that primarily affects members of the Equidae family (OIE, 
2007). The African horse sickness virus (AHSV) (NCBI Taxonomy ID: 40050) is a 
double stranded RNA orbivirus of the Reoviridae family (Mellor & Hamblin, 2004; OIE, 
2004a). Other names for the disease include Perdesiekte, Pestis Equorum, La Pesta 
Equina and Peste Equina Africana. AHSV is also considered an arbovirus as it „can 
infect haematophagous arthropods after the blood from an infected vertebrate has 
been ingested. It multiplies in the arthropod‟s tissues and is transmitted by bite to other 
susceptible vertebrates‟ (Mellor, 2000). Mortality in horses may reach 95% and in 
donkeys 50%. Due to its severity and ability to spread rapidly, AHS is considered as 
one of the most fatal diseases that affect equids and is listed by the World Organisation 
for Animal Health (OIE) (previously List A) (Mellor & Hamblin, 2004; OIE, 2009). 
 
2.2 History 
The first recorded epidemic of African horse sickness was in 1327 in the Yemen, 
although the disease almost certainly originated from Africa (Coetzer & Erasmus, 1994; 
Mellor & Hamblin, 2004). In Africa, a monk named Father Monclaro first described the 
disease from a 1569 account of journeys into central and east Africa, using Indian 
horses (Theiler, 1921). In South Africa, the disease first appeared in horses when they 
were brought to the Cape of Good Hope in 1652 by the Dutch East India Company 
(Coetzer & Erasmus, 1994). Only 60 years after the introduction of horses to the Cape 
did the first major, officially recorded, outbreak occurred in 1719 where 1700 horses 
died. It was, however, already apparent that frost appeared to retard the spread of the 
disease (Theiler, 1921; Mellor & Hamblin, 2004). The most severe recorded outbreak 
of AHS was in 1854/55 when it was estimated that over 70,000 horses, or 40% of the 
horse population, died from AHS. By 1921, reports of AHS outbreaks in Northern 
Rhodesia (Zambia), South West Africa (Namibia), Angola, British East Africa (Kenya), 
German East Africa (Tanzania), Zanzibar, Uganda, the Sudan, Abyssinia (Ethiopia) 





In the early 1900‟s, the cause of the disease was found to be a virus by the work of 
pioneers into AHS research (Coetzer & Erasmus, 1994). At the same time it was 
becoming apparent to Theiler (1921) that immunologically distinct strains existed. This 
theory gained further credibility with the work of Alexander in the 1930‟s. Alexander 
also started work that would have important vaccine-related consequences when he 
showed that the virus was attenuated during passage in chicken egg embryos (Coetzer 
& Erasmus, 1994). In 1944, it was confirmed that the AHS virus was vectored by 
Culicoides imicola (du Toit, 1944). Nine serotypes have been described, the last being 
in 1960 (Howell, 1962). Historically, it is apparent that major outbreaks of the disease 
occur approximately every 20-30 years. However, a decline in the zebra and horse 
population and the advent of the polyvalent vaccine produced by Onderstepoort 
Biological Products, in the last century, has largely prevented the massive outbreaks of 
the past, although outbreaks continue to have devastating consequences in certain, 




African horse sickness is caused by the African horse sickness virus (AHSV). The 
agent was first described as an ultravisible organism (Theiler, 1921). AHSV is a 
member of the Reoviridae family and is classified in the Orbivirus genus. Other closely 
related Orbiviruses include the bluetongue (BTV) and equine encephalosis viruses 
(EEV) (Spence et al., 1984; Mellor & Hamblin, 2004; OIE, 2004a). Orbiviruses were 
initially described in 1971 (in Gorman, 1979) to define arthropod-borne viruses with 
distinctive morphologies and physically and chemically identical characteristics. 
Reoviridae have a double-stranded RNA (dsRNA) genome encapsulated by a single 
viral particle that is quasi-spherical and displays icosahedral symmetry (Gorman, 
1979). AHSV is an arbovirus. It is transmitted biologically to vertebrates through blood-
sucking arthropod vectors, namely the biting midges of the Culicoides genus (Mellor, 
2000; Kuno & Chang, 2005). Theiler (1921) alluded to the presence of more than one 
type of the virus as equines supposedly immune to the virus could become fatally re-
infected. Nine immunologically distinct serotypes have since been found to exist, 
numbered 1-9, the last being isolated by Howell in 1960 (Howell, 1962; Hamblin et al., 





genetically stable virus with little to no antigenic changes (Howell, 1962; Erasmus, 
2004). No complete cross neutralisation is evident between any two strains although 
there is a degree of cross neutralisation between serotypes 6 and 9 (Howell, 1962) and 
between serotypes 5 and 8 (Mellor & Hamblin, 2004). Field evidence suggests that 
there is no intratypic variation (Coetzer & Erasmus, 1994). 
 
2.3.2 AHSV Properties 
The 68-70 nm diameter virion (Figure 2.1) is unenveloped with a double-layered capsid 
consisting of 32 capsomeres (Gorman, 1979; Bremer et al., 1990; Erasmus, 2004) with 
the outer capsid more diffuse and less discernable (Wood, 1973). The outer layer of 
the Orbivirus genus of viruses appears to be conserved (Nason et al., 2004) and the 
physico-chemical properties of the virion appear to be common to all Orbiviruses 
(Gorman, 1979; Mellor & Hamblin, 2004). The virus is relatively heat-stable, but can be 
inactivated at 50°C for 3 hours and 60°C for 15 minutes. It can survive at 37°C for 37 
days (OIE, 2002). Moreover, the virus may maintain its infectivity if isolated from putrid 
blood (Theiler, 1921). Infected blood samples may still yield virions for up to a year if 
stored at 4°C (House et al., 1990). The virus can survive in the pH range of 6.5 – 8.5, 
and is more sensitive to acidity than to alkalinity (Erasmus, 2004; Mellor & Hamblin, 
2004). AHSV is inactivated by ether, ß-propiolactone or formalin (OIE, 2002). 
 
 
Figure 2.1 A selection of electron micrographs of AHS viral particles purified by 
centrifugation through different gradients. Top left: Sucrose. Top right: CsCl. Bottom left: 









AHSV is a double-stranded RNA virus made up of 10 genome segments (Grubman & 
Lewis, 1992). This was first demonstrated when the RNA was analysed on 
polyacrylamide gels resulting in 10 bands (Gorman, 1979; Spence et al., 1984). 
Orbiviruses contain segmented genomes, which may allow for gene re-assortment and 
antigenic diversity. However this is contradictory to earlier reports that AHSV is a very 
stable virus (Howell, 1962). Segment numbers were assigned on the basis of molecular 
weight data (Spence et al., 1984; Bremer et al., 1990) and are numbered in order of 
their migration (Roy et al., 1994). However, there is some discrepancy in the literature 
and amongst published sequences with regard to coding assignments of segments 6, 
7, 8, 9 and 10. This is due to the fact that the segments are of almost identical 
molecular weight, hindering their differentiation on gel systems (Table 2) (Bremer et al., 
1990; Quan, Personal Communication). The coding assignments of Grubman and 
Lewis (1992) have segment 6 coding for VP5 and VP6 and an additional protein, NS4 
for Segment 10. However, this view is an isolated one and is incompatible with systems 
used for the bluetongue virus, the prototype orbivirus (Burroughs et al., 1994). The two 
proteins encoded in segment 6 have since been found to be related, the smaller one 
being a truncated version of the larger one (Roy et al., 1994). Table 2.1 gives the 
coding assignments from four sources for comparative purposes. For the purposes of 






Table 2.1: Coding assignments of Grubman & Lewis (1992), Roy et al. (1994), Quan (2008) 








Lewis, 1992)  




al., 2006)  
1 VP1 VP1 VP1 3965 
2 VP2 VP2 VP2 3205 
3 VP3 VP3 VP3 2792 
4 VP4 VP4 VP4 1978 
5 NS1 NS1 NS1 1748 
6 VP5 / VP6 VP5 VP5 1566 
7 VP7 VP7 VP6 1169 
8 NS2 NS2 VP7 1167 
9 NS3 VP6 NS2 1166 
10 NS4/NS4a NS3/NS3a NS3/NS3a 756 
 
The core particle is composed of the major proteins (VP3 and VP7) and the minor 
proteins (VP1, VP4 and VP6) and encloses the 10 genome segments. (Bremer et al., 
1990; Roy et al., 1994; Maree et al., 1998). Together, these proteins make up the 
serogroup-specific epitopes (Mellor & Hamblin, 2004). The outer capsid is made up of 







Figure 2.2: Schematic diagram of the structure of an orbivirus showing the organisation 
of the major and minor structural proteins (after Wilson et al., 2009). 
 
VP2 is the most variable among the nine serotypes (Burrage & Laegreid, 1994) with 
almost 90% of the sequences varying between 46% and 52% on a pair-wise alignment 
in one study (Huismans et al., 2004). As such, it is responsible for serotype diversity 
and specificity (Roy et al., 1994; OIE, 2004a). VP2 and VP5 are together responsible 
for virus neutralisation activity (OIE, 2004a). In addition to the above structural or viral 
proteins (VP), three non-structural proteins are present, namely NS1, NS2 and 
NS3/NS3a (Laviada et al., 1995; Mellor & Hamblin, 2004) and are mainly concerned 
with enzymatic activities (Table 2.2). It has recently been found that after VP2, NS3 is 







Table 2.2: Data derived from a number of sources describing the accepted functions of 
the ten proteins common to all orbiviruses and their molecular weight where available. 
 
Protein Molecular Weight 
(kDa) 
Function/s 
VP1 150 RNA-directed RNA Polymerase 
 





 Cell attachment, virus penetration 
 
VP3 103 Inner capsid structure 
 
VP4 34 Guanylyl transferase 
  RNA capping 
 
VP5 57 Outer capsid - structure 




VP6 38-46 Helicase 
 
VP7 38 Major component of inner core 
 
NS1 63 Major component of tubules in host cell 
 
NS2 41 Form inclusion bodies in host cells; ssRNA 
affinity 
 
NS3/3a 24 Possibly involved in the release of virions from 
cell  
(after Gorman, 1979; Huismans et al., 1987; de Sá et al., 1994; Roy et al., 1994; Martinez-
Torrecuadrada et al., 1996; Turnbull et al., 1996; Maree & Huismans, 1997; Maree et al., 
1998; Vreede et al., 1998; Potgieter et al., 2003; Huismans et al., 2004; Maree & 
Paweska, 2005; Bhattacharya et al., 2007; von Teichman & Smit, 2008; Chiam et al., 






2.3.4 AHSV Replication 
Once the virus has entered a mammalian cell, it removes VP2 and VP5. The removal 
of these two outer proteins causes the RNA polymerase to activate with an associated 
loss in infectivity (Gorman, 1979). The core structure that remains is transcriptionally 
active and protects the genome from host cell detection. Replication occurs in the 
cytoplasm of the host cell after the virion has depressed host cell protein synthesis 
(Gorman, 1979). However, bluetongue virus particles have been found under the cell 
surface as well as on the surface.  
 
Tubules and inclusion bodies are formed by NS1 and NS2 respectively. It is believed 
that NS2 may be involved in requisitioning core proteins and single stranded viral RNA 
into the inclusion bodies. The minor proteins (VP1, VP4 and VP6) form the 
transcriptase complex that is encapsulated by VP3. This subcore acts as a foundation 
for VP7 proteins to attach and form the stable core structure. It is not known at what 
point VP5 and VP2 attach to the subcore to complete the virus particle. NS3 appears to 
interact with VP2 to facilitate virus release. (Wood, 1973; Spence et al., 1984; 
Bhattacharya et al., 2007). In studies done on the bluetongue virus, it was found that 
the virus binds to glycophorins in human and porcine erythrocytes (Eaton & Crameri, 
1989). 
2.3.5 Dendrogram Analysis 
Relationships between serotypes of the AHS virus have not been studied to a large 
degree. The first dendrogram analysis was on Segment 10 (de Sá et al., 1994). 
Serotypes 1, 4 and 8 were sequenced and compared to previously sequenced 
serotypes 3 and 9. Serotypes 1 and 8 appeared to be closely related, as well as 
serotypes 4 and 9. Serotype 3 was more closely related to serotypes 4 and 9 than 







Figure 2.3: Relationships between serotypes 1, 3, 4, 8 and 9 of AHSV Segment 10. 
Preliminary dendrogram relationships based on the coding sequences of Segment 10. 
Tree length = 379, consistency index = 0.868, values above branches correspond to 
branch lengths under all character optimisation. Palyam represents another virus of the 
orbivirus group (de Sá et al., 1994). 
 
With the above sequence alignment, it was found that Segment 10 of the AHS virus is 
far more variable than Segment 10 of the bluetongue virus or equine encephalosis 
virus. 
 
2.3.6 AHS Virus Serotypes 
The role of serotypes in the epidemiology of AHS is poorly understood. The 
relationship between serotypes, geographical distribution, virulence and transmission is 
all unknown. One of the first studies looked at the basic reproduction number, R0, in an 
attempt to understand the implication of serotypes on the epidemiology of the disease. 
R0 is a measure of the probability of transmission of a pathogen. R0 can be used in the 
calculation of control strategies such as vaccination and the coverage required to halt 
an epidemic. However, R0 depends on the independence of the transmission of each 
serotype. It also depends on whether an infection of one serotype affects the infection 
of a second serotype.  
 
A study conducted on zebras found that the distribution of serotypes was non-
independent, implying some sort of relationship between the serotypes that has yet to 
be elucidated. Cross-immunity, biting rates, spatial and temporal variations and genetic 
susceptibilities may all be responsible. A very high R0 is indicative of the likely 
differences in infectivity of different serotypes for midges or zebras or both (Lord et al., 





horse that recovers from an infection from a particular serotype develops a life-long 
immunity to that serotype, but may remain susceptible to others (Mellor, 1993). A strain 
of AHSV that occurred in Kenya in the early 1990s was not neutralised by antiserum of 
any of the nine previous serotypes leading to speculation that a tenth serotype may 
exist (Mellor, 1993). However, only nine recognised serotypes exist today, which may 
indicate the genetic stability of the virus. Table 2.3 shows the nine recognised 
serotypes accepted as reference strains.  
 
Genetic re-assortment of the genome is always a concern when dealing with viruses. 
Segmented genomes, as exist in orbiviruses, are thought to facilitate genetic re-
assortment. New types may therefore arise if a cell is co-infected. However, Howell in 
1966 observed that only one strain of the bluetongue virus was ever found in infected 
sheep over a number of years (Gorman, 1979). This, combined with the fact that no 
additional AHSV serotypes have been described since the 1960‟s, lends itself to the 
idea that the AHS virus is genetically stable. 
 
 
The distribution of serotypes in South Africa is not well studied. A map of the serotype 
distribution from the 2008/2009 outbreak is given in Figure 2.4. Not all samples 
received by the Department of Agriculture are sent for serotyping due to expense and 
time. As a result, it is unlikely that the distribution map can be viewed as a correct 
representation of the actual situation and distribution. 
Table 2.3: AHSV Serotypes and historical isolates/reference strains (Ozawa & Dardiri, 
1970) 
 
















Figure 2.4: Serotype distribution in South Africa for the 2009 AHS season (DAFF, 2009). 
 
2.4 Epidemiology 
2.4.1 Epizootic Events 
The distribution of AHS is limited to geographical regions that favour the biology of the 
Culicoides spp. midge (Mellor, 1993). AHS is endemic to sub-Saharan Africa, including 
both the tropical and sub-tropical regions. AHS occurs from Senegal in the west to 
Kenya and Somalia in the east and south down to South Africa. The disease has been 
reported in North Africa, but it is generally constrained to the south of the Sahara due 
to the desert‟s large expanse that acts as a protective barrier. AHS has not been 
reported in Madagascar (Mellor, 1993; Mellor & Hamblin, 2004; Guthrie, 2008).  
 
Outside of Africa, AHS has occurred regularly in the Middle East. It was reported there 
in 1930, 1944 and 1959-1961. In 1965, AHS occurred in the northern-most African 
countries and crossed into Spain in 1966, but was quickly suppressed through a mass 
vaccination and slaughter policy (Lord et al., 1997b). The virus usually fails to persist 
outside of Africa due to the climatic conditions experienced in winter (Mellor & Hamblin, 
2004). The Iberian peninsula was again afflicted in 1987-1990 following the importation 





disappeared with the arrival of winter and that was considered the end of it. However, 
the same serotype surfaced again in 1988 and every year until 1991, spreading to 
Portugal and Morocco. The apparent ability of the virus to overwinter outside Africa 
caused widespread concern and led to a wave of AHS research in Europe, which the 
literature shows, but the research has sadly dwindled. It has been elucidated that the 
virus was able to overwinter on the Iberian Peninsula as the winters are mild enough 
and the Culicoides midge, a competent vector, native to the region and active 
throughout the year, exists (Mellor & Hamblin, 2004). However, with an increase in the 
international movement of horses, the possibility of an outbreak occurring in countries 
previously free of the disease has increased greatly (Archer, 1974; Anonymous, 2008). 
 
AHSV is only able to survive in a long-term fashion through continuous and 
uninterrupted cycles of transmission between vertebrate and invertebrate hosts. Any 
„vector-free‟ period cannot be longer than the duration of viraemia. In sub-Saharan 
Africa, no such „vector-free‟ periods exist and the virus is able to survive from season to 
season, year to year. The further north and south one goes, the climatic conditions 
become less conducive to the survival of the vectors and the cycle is broken, resulting 
in brief epizootics of the disease when specific environmental conditions are met, such 
as in the Iberian peninsular and Morocco (Mellor, 1994). 
 
2.4.2 Endemic Events - South Africa 
2.4.2.1 Geographical Distribution 
In South Africa, AHS occurs every year, mainly east of the Karoo and Kalahari deserts 
(Figure 2.5 and 2.6) (AHS-Trust, 2008), but depends largely on the immune barrier 
(vaccinated population) and the timing within the season with regard to rainfall and 
ambient temperature (Gerdes, 2006). The disease historically and commonly appears 
to originate in the north-eastern parts of the country and move southward. Indeed, Lord 
et al. (2002) describe the force of infection as being the strongest in the north-east, 
declining in a south westerly direction. However, the 300,000 doses of vaccine that are 
sold by OBP per year appear to have slowed this southward progression somewhat 
and formed what could be termed an „immune barrier‟ (Guthrie, 2008). Theiler (1921) 
reported the absence of the disease from large parts of the Free State and Lesotho. 







Figure 2.5: Confirmed outbreaks of African horse sickness in South Africa for the 
2008/2009 season according to the National Department of Agriculture (DAFF, 2009). 
 
 
Figure 2.6: Confirmed outbreaks of African horse sickness in South Africa for the 






Theiler (1921) also reported that the disease occurs predominantly in and around 
lakes, pans, vleis and rivers of the South Eastern and Eastern coastal belt. Heavy, 
early summer rainfall, followed by a drier period appears to favour the development of 
epidemics.  
 
2.4.2.2 Seasonal Distribution 
The disease seems to have both a seasonal (Figure 2.7) and cyclical nature. It is 
seasonal as it peaks during the late summer/autumn and cyclical as it has been 
proposed that the major outbreaks have occurred following El Niño warm-phase 
events, which occur approximately every 20 years (Theiler, 1921; Coetzee, 2000; OIE, 
2004a). In general, AHS first emerges during February with a peak in cases during 
March and April. Following the first frosts in May/June, the disease appears to be 
arrested (Coetzer & Erasmus, 1994; Guthrie, 2008). However, data collected by the 
AHS Trust shows that cases are being reported from early December to May or June 
(AHS-Trust, 2008). Generally, the severity of the annual outbreak is assumed to be 
largely due to a complex combination of El Niño  patterns, especially in a water-scarce 
country such as South Africa (Gerdes, 2006). Early and high precipitation summer 
rains tend to lend themselves towards an epizootic (Guthrie, 2008). 
 
 
Figure 2.7: Number of cases reported between 2000 and 2006 showing the seasonal 
nature of African horse sickness. The number of cases reported between September and 







Usually, during an outbreak of AHS, one serotype may dominate, but it does not 
exclude other serotypes (Guthrie, 2008). Moreover, serotypes are seldom detected in 
the same area in successive years. Serotypes 1-8 are mostly responsible for outbreaks 
in South Africa, while serotypes 3, 4 and predominantly 9 have been recorded in 
outbreaks outside of Africa (Mellor & Hamblin, 2004).  Serotypes 1-8 have been found 
to have a higher mortality (90-95%) than serotype 9 (70%) (Coetzer & Erasmus, 1994). 
All nine serotypes have been detected in eastern and southern Africa, with serotype 
nine being more dominant in the north west regions of sub-Saharan Africa (Guthrie, 
2008). In 2006, AHS serotype 2 was found to be responsible for the outbreak in Nigeria 
that subsequently spread to Senegal. This was the first isolation of serotype 2 in the 
Northern Hemisphere. Reasons for this incursion range from lax border controls in 
West Africa to the spread of the vector due to global warming (Fasina, 2008; Fasina et 
al., 2008).  
 
2.4.4 Simulation Modelling 
Simulation modelling of epidemics can facilitate understanding of the factors involved in 
the causation and duration of epidemics, particularly when they occur in non-endemic 
regions. Lord et al. (1996b) suggested that midge population size, the recovery rate in 
horses and the time of year that the virus is introduced to an area, were found to be the 
most significant factors to contribute to the establishment of an epidemic. The size of 
the epidemic was found to be influenced by the inter-bloodmeal interval of the midge, 
the mortality and recovery rates of the infected horses, midge population size and 
transmission rates. 
 
2.4.5 Host Range 
The range of hosts for AHS is confined mainly to equine species. The most susceptible 
are horses (70-95% mortality) followed by mules (50-70% mortality). Donkeys and 
zebras are the most resistant and seemingly remain subclinical for AHS (Theiler, 1921; 
Coetzer & Erasmus, 1994). The high mortality of horses and mules indicates that they 
are most likely accidental hosts (Erasmus, 2004). Varying individual responses to the 





endemic/enzootic regions descended from herds from 2000 BC may have acquired 
resistance to AHS equal to a zebra or donkey (Coetzer & Erasmus, 1994). This may 
support the anecdotal evidence of subclinically infected horses infected with the virus 
and acting as reservoirs. 
 
Another host for AHS is the domestic dog (Coetzer & Erasmus, 1994). However, the 
dog only becomes viraemic after the ingestion of infected meat or experimental 
infection (Mellor & Hamblin, 2004). They are thus not considered to play any role in the 
transmission of AHS (Coetzer & Erasmus, 1994; Braverman & Chizov-Ginzburg, 1996; 
Mellor & Hamblin, 2004). Other African carnivores that have been tested positive for 
AHS antibodies are the spotted hyena, lion, cheetah, African wild dog, jackal and genet 
(Alexander et al., 1995). AHS antibodies have not been found in any wild or domestic 
ruminants save for the camel (Mellor & Hamblin, 2004). Pigs, cats and monkeys are 
resistant to infection (Coetzer & Erasmus, 1994).  
 
Since the beginning of the 20th Century, the number of outbreaks occurring throughout 
South Africa appears to have been declining. This pattern coincides with a reducing 
number of free ranging zebra across South Africa because of hunting. However, the 
proliferation of game parks (and restocking of zebra) in certain areas is cause for 
concern. It is possible that at some undefined population density, a permanent host 
population may, therefore, become established in localised regions (Mellor & Hamblin, 
2004). 
 
The OIE reports that there is no evidence that humans could become infected with 
AHSV. However, it has been described previously that certain neurotropic vaccine 
strains may cause encephalitis and retinitis of the eyes in humans following aerosol 
infection during vaccine production (OIE, 2004a). 
 
2.4.6 Reservoirs 
“The continued circulation of an insect-transmitted virus depends on the availability of 
susceptible hosts and competent vectors in sufficient numbers” (Barnard, 1993). Zebra 
(Equus burchelli) are considered to be the natural vertebrate host and reservoir for the 
disease and are instrumental in the persistence of the disease in Africa (Bigalke, 1994). 





living zebra is strongly suggestive of the reservoir role that zebras might fulfil in the 
persistence of AHSV (Barnard, 1993). Furthermore, the viraemic state in zebra may 
extend to up to 40 days (and remain subclinical), whereas in horses it is less than 7 
days (Barnard et al., 1994; Meiswinkel & Paweska, 2003; Maree & Paweska, 2005). 
Zebra are known to have existed on the Highveld and southern savannah woodland in 
South Africa for perhaps millions of years and to have adapted to the infectious agents 
of the environment and so may act as carriers and maintenance hosts (Bigalke, 1994). 
The reservoir host theory has yet to be conclusively proven  (Erasmus, 2004; OIE, 
2007). The literature that exists concerning zebra makes this assumption without 
setting out to prove or disprove the assumption (Meyer, 2007). Although it is commonly 
accepted that viral transmission is halted in winter, it may still continue at a lower rate 
in warmer, low-lying, tropical regions. In South Africa, this description would apply to 
the Kruger National Park. Coupled with the large numbers of zebras in the park, this 
may indeed constitute the reservoir host system needed for the virus to overwinter 
(Meiswinkel et al., 1994). In a similar fashion, donkeys may perform the same role in 
other parts of the country where the population is high relative to the number of horses 
(Guthrie, 2008). The lack of zebra in areas outside Africa where outbreaks have 
occurred and not persisted, is indicative of the fact that the horse is not a long-term 
reservoir for AHS. However, serotype 9 persists in areas of West Africa where zebra do 
not naturally occur (Mellor & Hamblin, 2004). In 2007, it was reported that the Equine 
Research Centre at the University of Pretoria was looking into the role of zebras in 
AHS epidemiology (Anonymous, 2007d). It has been accepted that subclinically 
infected zebras imported into Spain were responsible for the Iberian outbreak in the 
late 1980‟s (Lubroth, 1988; Mellor & Hamblin, 2004). Dogs are unlikely to act as 
reservoirs (Braverman & Chizov-Ginzburg, 1996). 
 
2.4.7 Vectors 
The vectors for AHS are the crepuscular biting midges of the Culicoides genus (Figure 
2.8), which transmit the virus by biological means (Coetzer & Erasmus, 1994; Mellor, 
1994; OIE, 2007). They are distributed virtually worldwide (Meiswinkel et al., 1994). 
Generally, midges are only dispersed a few kilometres from their breeding sites, but it 








Figure 2.8: Culicoides spp. lateral view (Meiswinkel et al., 1994) 
 
The similarities between malaria and „Horsesickness‟ led Theiler (1921) to believe that 
the vector was a blood-sucking insect. Various arthropod vectors have been 
considered and studied, chief among them being mosquitoes, ticks and Culicoides spp. 
(Wetzel et al., 1970; Mellor, 1994), but only Culicoides spp. have been found to play 
any significant role in the spread of AHS (Mellor, 1993; Coetzer & Erasmus, 1994). In 
1944, it was shown that wild caught Culicoides midges were infected with AHSV (du 
Toit, 1944). This was later confirmed by Mellor et al. (1975) and Boorman et al. (1975) 
who also showed that the transmission of the virus was possible after 7-10 days 
incubation at 26°C. The majority of experimental epizootiological evidence 
overwhelmingly suggests that the Culicoides species are the primary vectors of AHSV 
(Mellor, 1994). According to the OIE, certain mosquito and tick genera may constitute 
an occasional mode of transmission (OIE, 2007). 
 
Culicoides imicola is found throughout sub-Saharan Africa, the Mediterranean Basin 
and South East Asia (Meiswinkel et al., 1994; Mellor, 1994). In sub-Saharan Africa, C. 
imicola has been accepted as the primary vector of AHSV (Mellor & Hamblin, 2004). In 
1982, it was found in Spain and has since been indentified throughout the 
Mediterranean and Southern Europe, even as far north as Switzerland (Goffredo & 
Meiswinkel, 2004). The occurrence of C. imicola across these regions may either be 
indicative of the improved and more intensive sampling strategies following the 
bluetongue epizootic (1998-2003), or that their range has moved further north due to 
global warming. Mellor and Hamblin (2004) suggest that it may be the latter. Culicoides 





similar locations reveal that C. imicola is „widespread and abundant‟. Mellor and 
Hamblin (2004) further suggest that the presence of a viable vector for AHS (as in the 
Bluetongue outbreaks between 1998 and 2003) in these regions renders these areas 
particularly vulnerable to an AHS epizootic. 
 
However, new research continues to surface about the role of the other species in the 
genus. As early as 1975, an American species, C. sonorensis (=variipennis) was 
shown to transmit the AHS virus (Boorman et al., 1975; Mellor et al., 1975). This also 
renders the North American continent susceptible to AHS outbreaks (Mellor, 2000). 
More recently, C. bolitinos was implicated in the transmission of AHS as a potential 
field vector. C. bolitinos is distributed widely in the cooler highland areas of South 
Africa where C. imicola is rare (Venter et al., 2000). Isolations from C. obsoletus and C. 
pulicaris catches during the Spanish outbreak of AHS indicated that they may also 
transmit AHSV (Mellor et al., 1990). Considering that C. obsoletus and C. pulicaris are 
the most common midge species across northern and western Europe, an AHS 
outbreak may not necessarily be confined to southern Europe. An additional Culicoides 
species that has been found to transmit the virus is C. nubeculosus that exists across 
Europe (Mellor et al., 1975). 
 
The distribution of C. imicola, geographically and seasonally, is dependent on a range 
of environmental factors. Temperature is probably the most influential extrinsic factor 
affecting the transmission, infectivity and virogenesis of AHSV in Culicoides vectors 
and the survival of the midges themselves (Mellor, 1994; Wellby et al., 1996; Mellor, 
2000). The optimum temperature range for adult Culicoides spp. activity is 12.5 – 29°C. 
An increase in ambient temperature results in increased infection rates, faster 
virogenesis and earlier transmission. Survival rates of the midges, however, decrease. 
On the other hand, as temperature decreases, the opposite is true (Mellor, 2000) 







Figure 2.9: Different effects of ambient temperature on AHSV infection rates, virogenesis 
and midge survival rates (after Mellor, 2000; Mellor & Hamblin, 2004). 
 
The infection rate falls to zero when ambient temperatures fall below 15°C. It appears, 
however, that virions persist in the midge at low temperature and when temperatures 
rise again, virogenesis commences (Wellby et al., 1996; Mellor, 2000). It has also been 
shown in other studies (Sellers & Mellor, 1993; Mellor, 2000) that midges may be active 
at temperatures as low as 3°C. However, the virus cannot replicate at these 
temperatures. These findings suggest that even if there were to be an incursion into 
northern Europe by AHSV, the midge populations would increasingly lose the ability to 
transmit the virus the further north it extends. Transmission would only be possible over 
the short summer months and be arrested in winter. A caveat exists, however, that at 
these low temperatures, midge survival increases dramatically, to 90 days in some 
cases, in an inactive state. Should the local climate have a winter period (below 15°C 
average) of less than 90 days, it would be possible for the midge to carry over latent 
virus from the previous summer and begin a new cycle (Mellor, 2000).  
 
Mellor & Hamblin (2004) view the above phenomenon as a possible over-wintering 
mechanism where vertebrate reservoirs are not available. However, Rawlings 
(personal communication in Mellor, 1994) suggested that an „accumulation of cold 
stress‟ might be a major fact in Culicoides mortality, as opposed to a single cold event. 
This theory discredits the commonly accepted fact that the first frost of the season 
totally arrests midge activity for the duration of the winter (Mellor, 1994). When 



















appear unable to pass trans-ovarially in midges (Meiswinkel et al., 1994). However, 
with the global warming phenomenon, the above factors that combine to prevent AHS 
over-wintering in Europe successfully now may not be enough to prevent AHS from 
making a permanent and resident incursion (Wittmann & Baylis, 2000; Wittmann et al., 
2001) 
 
2.4.7.1 Viral cycle in Culicoides spp. 
When a female Culicoides spp. takes a blood meal from a viraemic equine, the virus is 
deposited in the lumen of the mid-gut. The virus infects and replicates in these luminal 
cells from where the virus is released into the haemocoel and infects the secondary 
targets, such as the salivary glands. The virus continues to replicate in the salivary 
gland for the life of the midge. When the female takes another blood meal, the virus 
passes from the salivary glands into the blood stream of the animal (Mellor, 1993). 
 
2.5 Pathogenesis 
The severity of the disease depends largely on the virulence of the virus, the infective 
dose (related to the number of infected midges that bite the animal) and the 
susceptibility or immunological status of the animal. The factors and molecular basis 
that determine the virulence and pathogenesis characteristics of AHSV are not well 
known, although it is suspected that they lie with the proteins VP2, VP5 and NS3 and 
are multifaceted (Huismans et al., 2004). Clinical signs develop as a result of the 
damage to the endothelial cells in blood vessels and reduced function of the circulatory 
and respiratory systems (Mellor, 1993).  
 
Initial viral multiplication occurs in the regional lymph nodes resulting in a „primary 
viraemia‟ that disseminates the virus throughout the body via the blood and leads to the 
infection of target organs such as the lungs, spleen and lymphoid tissues. From the 
infected organs, a „secondary viraemia‟ occurs, of varying titre and duration, depending 
on the host species (Coetzer & Erasmus, 1994). In horses, the maximum titre is usually 
105 TCID50/mL with the viraemia lasting 4-8 days and paralleling the febrile reaction, 
although it may vary between 2-21 days (Erasmus, 2004). In donkeys and zebras, the 
viraemia is considerably lower and may last for up to 28 or 40 days depending on the 
study (Hamblin et al., 1998; Erasmus, 2004; OIE, 2004a). It has been found that in 





In experimental infections, the incubation period lasts 5-7 days with a minimum of 2 
days and a maximum of 10. This has been found to be dependent on the dose and 
virulence of the virus(Guthrie, 2008). The effect of infecting serotype has not been 
determined. 
 
Immediately after infection, AHSV rapidly accumulates in the spleen, lungs, caecum, 
pharynx, choroids plexus and most lymph nodes. AHSV subsequently moves to other 
highly vascularised organs (Mellor & Hamblin, 2004). Only trace amounts are found in 
secretions (Erasmus, 2004). AHSV was reported by Theiler in 1921 to be closely 
associated with erythrocytes. More correctly, it has since been found to be associated 
with the cellular fraction, i.e. the erythrocytes and lymphocytes, with very little in the 
plasma. This phenomenon may be similar to BTV infections where the virus is 
sequestered in the cell membrane of infected erythrocytes (Mellor & Hamblin, 2004). 
The damage inflicted by AHSV on mammalian cells is likely due to the damaging exit 
mechanisms from the cell that the virus employs (Mellor, 2000). In a 1999 study on the 
AHS virus and its effects on capillaries, it was found that the virus was most common in 
the myocardial vessels and least common in the lung, while endothelial cell infection 
was rare in the spleen and liver (Gomez-Villamandos et al., 1999). 
 
Since 1921, when Theiler first described them, the four „forms‟ of AHS have been used 
to categorise the disease. In ascending order of severity, these are the horsesickness 
fever, the subacute/oedematous (cardiac or „dikkop‟) form, the mixed form and the 
peracute (pulmonary or „dunkop‟) form. It has since become apparent that most 
infections are of the „mixed‟ form (Coetzer & Erasmus, 1994; Mellor & Hamblin, 2004).  
 
Horse sickness fever is the mildest form of the disease and usually involves a mild 
fever and slight oedema of the supraorbital fossae. Mortality is rare and occurs in 
animals with some immunity. It is the only form seen in zebras and donkeys. In the 
cardiac form, a fever may persist for a few weeks and there is significant subcutaneous 
oedema, particularly of the supraorbital fossae, but none in the lower limbs. Petechial 
and ecchymotic haemorrhaging (of the eyes and of the tongue respectively) may be 
present and mortality may exceed 50%. Colic is often a feature. The most severe form 
is the pulmonary form, where there is a mortality rate of 95%. It develops very rapidly 
with a fever of up to 41˚C followed by signs of respiratory distress. Foam exudes from 





afflict the animals simultaneously. This mixed form is the most common with a mortality 
rate of 70%. Animals usually die within 3-6 days (Coetzer & Erasmus, 1994; Mellor & 
Hamblin, 2004). 
 
Laegreid et al. (1993) observed that the infecting serotype determines to some extent 
the form of the disease that is exhibited in the animal. Sailleau et al. (1997) added to 
this observation when horses experimentally infected with serotype 4 developed the 
pulmonary form and those infected with serotype 9 developed the cardiac form. 
However, the relationship between each serotype and the form of the disease or 
mortality rate remain undetermined. 
 
2.6 Control and Prevention 
There is no specific treatment for African horse sickness (Mellor & Hamblin, 2004). 
Theiler (1921) reported that the best treatment might be to leave the horse alone. 
Combating AHS therefore moves towards prevention of an infected insect bite and 
control by „rendering the animals immune‟ (Theiler, 1921). Foremost among these 
measures are introducing good husbandry practices, controlling the Culicoides midge 
vector and vaccination (Meiswinkel et al., 1994). The large number of horses that 
transverse international boundaries in today‟s modern equine industry constitute an 
increasing concern due to the threat of various viral diseases of equines (MacLachlan 




Since Culicoides midges are crepuscular (Wittmann & Baylis, 2000), husbandry 
measures include housing animals from before dusk to after dawn and preventing 
access of the midge to the building (Wittmann et al., 2001; Erasmus, 2004). The 
application of insecticides to the animals‟ coats may deter the midge from biting. These 
measures aim to limit the amount of time the animals can be exposed to the vector 
(„bite load‟). Even before the nature of the vector species was determined, the above 
measures were found to be highly effective at preventing infections (Theiler, 1921) and 
are still effective today. Controlling vector populations aims to reduce the number of 
potential bites that susceptible animals receive. Eradicating the midge population 





includes altering their habitat, adultciding, larvaciding and repellents (Jenkins, 2008; 
Simpkin, 2008). Additionally, in the case of outbreaks, movement restrictions may be 
put in place and slaughter policies introduced in the case of currently AHS-free 
countries (Portas et al., 1999; Mellor & Hamblin, 2004). 
 
2.6.2 Vaccination 
The most practical approach and primary means to the prevention of viral diseases is 
vaccination (OIE, 2004b; MacLachlan et al., 2007). The distribution of the nine AHS 
serotypes is throughout South Africa, although they may differ temporally (Coetzer & 
Erasmus, 1994). For this reason, a polyvalent, attenuated vaccine was developed by 
OBP.  
 
There have been a number of different vaccines developed for AHS over the last 
century. The initial approach was to inoculate horses with virulent virus and immune 
sera (MacLachlan et al., 2007). Early vaccines were produced in the 1930s by 
passaging the virus approximately 100 times intracerebrally in suckling mouse brain 
and were called „horsesickness neurotropic mouse brain vaccines‟. Despite the good 
protection that these vaccines provided, they occasionally resulted in serious side-
effects with some horses dying of encephalitis (Nobel & Neumann, 1961; Pavri & 
Anderson, 1963) and proved to be infectious to humans (MacLachlan et al., 2007). 
These problems were solved in the 1960s by passaging in cell cultures instead 
(Mirchamsy & Taslimi, 1964; Mirchamsy & Taslimi, 1968). Also in the 1960s live-virus 
and killed-virus vaccines were investigated (Ozawa et al., 1965; Ozawa & Bahrami, 
1966). In 1974, however, these vaccines began to be replaced with plaque variants of 
AHSV grown in Vero cells (Coetzer & Erasmus, 1994; OIE, 2004a).  
 
The current vaccine produced by OBP remains the best and most practical means of 
protection against AHS (Figure 2.10). However, the vaccine cannot be relied upon to 
give full protection to the animal. The individual‟s response may vary, there may be 
some interference between the serotypes in the polyvalent vaccine or over attenuation 
of some of the vaccine strains, leading to weakly immunogenic vaccine strains 
(Coetzer & Erasmus, 1994). Historically, however, the development of the polyvalent 
vaccine has significantly reduced the losses associated with AHS (Guthrie, 2008). In a 





of horses and donkeys or 90% of horses only were vaccinated before the introduction 
of the virus. Importantly, donkeys needed to be included in vaccination programs to 
reduce overall losses. However, this model was based on a two host, one vector 
system in Spain (Lord et al., 2002). This is far from the situation in South Africa, but 
gives an indication of the importance of vaccination. 
 
 
Figure 2.10: African horse sickness vaccine manufactured by Onderstepoort Biological 
Products (http://www.obpvaccines.co.za/prods/54.htm) 
 
Annual immunisation is recommended for September each year, before the peak AHS 
season, with yearlings normally receiving two vaccinations in the first year (Coetzer & 
Erasmus, 1994; Anthony et al., 2004), with the timing of these vaccinations having 
been found to be of crucial significance (Crow, 2005). OBP manufactures two 
quadrivalent vaccines containing live, attenuated strains. The seed virus is selected 
from genetically stable macroplaques from Vero cells (OIE, 2004a). The first vaccine 
contains serotypes 1, 3 and 4 (AHS1), while the second vaccine contains 2, 6, 7 and 8 
(AHS2). The vaccines must be administered at least three weeks apart. Serotype 9 is 
not included in the vaccine since it is very rare in South Africa and serotype 6 affords 
sufficient cross-protection. Serotype 5 was removed from the vaccine in 1993 due to 
reports of severe reactions in workers and deaths in horses and is cross protected by 
serotype 8 (Mellor & Hamblin, 2004; MacLachlan et al., 2007). Repeated vaccinations 
over time are believed to assist the animal in gaining greater immunity to the serotypes 
contained in the vaccines (Coetzer & Erasmus, 1994). It is interesting to note, that in 
the last outbreak on the Iberian Peninsula from 1987 to 1991, a polyvalent vaccine was 
initially used. It has been claimed by some workers, although unpublished, that 
subsequent to these polyvalent vaccinations, different serotypes began appearing in 





produced a viraemia in the animals vaccinated with it and it was then transmitted by the 
resident vectors. This has, however, yet to be substantiated (Mellor & Hamblin, 2004). 
 
Some anecdotal comments suggest that the vaccine itself may be responsible for 
inducing a fatal viraemia, particularly in younger horses (MacLachlan et al., 2007). 
There is little literature to back up this claim and the vaccines used to control the last 
epizootic in Spain have „never been known to revert to virulence‟ (Mellor, 1993). 
„Vaccine-related deaths‟ during the Iberian outbreak of 1987-1991 were later said to be 
due to the vaccination of already infected horses or that, due to a lack of education, the 
horses were worked after vaccination (Portas et al., 1999). A serology assay has been 
developed that could be used to differentiate a vaccine viraemia versus a natural 
viraemia (Laviada et al., 1995). However, this assay requires specific reagents and is 
unlikely to find widespread acceptance. In 2008, a study was conducted to determine 
whether the vaccine manufactured by OBP could induce clinical symptoms. The study 
concluded that “assumptions of virulence or reversion to virulence of vaccine re-
assortments post-vaccination in horses could not be substantiated” (von Teichman & 
Smit, 2008).  
 
It would, however, be advantageous to conclusively trace the origin of the virus in an 
infected horse, be it wild type or vaccine strain. Vaccine and wild-type strains of the 
avian pathogen Mycoplasma gallisepticum have successfully been differentiated with 
standard PCR techniques (Evans & Leigh, 2008). More importantly, field and vaccine 
strains of the bluetongue virus were differentiated rapidly using real-time RT-PCR 
following reports of vaccine virulence in European outbreaks (Elia et al., 2008). 
 
Inactivated vaccines are an alternative to live, attenuated ones. They are 
advantageous in that they do not contain a potentially dangerous live agent. However, 
they are expensive to produce and require multiple inoculations. Complete vaccine 
inactivation may also be difficult. No such vaccines currently exist, although they have 
been developed and successfully used in the past (Mirchamsy & Taslimi, 1964; Mellor 
& Hamblin, 2004).  
 
Howell (1962) recognised the advantages of monovalent vaccines over polyvalent 
vaccines, especially when outbreaks occurred in non-endemic regions. Monovalent 





losses in an outbreak. Inactivated monovalent vaccines are used extensively in West 
Africa, where serotype 9 is the dominant circulating serotype (National Laboratory, 
Senegal) (Mellor & Hamblin, 2004). Whenever AHSV has appeared outside Africa, 
monovalent vaccines have successfully been used for the particular serotype involved. 
In the Spanish outbreak of 1987-1991, an inactivated monovalent serotype 4 vaccine 
was produced from the attenuated vaccine strain (OIE, 2004a). 
 
Although popular and efficacious, live attenuated and inactivated vaccines are 
perceived to have many flaws. As far as AHS-free countries are concerned, the use of 
a live, attenuated vaccine as a preventative measure against an outbreak is equal to 
declaring that the AHS virus itself was present (Portas et al., 1999). Recombinant 
vaccines represent a modern alternative, but few have reached a commercial phase 
(MacLachlan et al., 2007). A considerable amount of research has been done on sub-
unit vaccines, albeit for BTV (Savini et al., 2007). Subunit vaccines have also been 
tested successfully with AHSV, although they are no longer commercially available. 
VP2, VP5 and VP7 of serotype 4 were expressed in baculovirus expression systems 
and used to immunise horses (Martinez-Torrecuadrada et al., 1996). A complete 
protective immune response was achieved, although only VP2 was soluble and 
produced neutralising antibodies. Recombinant VP2 from serotypes 3, 4, 5 and 9 have 
since also been used to successfully immunise horses (Bentley et al., 2000; Martinez-
Torrecuadrada et al., 2001; van Niekerk et al., 2001; Scanlen et al., 2002). 
 
Mellor and Hamblin (2004) recognise the success of the live, attenuated, polyvalent 
vaccine in endemic situations such as South Africa, but the authors have concerns 
regarding its use elsewhere, in epidemic situations: 
1. There is no AHSV vaccine licensed for manufacture outside of Africa at present. 
2. The vaccines produced by OBP are, as mentioned above, only available in two 
polyvalent live attenuated forms. In the case of an epidemic requiring 
emergency vaccination, there will be a delay in the implementation of a suitable 
vaccination program while a monovalent or different form of the polyvalent 
vaccine is manufactured. 
3. The live nature of the current OBP vaccine renders it unsuitable for vaccination 





4. The vaccine strains used in South Africa are of South African origin. Using the 
vaccine outside of sub-Saharan Africa, could introduce a different virus type or 
strain into the eco-system. 
5. It has also been suggested that since the vaccine is live, re-assortment of 
genome segments may occur between the vaccine strains and wild-type 
viruses. In a worst-case scenario, this may result in „new‟ strains of the virus 
that may be more virulent with unique antigenic properties. 
6. Using a live virus may result in a vaccine virus viraemia in some vaccinated 
equids. However, this has yet to be conclusively studied. 
7. It is unknown whether Culicoides spp. would be able to transmit vaccine strains 
and facilitate re-assortment. 
 
The concerns expressed above are those of Mellor and Hamblin (2004) and are 
echoed by Guthrie et al. (2009). In addition, the dangers surrounding live virus 
vaccines were already being discussed in the 1960s (Mirchamsy & Taslimi, 1968).  
 
In response to a  growing call for a modern vaccine candidate, Guthrie et al. (2009) 
have developed a recombinant canarypox-vectored monovalent vaccine for serotype 4. 
The genes of the outer capsid proteins VP2 and VP5 of AHSV were cloned into a 
canarypox vector. The proteins were expressed through the canarypox vector and, 
when inoculated into horses, induced neutralising antibodies, while remaining avirulent. 
An identical method had been successfully used previously for bluetongue virus, West 
Nile virus and equine influenza virus. Vaccination of horses with this new vaccine 
prevented the horses from becoming viraemic after inoculation with live AHS virus and 
resulted in appropriate circulating antibodies. This vaccine represents a huge step 
forward for the successful prevention of AHS, but it is monovalent and the infecting 
serotype will have to be determined prior to immunisation with the vaccine. 
Unfortunately, however, the complete development of a veterinary vaccine, from proof 
of concept to marketing authorisation, will take many years and must overcome many 
obstacles (Heldens et al., 2008). 
 
The design of modern vaccines, with a tendency to be serotype specific, must be 
based on a sound understanding of the molecular biology and pathogenesis of each 
serotype within the horse (MacLachlan et al., 2007). Serotyping assays are crucial to 






Of concern with any viral disease and its control by vaccination is the antigenic 
diversity that exists because of mutation, recombination or re-assortment between 
different strains. Although AHSV appears to be a relatively stable virus genetically, 
surveillance programs to monitor the circulating serotypes are important to keep ahead 
of the virus (Mumford, 2007). Rapid serotyping assays would have the potential to 
identify shifting genotypes during an outbreak and facilitate monitoring of its progress in 
real time. 
 
Apart from the above-mentioned vaccines, virus-like particles (VLPs) have also been 
used to induce an immune response. VLPs are a virtual replica of the virion, without a 
genome – in essence, a protein shell without the ability to replicate and induce a 
viraemia. This takes into account the disadvantages and shortcomings of other vaccine 
types, such as a lack of immunogenicity (sometimes experienced with sub-unit and 
recombinant vaccines) and incomplete activation of some viruses in inactivated 
vaccines. It also cannot revert to virulence due to its lack of (or partial lack of) a 
genome. VLPs have been developed for BTV (Noad & Roy, 2003). 
 
2.6.3 Antiviral Therapy and Prophylaxis 
In many epizootics, emergency vaccination is far from ideal due to the time lag 
between immunisation and the immune response. Some form of antiviral treatment for 
a confirmed, perhaps serotyped, infection would be ideal. Evidence exists that 
suggests that foot and mouth disease viral infections may be treated, but other RNA 
viral infections will have to wait until the disease and the virus are better understood 
(Goris et al., 2008). Treatment at the moment is merely symptomatic and supportive 
(Guthrie, 2008). 
 
2.6.4 AHS in the Global Village and International Control 
The increase in the international movement of horses for the racing and sport horse 
industries has made AHS a very important disease to researchers and animal disease 
control officials across the world (Sakamoto et al., 2000). The movement of horses 
increases the risk of spreading infectious diseases (Archer, 1974). The United States 





million people (Dvorak et al., 2004). An outbreak in the United States would be very 
damaging and distressing. In recent years, the bluetongue virus has been detected in 
increasingly northern regions in Europe, historically free of bluetongue (Mullens et al., 
2004; Vellema, 2008). Presently, AHSV is endemic to sub-Saharan Africa, having 
occasionally spread into regions geographically associated with Africa‟s boundaries, 
rapidly and without warning. The distribution of AHSV is associated with the distribution 
of Culicoides spp. capable of transmitting the disease. C. imicola has expanded its 
range northwards through Europe because of climate change and this is the most 
probable answer to the Bluetongue outbreaks in Europe in recent years (Mellor & 
Hamblin, 2004; Guthrie et al., 2009; Maclachlan et al., 2009). Serious concerns have 
been expressed in a number of news articles published online as to the possibility of 
AHS spreading into Europe as bluetongue did. Horsetalk.co.nz reports that the arrival 
of AHS into Britain would be a „death knell‟ for all forms of equine sport according to 
The Horse Trust (Anonymous, 2007b; Lesté-Lasserre, 2007). With the first case of 
bluetongue in Britain in the latter half of 2007, many consider the arrival of AHS 
inevitable (Anonymous, 2007a). Medreonet, a French Agricultural Research Centre for 
International Development (CIRAD) research unit has been formed to monitor three 
Orbiviruses, including AHS, since the emergence of bluetongue in Europe 
(Anonymous, 2007c).  The importance of a rapid assay for diagnostics becomes 
exceptionally important should an outbreak of AHS occur in a country free of the 
disease and with an equine population 100% naive to the virus. 
 
AHS is considered to be the most important disease of equines to be evaluated when 
moving horses across international borders (Guthrie, 2008). It was first discussed at an 
international conference in 1967 (Ditchfield & Thomas, 1967) and has since featured 
prominently in many related conferences. The OIE has defined a number of zones for 
the control of AHS globally. A „free country‟ is a country where no confirmed infection 
has occurred for the last two years and where no horse has been vaccinated in the last 
year. In a country where the disease is endemic, a free zone may be declared as for a 
free country, and should preferably be delineated by substantial geographic boundaries 
with suitable animal movement controls (OIE, 2007).  
 
In South Africa, after the European Commission Decision in 1997 (97/10/EC), exports 
were allowed to move directly out of the Cape Town Metropolitan area as long as the 





appropriate buffer zones throughout the Western Cape (Figure 2.11). However, this 
has not been foolproof as AHS cases occurred in the controlled area in 1999, 2004 and 
2006 (Parker, 2008). Export of horses from an infected country must take place 
through quarantine stations within the free zone (OIE, 2007). In South Africa, the 
Department of Agriculture has devised a control policy for AHS in line with EU and OIE 
regulations. These policies are laid out in the regulations pertaining to the Animal 
Diseases Act (Act No. 35 of 1984)1. Importantly, it states that all horses, mules and 
donkeys must be vaccinated annually and in the free and surveillance zones of the 
Western Cape, permission must be obtained from the relevant Director of Veterinary 
Services to vaccinate equines. 
 
 
Figure 2.11: South African AHS Controlled Area devised in 2001 for the continued export 
of horses from South Africa (DoA, 2003). 
 
Some of the more salient points with regard to the AHS Controlled Area include (DoA, 
2003): 
 Horses moving into the control zone must be vaccinated by a veterinarian or 
under supervision of the State Veterinarian and 60 days must have elapsed 
between vaccination and movement into the control zone. 
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 Appropriate Health Certificates and Movement Permits must be in order 
 All movement of equines is prohibited into the Control Zone during the height of 
the season, i.e. March to June each year unless they are quarantined for three 
weeks in the Protection Zone. 
 
In countries previously free of the disease, determining the serotype and producing a 
monovalent vaccine is of a priority, should there be an outbreak. A monovalent vaccine 
is the most successful control measure as it results in long-lasting immunity in most 
animals. 
 
In countries/territories where an epizootic of AHS has occurred, the disease has 
successfully been eradicated and declared AHS free. In Morocco, which suffered an 
epizootic following the outbreak on the Iberian Peninsula in 1989, a number of steps 
were taken. Surveillance committees were set up, insect control was initiated at all 
ports of entry from Spain, equine imports were banned, a bank of monovalent vaccine 
was raised and rapid diagnostic assays were bought. Following the first case in 
Morocco, a vigorous vaccination program was started. More than 72% of the equine 
population at risk were vaccinated. Although only 17% of the diagnosed animals were 
reported to have died, all confirmed cases were destroyed. Subsequently, a 
vaccination program continued into 1994, with a reported coverage of 92%. Morocco 
remains free of AHS to this day (Benazzou et al., 2006). 
 
In some spheres of European and American society (where AHS is non-endemic) there 
is a concern that the AHS virus may be used as a biological weapon (Beck, 2003). This 
scenario, whether likely or not, would create the same environment that a naturally 
occurring outbreak would in a non-endemic region. In the author‟s opinion, rapidly 
serotyping and distributing the correct monovalent vaccine is of utmost importance. 
 
After the 2004/2005 outbreak of African horse sickness in South Africa, a task team 
was formed by various role-players of the SA equine industry and it has subsequently 
evolved into the AHS Trust. As part of its mission, the Trust has initiated an extensive 
publicity campaign, is working with national authorities on reporting strategies and 
embarks on regular vaccination campaigns. As part of an ultimate goal, it seeks to 






2.7 AHS in rural, subsistence communities 
One of the major problems in South Africa with regard to the outbreaks is the large 
population of unvaccinated equids living in the rural parts of the country, away from the 
concentrated racing and sport horse communities (Gerdes, 2006). Many of these 
equids (mainly rural subsistence horses and donkeys) are used as traction animals or 
for farming in a variety of activities. A survey of animal traction in South Africa by 
Simalenga and Joubert (1997) defines animal traction as the use of animals (including 
donkeys, mules and horses) to assist farmers: 
 in agriculture (e.g. ploughing, harrowing, planting, ridging, weeding, mowing 
and harvesting); 
 in transport, for pulling carts and loads over a surface, logging and carrying 
loads (pack animals); 
 in irrigation, for driving water-pumps and pulling water from wells; 
 in the building industry, for assisting in earth moving for road works, for carrying 
bricks, etc.; 
 to provide power for the operation of stationary implements such as threshing 
machines, grain mills and food processing machines. 
 
It is estimated that over 100 million equines are still used and relied upon for draught 
and transport in subsistence agricultural communities around the world. Despite the 
enormous role that these equines play in their communities, little attention is given to 
health and welfare of these animals and veterinary authorities largely ignore these 
populations that may play an important role in endemic and non-endemic situations of 
AHS (El Idrissi & Lubroth, 2006). 
 
In an earlier survey carried out in 1994, it was established that in the rural areas of the 
South Africa, 40 to 80 % of the smallholder farmers visited were using animal power for 
transport and cultivation. Simalenga and Joubert (1997) pointed out numerous benefits 
of using equids in animal traction, chief among them being their low cost and versatility 
compared to cattle. The result of the above is a large number of equids being used in 
rural areas for small-scale, subsistence farming (Segwagwe et al., 2000), with most, if 
not close to all, animals being unvaccinated against AHS. When an outbreak occurs, 






It has been recognised, particularly in eastern Africa, that community involvement in 
animal disease control provides an effective channel through which rural, subsistence 
communities can be reached. Vaccinations and diagnostics can be performed by 
community based health care workers with success (Catley & Leyland, 2001). With 
regard to AHS, communities that rely on horses, mules or donkeys should be targeted 
in order that a more effective national campaign to control AHS might enjoy more 
success. 
 
2.8 Diagnostic Methods for African horse sickness 
Our understanding of AHS depends largely on accurate diagnostics and the type of 
assay used. Field diagnosis is limited to clinical symptoms. The diagnosis of trans-
boundary diseases, such as AHS becomes particularly important as the diagnosis will 
significantly effect the export/import status of that country or region (Rodriguez-
Sanchez et al., 2008b). Laboratory diagnosis of AHS is essential due to its notifiable 
status and should be confirmed by isolation or identification of the actual virus (OIE, 
2004a). Usually this can be achieved through whole blood collected in the presence of 
an anti-coagulant or samples of the spleen, lung, lymph nodes or salivary glands 
(Mellor & Hamblin, 2004; OIE, 2004a). In turn, due to the multi-serotype nature of the 
virus, diagnostic assays may go further than a simple positive or negative result to 
serotype the virus. 
 
2.8.1 Antibody Identification / Serological Tests 
A number of diagnostic assays have been developed to detect group specific 
antibodies, mainly against VP7 (Segment 8) due to its highly conserved nature across 
all nine serotypes (Roy et al., 1994). The main tests used locally and globally are 
complement fixation, agar gel immunodiffusion, immunofluorescence and enzyme-
linked immunosorbent assays (ELISA) (Williams, 1987; Hamblin et al., 1990; House et 
al., 1990; Hamblin et al., 1991; OIE, 2004a). To detect serotype specific antibodies, 
serum neutralisation tests (SNT) are available (Blackburn & Swanepoel, 1988; House 
et al., 1990). SNTs are applied mainly in epidemiological surveillance and transmission 
studies (Mellor & Hamblin, 2004). Although VP7 may be desirable for serological 
detection due to its conserved nature, anti-VP7 antibodies are only formed 15 days 





markers to be detected are against VP5 followed by VP6 and NS3; VP6, however, 
appears to be well conserved across orbivirus species (Martinez-Torrecuadrada et al., 
1997) 
 
The OIE prescribed test for international trade for AHS is the indirect ELISA. OIE 
Reference Sera exist in order to standardise the test and are held by the OIE 
Reference Laboratories. In South Africa, this laboratory is located at the Onderstepoort 
Veterinary Institute (OVI) (OIE, 2004a). Recombinant VP7 is the antigen of choice due 
to its stability, lack of infectivity and highly conserved nature (Roy et al., 1994). Using 
VP7, the tests are also highly sensitive and specific (OIE, 2004a). An indirect ELISA 
using NS3 as the antigen was developed by Laviada et al. (1995) to distinguish 
between circulating antibodies produced because of vaccination or infection. However, 
inactivated monovalent vaccines were used. This does not apply to the polyvalent 
vaccines produced by OBP in South Africa. 
 
Immunoblotting (Western Blotting) involves the separating of viral proteins by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferring 
them to a nitrocellulose membrane. The nitrocellulose membrane is subsequently 
incubated in the test sera and then enzyme-conjugated immunoglobulins and positive 
bands are revealed using the appropriate substrate. When compared to positive and 
negative controls, two or more bands that correspond to bands on the positive control 
can be regarded as a positive result (OIE, 2004a). 
 
Complement fixation (CF) is the second assay recognised by the OIE as a prescribed 
test for international trade. CF is being used less and less today because of the high 
sensitivity and specificity achieved with the ELISA tests. It is often used for the 
detection of group-specific antibodies to AHSV (OIE, 2004a). 
 
Virus neutralisation is the OIE‟s choice for serotyping and the method is based on the 






2.8.2 Antigen Identification / Identification of the Virus 
Haemagglutination 
One of the first methods used to identify viruses is the haemagglutination assay and 
uses erythrocytes of avian or mammalian origin to agglutinate with viral particles, giving 
a directly visualised diagnosis of the presence of a virus or not (Hierholzer & Suggs, 
1969; Hierholzer et al., 1969). 
 
Viral isolation 
The gold standard for identifying AHSV is viral isolation and this represents the only 
way of positively identifying an active infection (Koekemoer et al., 2000). Virus isolation 
has been the traditional choice for the successful identification of orbivirus species 
(Eaton & White, 2004). Viral isolations can be achieved using baby hamster kidney 
cells (BHK21), African green monkey (Vero) or monkey kidney (MS) cells (Erasmus, 
1963; Ozawa et al., 1965; Ozawa & Bahrami, 1966; Mellor & Hamblin, 2004; OIE, 
2004a). Hamster kidney cells were the first reported cells used for the tissue culture of 
AHSV (Erasmus, 1964). According to Mellor & Hamblin (2004), intracerebral 
inoculation of suckling mice (1-3 days old) is the preferred method today. If the mice 
develop neurologic symptoms within 3-15 days post-infection, the result is positive. A 
second passage must be performed using the initial mice‟s brains, homogenised and 
again inoculated intracerebrally to result in 100% infectivity in an incubation period of 2-
5 days (Eaton & White, 2004; OIE, 2004a). Embryonated chicken eggs can also be 
used successfully (Erasmus, 1964; Mellor & Hamblin, 2004; Paweska, Personal 
Communication). It has, however, been reported that viral isolation may not be possible 
in less severe forms of the disease or strains that produce mild symptoms (Mellor & 
Hamblin, 2004). Transport and storage conditions also appear to affect the viability of 
the virus for isolation. For best results, inoculation of the cell cultures should happen 
immediately after collection of the virus. Viral isolation may also prove more difficult 
when the strain is less virulent (Sailleau et al., 1997). 
 
Enzyme-linked immunosorbent assay (ELISA) 
An ELISA has also been developed that is very useful and rapid in identifying AHS viral 
particles in tissue samples from dead animals. Antigen is detected using two „sandwich 
ELISAs‟ with polyclonal or monoclonal antibodies (Hamblin et al., 1991; Laviada et al., 





are noted for their high sensitive and specificity, with the added advantage that the 
results are available in 2-4 hours (Rubio et al., 1998). Chicken egg yolk antibodies 
(IgY) have also been successfully used in a double-antibody sandwich setup to detect 
all nine serotypes (du Plessis et al., 1999). The protocol is available from the OIE 
Manual (OIE, 2004a) and uses a biotin-avidin/peroxidase system for detection. 
 
Virus Neutralisation (VN) 
Serotyping the virus has important epidemiological functions. Virus Neutralisation (VN) 
is the traditional test (Howell, 1962; Mellor & Hamblin, 2004). However, this very 
tedious and time-consuming procedure will take at least five days for a result, often up 
to two weeks, in order to grow up the respective cells. VN requires live, replicating 
virions and uses mammalian cells or suckling mice (Hazrati & Ozawa, 1965).  
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Other means of identifying the virus include the reverse transcription-polymerase chain 
reaction (RT-PCR). Infectious disease diagnosis has been revolutionised by PCR-
based molecular detection systems (Eaton & White, 2004). Various PCR assays have 
been developed since the mid-1990‟s for AHSV. The first RT-PCR assay was 
developed in 1993 and used primers to amplify segment 5 (NS1) from an attenuated 
strain in Vero cells (Mizukoshi et al., 1994). Other protocols used group-specific 
primers for either VP3 (Sakamoto et al., 1994) or VP7 (Zientara et al., 1995b). The OIE 
recommends the protocols developed by Stone-Marschat et al. (1994), Zientara et al. 
(1994) and Laviada et al. (1997) which amplify the NS2 gene. As AHSV is a dsRNA 
virus, reverse transcriptase-PCR (RT-PCR) must be performed where the RNA is 
reverse transcribed to complementary DNA (cDNA) first, followed by the amplification 
process. RNA is isolated using either the phenol : chloroform method or a commercial 
kit can be used as successfully. The OIE Manual contains the particulars for the PCR 
reaction. Zientara et al. (1995a) was able to partially differentiate the nine serotypes 
using restriction patterns following PCR amplification of Segment 10. In 2000, the first 
RT-PCR to distinguish all nine serotypes was developed, amplifying sequences from 
Segment 2 (VP2), the most serotype specific segment. According to the OIE Manual of 
Diagnostic Tests and Vaccines for Terrestrial Animals, the results showed a perfect 
correlation with a virus neutralisation test. However, nine pairs of primers were used in 





and time-consuming. Molecular probes have also been used in conjunction with RT-
PCR (Moulay et al., 1995). 
 
PCR has additional advantages in that it can detect the virus during the early stages of 
viraemia and in samples that have been poorly preserved, unlike viral isolation 
techniques (Sailleau et al., 1997). Some caveats exist when performing PCR on blood 
samples. It has been reported that PCR may be inhibited by components of haem, and 
anti-coagulants such as heparin and EDTA although in studies of PCR on other 
organisms this was not found to be the case (Holodniy et al., 1991; Barker et al., 1992). 
Washing the blood samples at least twice appears to eliminate the inhibitory effects 
previously described (Sailleau et al., 1997). Sailleau et al. (1997) further reports that 
PCR achieves results in less than 24 hours as opposed to the more traditional viral 
isolation methods where it may take up to 15 days for a positive result in less virulent 
strains. 
 
PCR is now routinely used in most diagnostic laboratories. In these settings, sample 
volume and cost become a priority. Multiplex PCR provides the answer by allowing 
more than one target sequence to be amplified simultaneously. However, the 
optimisation of multiplex PCRs can be complicated. In terms of diagnostic virology and 
differential diagnosis, multiplex PCR has many obvious advantages as a rapid and 
convenient screening assay, especially when considering multiple products (Rachlin et 
al.; Henegariu et al., 1997; Elnifro et al., 2000). 
 
2.8.3 Differential Diagnosis 
It is important to distinguish AHS from other similarly presenting diseases as their 
consequences differ greatly. AHS shares many of the clinical signs and symptoms that 
are seen in the closely related Orbivirus, equine encephalosis virus (EEV). The 
diseases have similar epidemiological patterns and occur simultaneously in South 
Africa, both being vectored by Culicoides, although mortality is higher for AHS (Coetzer 
& Erasmus, 1994; Lord et al., 2002; Venter et al., 2002; Mellor & Hamblin, 2004). 
AHSV and EEV may also occur simultaneously in the same animal (Mellor & Hamblin, 
2004; Howell, Personal Communication). A standardised test must be used to confirm 
either diagnosis. An indirect sandwich ELISA has been developed to indentify EEV 





determine the presence of AHS virus to determine whether a co-infection is present. In 
addition, the transmission dynamics of these two closely related viruses are not fully 
understood and additional data on their outbreak will assist in comprehending the 
geographical variation in transmission (Lord et al., 2002) 
 
Other differential diagnoses for AHS include babesiosis, purpura haemorrhagica, 
equine viral arteritis, equine infectious anaemia and equine morbillivirus pneumonia 
(OIE, 2004a). Purpura haemorrhagica and equine viral arteritis share similar symptoms 
to the pulmonary form of AHS (Coetzer & Erasmus, 1994). 
 
2.9 Proposed Research Methodology 
2.9.1 Research Methods  
An accurate and rapid diagnosis of equine infectious diseases has always been a 
priority for researchers and veterinarians alike throughout the ages. An early detection 
of the causative agent has immediate benefits that includes applying the correct 
treatment regime for the animal, notifying authorities in the case of notifiable diseases, 
implementing suitable control measures to prevent further spread of the disease and 
possibly using advanced targeted treatment strategies. The last two decades have 
seen a shift in the pursuit for rapid diagnostics from classical microbiology to molecular 
biology based techniques, such as nucleic acid detection, particularly the polymerase 
chain reaction (PCR). The applicability of PCR has increased dramatically by the 
advent of real-time or quantitative PCR (Desmettre, 1999; Powell, 2000; Wolk et al., 
2001; Pusterla et al., 2006). 
 
2.9.2 Propagating the AHS virus 
Various methods have evolved that aim to multiply viruses to sufficient quantities so 
that they may be studied. Most viruses can now be propagated using artificial cell 
culture methods. Another method that was popular before the advent of cell culture 
was propagation in embryonated chicken eggs (ECE) that provided a sterile vessel for 
a virus to multiply. Both ECE and cell culture also provide the means to perform viral 
isolations for various diagnostic assays (Eaton & White, 2004). Newcastle disease 
virus of chickens is still isolated using ECE (Bouzari & Spardbrow, 2006; Maharaj, 





via the intravascular route and is reported to be more sensitive than cell culture 
(Hosseini et al., 1998; Clavijo et al., 2000). The equine influenza virus and the swine 
influenza virus (single-stranded RNA virus) have also been found to be more suited to 
propagation in ECE rather than cell culture (Clavijo et al., 2002; Quinlivan et al., 2004). 
In addition, it has been reported that chicken egg yolk has stabilising properties for 
reverse transcriptase reactions and may protect viral particles from freeze-thaw cycles 
(Gazit et al., 1978). 
 
Initially, the AHS virus was successfully propagated in the brains of mice. However, this 
posed some problems in that large numbers of mice needed to be maintained, many of 
the mice would die and it was a labour intensive process. Alternative methods were 
therefore sought, embryonated chicken eggs being one of the early alternatives. 
Goldsmit (1967) successfully inoculated embryonated chicken eggs via the yolk sac 
route and recorded the distribution of the virus between extra-embryonic fluids and the 
embryo itself. The head contained the highest titre of both the neurotropic (Serotypes 
1, 2, 3, 4, 5 and 6)  and viscerotropic strains (Serotypes 7, 8, 9), while  the viscerotropic 
strain was more widely distributed throughout the embryo and extra-embryonic fluids 
(Howell, 1962; Goldsmit, 1967). 
 
Cell culture methods using monkey kidney cells (such as Vero cells) were developed in 
the 1960‟s (Ozawa et al., 1965; Ozawa & Bahrami, 1966; Hazrati & Ozawa, 1968; 
Mirchamsy & Taslimi, 1968; Breese & Ozawa, 1969) and are currently the most 
popular. 
 
2.9.3 Overview of the Polymerase Chain Reaction (PCR) 
PCR is an in vitro cyclical method of rapidly amplifying nucleic acids. The basic 
components of PCR are two primers, a mixture of all four deoxynucleotides (dATP, 
dTTP, dGTP and dCTP), a heat-stable polymerase and a suitable buffer. In the 
simplest of terms, double stranded DNA is denatured, the primers anneal specifically to 
the DNA, a polymerase lengthens the sequence and the cycle begins again. All the 
steps are temperature dependent and each PCR must be optimised for this. Usually, 
the amplified nucleic acids are resolved in agarose gel and stained using ethidium 







Figure 2.12: Simplified overview of the polymerase chain reaction.  
(1) The parental strands are denatured at 94-96°C. (2) Primers anneal to the single 
strands at a calculated, specific temperature. (3) The DNA polymerase elongates the 
sequences at 72°C. (4) The resulting DNA strands form the template for the next round of 
amplification. (Rice, 2009). 
 
2.9.4 Advantages and Disadvantages of PCR 
Advantages 
 Identification of slow-growing, difficult-to-cultivate or non-cultivatable organisms 
(Pusterla et al., 2006). 
 Clinical situations where conventional microbiology is inadequate, time-
consuming or labour-intensive (e.g. cell culture), difficult or hazardous (Pusterla 





 The rapid output of PCR results provides a means of limiting the spread of 
highly contagious pathogens (Pusterla et al., 2006). 
 Results available in less than 24 hours (Stone-Marschat et al., 1994) 
 
Disadvantages 
 Viewing PCR products using gel electrophoresis in conventional protocols 
carries an inherent risk of product carryover from the 'master mix' leading to 
false positives (Pusterla et al., 2006). 
 The high sensitivity of PCR involves the risk of false positives (Stone-Marschat 
et al., 1994) 
 
Alternatives to PCR for nucleic acid amplification exist, and include, among others, 
loop-mediated isothermal amplification (LAMP) (Notomi et al., 2000; Rodriguez-
Sanchez et al., 2008b). This novel method has as its primary advantage, static 
temperature ranges for its amplification process whereby various chains of stem loop 
structures are produced. As a result, only basic laboratory equipment is required. 
 
2.9.5 Reverse Transcription PCR (RT-PCR) 
RNA cannot be used as a template under standard PCR conditions. It must first 
undergo a transcription process to convert the RNA stands into complementary DNA 
(cDNA). This is usually achieved by a preliminary step involving a reverse 
transcriptase. From this point on, PCR continues as normal. In single tube, one-step 
RT-PCR protocols, the synthesis of cDNA and PCR occur sequentially but 
uninterrupted (Lee et al., 1994). In most RT-PCR reactions, a reverse transcriptase is 
used to transcribe RNA into DNA and then a DNA polymerase synthesises the DNA 
amplicons. However, should an enzyme be available that will perform both functions, 
the entire procedure becomes many times simpler. The Tth DNA polymerase is an 
enzyme that has been successfully used to detect small quantities of mRNA. Tth DNA 
polymerase has an inherent reverse transcriptase activity and has also been reported 
to be able to work directly without time-consuming RNA isolation steps either 
(Chiocchia & Smith, 1997). In addition, Tth DNA polymerase was shown to work in the 






2.9.6 Using RT-PCR to detect AHS 
A number of researchers have developed PCR assays to detect the AHS virus since 
the early 1990‟s and a brief overview of their experimental designs and differences are 
described below. 
 
2.9.6.1 Isolation of AHSV genomic material 
The double stranded RNA genome of the AHS virus that is the target of a PCR would 
ordinarily need to be isolated from the virus structure and surrounding biological 
components. In some cases it may be possible to perform a PCR on crude samples 
which would drastically reduce the cost of the test (Watson, Personal Communication). 
Stone-Marschat et al. (1994) purified viral dsRNA from infected Vero cell lysates  by 
phenol extraction and lithium chloride precipitation based on the method of Clarke and 
McCrae (1981).  Zientara et al. (1995b) isolated total RNA from cell cultures and spleen 
tissue samples using the guanidinium-thiocyanate-phenol-chloroform method of 
Chomczynski & Sacchi (1987). Commercial kits based on this method are now 
available such as the TRIzol™ group of reagents (Rodriguez-Sanchez et al., 2008a). 
The quantity of AHSV genomic dsRNA can be determined spectrophotometrically at 
260 nm (Wade-Evans et al., 1990).  
 
In terms of field samples, it has been reported that the AHS viral genome was 
successfully extracted and purified from clotted blood. This has the potential to reduce 
costs further since special blood collection vials containing anti-coagulants may no 
longer be needed (Fasina, 2008; Fasina et al., 2008). In addition, direct PCR from 
whole blood may be possible by modifying the initial denaturation steps (Mercier et al., 
1990; McCusker et al., 1992). 
 
However, the possibility exists to eliminate viral RNA extraction procedures by using 
specially prepared filter paper (FTA® cards). In 1997, this was achieved with the 
Human Immunodeficiency Virus (HIV) Type 1. In addition, RNA levels on the filter 
paper had not decreased after two weeks at 20°C and three days at 37°C. This has 
important consequences for field studies and the development of field applicable 
diagnostic assays (Cassol et al., 1997). FTA cards have also been examined and for 
their ability to inactivate pathogens and for their storage ability and stability of nucleic 





Nassuth, 2005; Purvis et al., 2006). In 2007, real-time RT-PCR was performed on RNA 
porcine reproductive and respiratory virus using FTA® cards (Inoue et al., 2007). By 
using a higher pH PCR buffer, Bu et al. (2008) were able to amplify genomic DNA 
directly from blood that had dried on the filter paper. This has an enormous potential to 
reduce costs involved in such diagnostic assays, as expensive reagents to extract 
genomic material will no longer be needed. 
 
The extraction of viral RNA from the OBP manufactured freeze-dried vaccines may 
also be necessary. This has been achieved previously, albeit with an avian dsRNA 
reovirus (Bruhn et al., 2005) 
 
2.9.6.2 Selection of primers 
Short, complementary DNA sequences, or oligonucleotides, designed to anneal to 
target DNA are termed primers. Primers are selected to amplify a specific sequence. 
There is a variety of software programs available that choose the most appropriate 
primers for a sequence such as the free, internet-based Primer3 (Rozen & Skaletsky, 
2000) and Primaclade (Gadberry et al., 2005). There are a few general characteristics 
of primers that should be adhered to (Rybicki, 2001): 
 The primers should be between 17-28 nucleotide bases in length 
 The composition of the guanidine and cytosine (GC) bases should be 50-60%  
 The 3′ end of the primer should end in a guanidine or cytosine. Guanidine and 
cytosine are joined by three hydrogen bonds and are therefore stronger than 
the double hydrogen bonds of an adenine-thymine pairing.  
 The melting temperatures should be between 55-80°C  
 A series of three or more Gs or Cs at the 3′-ends of primers should be avoided. 
As they are more stable, they may mis-prime at G or C-rich sequences 
 Complementary 3′-ends of primer pairs should be avoided. This may result in 
primer dimers forming  
 Primers that contain self-complementary regions will form secondary structure 
and be prevented from annealing  
 
Previous workers have selected a range of sequences from different genome 
segments of the AHSV. The NS2 gene was used in the first PCR published to detect 





serogroup, but was divergent enough among serogroups not to detect other 
Orbiviruses. A single-tube RT-PCR was developed targeting regions on the VP7 and 
NS3 gene a year later and all nine serotypes were detected (Zientara et al., 1995b). 
Following on from that work, the NS3 gene (Segment 10) was used to differentiate the 
nine serotypes using restriction fragment length polymorphism (RFLP). This novel 
method used restriction enzymes that hydrolysed the amplified regions resulting in 
specific, unique patterns on agarose gels (Zientara et al., 1995a). In 1997, VP7 was 
targeted again, coupled with a dot-blot hybridisation technique (Sailleau et al., 1997). In 
2000, all nine serotypes were individually identified using 15 different primers in 
different combinations, but in nine separately optimised PCR runs (Sailleau et al., 
2000). In South Africa, the first PCR assay was developed in 2004. It serotyped the 
virus using 16 primers under identical reaction conditions (Koekemoer & van Dijk, 
2004). However, it required lengthy post-PCR analysis. Rodriguez-Sanchez (2008a) 
used the NS1 gene as a target and combined it with gel-based techniques. Most 
recently, the VP7 gene was used to develop an assay for AHS coupled with probe-
based technologies (Fernández-Pinero et al., 2009). 
 
2.9.6.3 cDNA synthesis 
PCR can only work from DNA templates, as the polymerase used is a DNA 
polymerase. RNA therefore needs to be transcribed into DNA (complementary DNA or 
cDNA). When double stranded RNA is the initial nucleic material, such as is the case 
for the AHS virus, it must be denatured so that cDNA can be synthesised from it. This 
is achieved by either heat denaturation or adding a methyl mercuric hydroxide solution 
to dsRNA material (Wade-Evans et al., 1990; Zientara et al., 1995b) in the presence of 
each primer and incubating at room temperature for 10 minutes. Compared to heat 
denaturation, methyl mercuric hydroxide increases the sensitivity of RT-PCR by ten-
fold (Wilson & Chase, 1993), although heat denaturation is the most often used in 
recent years. The now single stranded RNA can then be combined with a solution of 
each deoxynucleotide triphosphate (dNTP) (i.e. dATP, dTTP, dGTP and dCTP) in a 
suitable buffer and a reverse transcriptase. The solution will then undergo a series of 
temperature changes for example: incubation at 37°C for 1 hour, heated to 95°C for 5 
minutes to denature the reverse transcriptase and chilled on ice for 5 minutes. The 







The cDNA template can now be subjected to standard PCR protocols. One of the OIE 
recommended protocols is as follows: 30 cycles of 95°C for 1 minute, 42° for 1 minute, 
70°C for 2 minutes and followed by 70°C for 10 minutes (Stone-Marschat et al., 1994). 
Articles published recently have tended towards kit-based PCR protocols such as the 
Brilliant® QRT-PCR Master Mix One-Step kit (Rodriguez-Sanchez et al., 2008a), the 
Applied Biosystems GeneAmp Gold RNA PCR core kit (Quan et al., 2008) or the 
Qiagen One Step RT-PCR kit (Fernández-Pinero et al., 2009). 
 
2.9.6.4.1  Real-time fluorogenic RT-PCR 
To overcome the shortfalls of standard PCR, such as the gel-based nature of results 
and the increased time that this takes, Agüero et al. (2008) developed the first real-time 
fluorogenic RT-PCR for AHSV. This method was based on a TaqMan® probe and was 
directed towards Segment 7 of the AHSV genome. The authors claimed a 1000-fold 
increase in sensitivity compared to the OIE referenced method. TaqMan® probes are, 
unfortunately, not a cost-effective option. Hybridisation probes have also been used to 
serotype AHS isolates, and are an improvement on virus neutralisation assays 
(Koekemoer et al., 2000). 
 
2.9.6.4.2  Nested RT-PCR 
A nested RT-PCR has been developed with equal sensitivity to the real-time 
fluorogenic RT-PCR described above (Aradaib, 2009). Remarkably, the authors claim 
that the RT-PCR that they describe can detect as little as 0.1 fg of viral RNA, 
equivalent to six viral particles. In terms of a rapid, cost-effective assay, this assay was 
also successfully used directly on clinical samples (blood, lungs, liver, and spleen). 
However, this method involves two PCR reactions that offset the time saved by the 
absence of RNA extraction procedures. 
 
2.9.7 Using RT-PCR to detect other Orbiviruses 
RT-PCR has been used successfully to amplify genomic material from other 
Orbiviruses. These include the bluetongue virus (Aradaib et al., 1998; Johnson et al., 
2000; Billinis et al., 2001; Abdalla et al., 2003; Aradaib et al., 2003a; Aradaib et al., 





2004; Jimenez-Clavero et al., 2006; Monaco et al., 2006); epizootic haemorrhagic 
disease virus (Abdalla et al., 2002; Aradaib et al., 2003a; Aradaib et al., 2003b) and the 
Chuzan and Ibaraki viruses (Ohashi et al., 2004). Importantly the sensitivity of these 
RT-PCR assays compares very favourably to the conventionally accepted norm of 
virus isolation (Abdalla et al., 2002). 
 
In a study done in 1995 on epizootic haemorrhagic disease virus (Orbivirus group), 
PCR assays were already being identified as equal to, if not superior to the 
“cumbersome and time-consuming” virus neutralisation assays (Aradaib et al., 1995). 
 
2.9.8 High Resolution Melt (HRM) Analysis  
High resolution melting was introduced in 2002 through the collaborative efforts of 
academia (University of Utah) and industry (Idaho Technology) to detect genetic 
variations of double stranded DNA (Reed et al., 2007). Various methods have 
previously been developed to detect DNA sequence variation of PCR products. 
However, these involve extra, lengthy processing and separation steps subsequent to 
the PCR run and include additional apparatus (Reed et al., 2007). Gundry et al. (2003) 
described the ability of melting temperatures to distinguish unique variants in a 
homogenous, closed tube procedure performed automatically after PCR. The 
denaturation of double stranded DNA into two separate strands is a fundamental 
property of DNA when subjected to heat (Erali et al., 2008). HRM requires normal PCR 
reagents, a fluorescing dsDNA dye and approximately 10-15 minutes of closed-tube, 
post PCR analysis (Reed & Wittwer, 2004). Reed et al. (2007) considers HRM the 
simplest method of determining sequence variation and recognises its increasing 
popularity. 
 
Historically, DNA melting was monitored by UV absorbance, requiring microgram 
amounts and very slow melting rates. HRM, on the other hand, requires only nanogram 
amounts, provided by PCR products (Reed et al., 2007). Earlier HRM applications used 
primers as well as various probes. However, these proved to be too limiting for routine 
use (Wittwer et al., 2003; Liew et al., 2004). Following standard PCR, which results in a 
high copy number of a purified amplicon, HRM analysis is an advancement of previous 
melting analyses based on DNA denaturation or dissociation. It is based on the release 





or dissociated into ssDNA with increasing temperature (Figure 2.13). The melt curve is 
generated by heating the sample through a range of temperatures as fluorescence 
data is continuously collected. At low temperatures, the dsDNA fluoresces strongly. As 
the temperature is increased, so the dye is released from the dsDNA structures, and at 
a characteristic point, the fluorescence drops rapidly, indicating the dissociation of the 
dsDNA into single strands (the melting temperature of the DNA (Tm)). 
 
 
Figure 2.13: Simplified melt profile demonstrating the release of the fluorescent dye as 
the DNA moves from a double-stranded structure to a single-stranded one. The dye is 
intercalated into the strands of the dsDNA at low temperaures, where it fluoresces 
strongly. As the temperature is increased, so the dsDNA structure begins to dissociate 
into ssDNA and the dye is released and no longer fluoresces. 
 
The characteristic melting of a DNA sequence is defined by the relative stabilities and 
kinetic melting rates that are dependent on sequence length, GC content and 
sequence complementarity, which are unique among genetic variants of the same 
genome segment. Based on this, HRM has a number of applications including mutation 
detection, genotyping and species identification (Gundry et al., 2003; Corbett, 2006; 
Hubbart et al., 2007; Reed et al., 2007). The decrease in fluorescence is measured 
with a high degree of optical and thermal precision and is analysed in silico (Corbett, 
2006). HRM is simple, cost-effective and requires no post-PCR processing such as 
agarose gel electrophoresis. It also compares favourably with other similar, expensive 






Part of the recent success of HRM is the introduction of 3rd generation fluorescent 
dsDNA dyes. SYTO®9 (Invitrogen Corp., Carlsbad, CA), LCGreen® (Idaho 
Technologies, Salt Lake City, UT) and EvaGreen® (Biotium Inc, Hayward, CA) have 
lower toxicity levels than previous, older dyes and, as such, can be used at higher 
concentrations that ensure saturation of the dsDNA. Previous dyes had to be used at a 
lower concentration resulting in low levels of saturation and low sensitivity (Gundry et 
al., 2003; Wittwer et al., 2003; Corbett, 2006). Previous dyes also had a tendency to 
preferentially bind to sequences with a higher melting temperature (Tm) and GC-rich 
regions (Zhou et al., 2004). Older dyes, such as SYBR Green I, had to be optimised 
further when used in standard PCR buffers by the addition of dimethyl sulfoxide 
(DMSO), bovine serum albumin or Triton X-100. In addition, the dye was reported to 
inhibit the PCR reaction without an increase in MgCl2 and interferes in multiplex PCRs. 
SYTO 9 supports PCR in a wide range of applications, produces robust melting curves 
unaffected by DNA or dye concentration and can be used in multiplex PCR reactions 
(Monis et al., 2005). 
 
The sensitivity of HRM is evident in its ability to detect the smallest genetic change 
such as single base changes (single nucleotide polymorphisms, SNPs). In general, the 
greater the number of changes, the easier they are to detect using HRM (Corbett, 
2006; White & Potts, 2006). 
 
HRM is best performed on highly pure PCR products of less than 250 base pairs (bp), 
although 44-304 bp amplicons have been analysed previously (Gundry et al., 2003; 
Corbett, 2006). Amplicons of up to 1000 bp have also been successfully analysed 
using HRM (Reed & Wittwer, 2004) The largest recorded amplicon for HRM application 
has been 1330 bp (Chateigner-Boutin & Small, 2007). The larger the amplicon, the 
lower the resolution as the difference between the sequences decreases. This can be 
overcome to some extent by melting at slower rates at the expense of an extended 
analysis time (Gundry et al., 2003). Additionally, certain sequence motifs, secondary 
structures, localised regions of high or low GC content or repeat sequences can all 
affect the results unpredictably (Corbett, 2006). 
 
An HRM analysis must be preceded by a good quality and accurate PCR, as would be 
a normal real-time PCR assay. This includes the design phase where the target 





has been successfully performed on samples from dried blood spots (Gundry et al., 
2003; Corbett, 2006). 
 
The post-PCR/HRM analysis results are viewed as fluorescence versus temperature 
graphs and mathematical derivatives of this (Figure 2.14). The graphs are normalised 
for each sample by defining linear baselines before and after the melting transition 
(Figure 2.14B). The fluorescence for each acquisition within the sample is calculated as 
a percentage between the top and bottom baselines at the acquisition temperature 
(Figure 2.14C) (Gundry et al., 2003). Normalised curves represent the basic 
interpretation for sequence variation and are based on curve shifting, shape change 
and position (Wittwer et al., 2003). Wittwer et al. (2003) also described fluorescence 
difference as a useful method of differentiation (Figure 2.14D). This allows better visual 
grouping of genotypes. One melting curve is chosen as the reference and the rest are 
plotted against it as a difference. The HRM software now also allows for the automatic 
calling of genotypes with a set confidence interval (Corbett, 2006). 
 
 
Figure 2.14: Variations of the interpretations of the fluorescent data post HRM.  
A) Raw fluorescent data in real-time. B) Normalised fluorescence. C) Temperature shifted 
normalised fluorescence. D) Difference plots of the normalised, temperature shifted data 






In studies that used HRM to detect mutations, DNA sequencing confirmed that normal 
melting curves correlated with normal DNA sequences and abnormal melting curves 
correlated with abnormal DNA sequences (Willmore et al., 2004). In a study performed 
in 2004, large sequence differences were found to be detectable by HRM analysis 
(Vaughn & Elenitoba-Johnson, 2004). Previously, only single point mutations had been 
studied. Using HRM analysis, amplicons of 335 to 431 bp in length were analysed for 
insertions of 6-102 bp in length. 100% concordance was achieved compared to more 
standard methods such as capillary electrophoresis-based fragment analysis, 
temperature gradient capillary electrophoresis detection and sequencing. HRM 
analysis was also found to be effective at detecting mutations across the length of the 
amplicon, despite the mutations occurring at various positions. 
 
Developing technically simple and reliable methods for detecting sequence variations 
in related genes has become an important goal of molecular diagnostics. Although 
DNA sequencing still remains the “gold standard”, it is significantly labour- and time-
intensive for clinical, routine use (Highsmith, 2004). 
 
Various programs have been developed that have attempted to produce melt curves 
entirely in silico, such as POLAND and MELTSIM. Although the programs were 
successful in accurately typing the samples, it was suggested that they were best 
suited to assay design (Rasmussen et al., 2007). 
 
2.9.9 Species differentiation using HRMA 
A review of the literature pertaining to HRM applications will reveal that most HRM 
applications have sought the detection of single point mutations. Genotyping was 
achieved in platelet antigens using unlabelled probes and HRM (Liew et al., 2006). 
However, in 2006, Robinson et al. (2006) successfully and reproducibly differentiated 
between species of the amoebaflagellate genus Naegleria using a single primer set. 
The sequences amplified were almost invariant in individual species, but divergent 
among species. The melting curves that resulted were distinguishable and unique for 
each species due to the differences seen in the positions and relative heights of the 
peaks (Figure 2.15). Feline caliciviruses (Helps et al., 2002), Cryptosporidium species 
(Limor et al., 2002; Tanriverdi et al., 2002), Leishmania species (Nicolas et al., 2002), 





and Camphylobacter jejuni (Price et al., 2007) have also all been successfully species-
differentiated using HRMA. 
 
 
Figure 2.15: Melt curves obtained from Naeglaria species using HRM demonstrating 
unique positions and relative heights of peaks between the species. Each graph 
represents (Robinson et al., 2006) 
 
HRM analysis has been used to detect and identify 25 clinically important bacteria 
(Cheng et al., 2006). As little as 1 pg of bacterial DNA was detectable. In addition, 
there appears to be little difference in the melting curves of DNA amplified from 
bacteria and bacterial suspensions. 25 bacterial species were studied, nine of them 
being identifiable from their characteristic melting curves. The remaining 16 species 
were grouped into four melting groups for further assessment. Twelve of these species 
were identified through a heteroduplex formation with a chosen reference species and 





subjected to a second real-time PCR using a modified primer pair. All the species were 
able to be identified via their unique melting curves except two whose curves were 
undistinguishable. 
 
More recently, HRM was used to distinguish Bacillus anthracis species using LC 
Green® I (Fortini et al., 2007). In this study, while it was suggested that DNA 
concentration and quality were key factors in reproducible melting curves, it was found 
that by reducing the amount of DNA intercalating dye by half, the melting curves 
became more reproducible. 
 
In 2009, the use of HRM combined with a unique mathematical model was used to 
differentiate strains of infectious bronchitis virus (IBV) on  230-436 bp products such 
that the most effective vaccination program could be applied (Figure 2.16). Rapid 
control of IBV outbreaks was mooted as a potential application of this assay (Hewson 
et al., 2009). 
 
 
Figure 2.16: Conventional melt curves of various wild-type and vaccine strains of IBV 
(Hewson et al., 2009) 
 
Also in 2009, Chlamydophila psittaci species and Bartonella spp. were genotyped 
using HRM analysis (Mitchell et al., 2009; Morick et al., 2009). 
 
In addition to species differentiation, characterisation of isolates has also been 
performed for the poultry pathogen Mycoplasma synoviae. Amplicons of approximately 





authors claimed that the HRM curve analysis is a „rapid and effective technique that 
can be performed in a single test tube in less than two hours‟ (Jeffery et al., 2007). 
 
2.9.10 HRM Instrument Comparison 
A study by Herrmann et al. (2006) compared the available instrumentation for DNA 
amplicon melting analysis. Nine instruments were compared, namely, the Prism® 7000 
SDS and 7900HT (Applied Biosystems), iCycler iQ (Bio-Rad), SmartCycler® II 
(Cepheid), Rotor-Gene™ 3000 (Corbett Research), LightScanner® (Idaho Technology), 
HR-1™ (Idaho Technology) and the LightCycler 1.2 and LightCycler 2.0 (Roche). The 
Corbett Rotor-Gene™ 3000 (and its successor, the Rotor-Gene™ 6000) approaches 
HRM slightly differently to other machines. Melting is performed at a much slower rate 
such that the melting is performed step-wise, enabling more data points per second to 
be acquired and for the fluorescence to normalise before each reading. However, this 
does increase the noise ratio (Herrmann et al., 2006; Reed et al., 2007). It is also 
important to note that this study remains the only instrument comparison available. 
 
2.9.11 HRM and probes 
Melt curves can, however, be complicated to analyse and distinguish between closely 
related genotypes. The addition of unlabeled probes to the reaction mixture may 
provide additional information. The melt analysis will now include both the amplicon 
melting and the probe melting in two distinct phases. The probes are blocked at the 3‟ 
end and the PCR is run in an asymmetric fashion such that there is a limiting primer 
and an excess primer (Figure 2.17) (Graham et al., 2005; Montgomery et al., 2007; 






Figure 2.17: Asymmetric PCR with amplicon and unlabelled probe melting.  
A) In asymmetric PCR, strand W is produced in excess while strand C is produced in a 
limited fashion. The excess strand W’s are hybridised with the unlabelled probe and 
subsequently melted off. Strand C produces undergoes standard PCR reactions and 
produces full-length amplicons that are melted with the unlabelled probes. B) Both probe 
and amplicon melts are seen distinctly on the melt analysis (Erali et al., 2008). 
 
Real time RT-PCR and melt curve analysis were used to serotype the AHS virus in 
2008 using Segment 2. However, it involved nine pairs of hybridisation probes and 
displayed some peak melting temperature shifts. Ultimately, it was found that this 
method was far from ideal for serotype detection and could not be regarded as a rapid 
and cost-effective assay. In addition the data did not appear to be statistically 
interrogated, nor was the possibility of targeting alternate regions discussed 






2.10  Conclusion 
African horse sickness has long plagued the equines inhabiting Southern Africa. The 
often-elite profile of sporting and racing horses tends to encourage the sidelining of 
rural subsistence and traction animals and those who rely on them. AHS may have 
socio-economic consequences for rural communities, but this has yet to be assessed. 
The high cost of research has led to a dearth of work being done in the field of AHS 
and the current knowledge about AHS is somewhat lacking in many respects. In order 
to counter this, rapid, cost-effective assays are crucial to enable a greater 
understanding of the disease, its epidemiology and its control. The assay that is 
proposed will provide a unique method for rapid serotyping of the African horse 
sickness virus.  
 
The development of this assay, however, requires that certain preliminary 
investigations be carried out. These include the design of particular primer pairs, the 
propagation of the AHS virus, viral RNA extraction and the analysis of HRM curves 











In terms of preliminary investigations for a rapid assay, known viral stocks are required 
from where copious amounts of RNA would be readily available. The extraction of viral 
RNA from inoculated ECE remains a common method, but is a laborious process with 
many extraneous circumstances. Cell culture represents the modern alternative in that 
it is quick and controlled. Propagating the AHS virus in monkey kidney cells, MS and 
Vero cultures have been reported as early as the 1960‟s (Ozawa et al., 1965; Ozawa & 
Bahrami, 1966; Hazrati & Ozawa, 1968; Mirchamsy & Taslimi, 1968; Breese & Ozawa, 
1969). The Vero cell line (Figure 3.1) originated from the kidney of an African green 




Figure 3.1: Micrograph of a high density monolayer of Vero cells cultured in EMEM 
containing 10% FBS (after ATCC, 2009). 
 
The AHS virus was initially propagated successfully in the brains of mice. However, this 
posed some problems in that large numbers of mice needed to be maintained, many of 
the mice would die and it was a labour intensive process. Alternative methods were 





therefore sought, embryonated chicken eggs being one of the early alternatives. 
Goldsmit (1967) successfully inoculated embryonated chicken eggs via the yolk sac 
route and recorded the distribution of the AHS virus between extra-embryonic fluids 
and the embryo itself. The head contained the highest titre of both the neurotropic 
(Serotypes 1, 2, 3, 4, 5 and 6) and viscerotropic strains (Serotypes 7, 8, 9), while the 
viscerotropic strain was more widely distributed throughout the embryo and extra-
embryonic fluids. All serotypes, however, were distributed throughout the embryo and 
extra-embryonic fluids (Howell, 1962; Goldsmit, 1967). The extra-embryonic fluids 
(particularly the yolk sac) are the easiest to inoculate and harvest. The embryo will 
require specialised, trained personnel to inoculate and requires extra steps for 
harvesting (Taylor, 1952; Boorman et al., 1975; Kelling & Schipper, 1976; Clavijo et al., 
2000) 
 
Where laboratories are not equipped to deal with specialised cell culture techniques, 
embryonated chicken eggs (ECE‟s) provides a valuable alternative for the propagation 
of AHSV. ECE‟s provide a sterile vessel for a virus to multiply. Newcastle disease virus 
(Bouzari & Spardbrow, 2006; Maharaj, Personal Communication), bluetongue virus 
(Hosseini et al., 1998; Clavijo et al., 2000), equine influenza virus and swine influenza 
virus (Clavijo et al., 2002; Quinlivan et al., 2004) are still isolated using ECE. In 
addition, it has been reported that chicken egg yolk has stabilising properties for 
reverse transcriptase reactions and may protect viral particles from freeze-thaw cycles 
(Gazit et al., 1978). 
 
Additionally, in the absence of AHSV reference strains, virus can theoretically be 
obtained from the Onderstepoort Biological Products (OBP) manufactured AHS 
vaccine. Isolated virus preparations are required to produce PCR products, as can be 
easily obtained from inoculated ECE. This protocol was tested on vaccine live, 
attenuated virus produced by OBP to provide virus for RNA extraction and RT-PCR 
using TRIzol® (Invitrogen, Carlsbad, USA) as the industry standard. In order to study 
particular AHSV genome segments, original reference strains of the AHS virus were 






3.2 Materials and Methods 
3.2.1 Embryonated Chicken Egg Inoculation and Harvesting 
Inoculation and harvesting work was carried out at the Allerton KwaZulu-Natal 
Provincial Veterinary Laboratory in Pietermaritzburg and was based on the work of 
Boorman et al. (1975). Ethics approval was obtained through the University of 
KwaZulu-Natal Animal Ethics committee. AHS vaccine vial 1 (Batch #181) produced by 
OBP and containing live attenuated strains of serotypes 1, 3 and 4 was used in the 
experimental inoculation of 11 specific pathogen free embryonated broiler chicken 
eggs, incubated under standard incubation procedures. 
 
The vaccine contains at least 105 PFU per attenuated, freeze-dried pellet of AHS vial 1 
(OIE, 2004). This was reconstituted with sterile, distilled water to produce dilutions of 
1:2, 1:8, 1:64, such that the embryo survives to propagate the virus (Maharaj, Personal 
Communication). 200 µL of each dilution was inoculated into each egg. The eggs were 
set and incubated at 37°C, 60-65% humidity in an incubator, of which 11 were to be 
inoculated at seven days old. Harvesting of the ECE yolks occurred at 48 hours post-
inoculation. The treatments are shown in Table 3.1. 
 
Table 3.1: Treatment structure for the AHS virus inoculation of 7 day old embryonated 
broiler chicken eggs. 
 
Treatment Dilutions # eggs 
Control no inoculation 1 
Control water only inoculation 1 
Vaccine vial 1  1:2 3 
 1:8 3 
 1:64 3 
   
 
To inoculate the eggs, they were placed air sac up in an egg tray and sterilised with a 
0.01% (w/v) merthiolate solution. An eggshell punch was used to create a hole in the 
shell, without breaking the underlying membranes. Using a 21G, 1½” needle and a 1 
mL syringe, 200 µL of inoculum was injected directly into the yolk sac. The hole was 
sealed with wood glue and the eggs returned to a lower temperature incubator and 






Eggs were checked and candled daily for any deaths. Yolk sacs were harvested at 48 
hours post-inoculation. Three eggs from each vaccine dilution treatment as well as one 
egg each from the control treatments were randomly selected. The eggs were placed 
air sac up on an egg tray and disinfected with a 0.01% (w/v) merthiolate solution 
(Maharaj, Personal Communication). The top of the egg was cracked open with 
forceps. Using the forceps, the embryo was immediately decapitated and removed 
along with the albumin such that only the yolk remained in the shell and it was 
extracted with a needle and syringe and placed in suitable storage vessels and frozen 
at -20°C. All the above procedures were carried out under BSL2 levels. 
 
3.2.2 Vero Cell Culture 
A 2 mL vial of Vero cells (passage #14) was split into 3 T75 flasks (75 cm2) and 10 mL 
growth media added. Growth media contained: 10% foetal bovine serum (FBS) (Delta 
Bioproducts, Johannesburg, RSA); 1% Pen/Strep/Amphotericin B 100x (10,000 U 
penicillin/mL, 10,000 µg Streptomycin/mL, 25 µg Amphotericin B/mL) (Lonza, 
Walkersville, USA); 1% non-essential amino acid (NEAA) mixture 100x (Lonza, 
Walkersville, USA) and 1% L-glutamine (200 mM) (Lonza, Walkersville, USA) in 
Eagle‟s Minimum Essential Medium (EMEM) with EBSS and 25 mM Hepes and without 
L-glutamine. 
 
At passage 20, nine T75 flasks with a confluent monolayer of Vero cells were selected 
for inoculation with the AHS virus reference strains provided in freeze-dried pellets 







Table 3.2: Details of the AHS Virus Reference strains (NICD) for use in Vero cell culture 
for RNA viral isolation. 
 
Serotype Isolate Year of original isolation Year of last isolation 
1 A501  1965 1997 
2 OD 1965 1997 
3 L 1965 1997 
4 Vry 47/58 1965 1997 
5 VH 1965 2000 
6 114 1965 1997 
7 Karen 1965 1997 
8 18/60/22 1962 1998 
9 AHS 9 1995 2000 
 
The reference strains represent the original field virus isolates identified in the 1960‟s 
and are preserved as reference material in Reference Laboratories across the world. 
They also serve to confirm the genetic conservation of the virus through time. The 
reference strains at the NICD were received from Prof PG Howell (University of 
Pretoria) in 2000 who originally obtained the strains from the Onderstepoort Veterinary 
Institute and from the National Institute of Virology. The freeze-dried pellets obtained 
from the NICD are the product of a succession of mouse brain passages, baby hamster 
kidney (BHK) cell culture and Vero cell culture. 
 
The freeze-dried pellets were resuspended in 250 µL of sterile phosphate buffered 
saline (PBS), aliquoted into 50 µL and stored at -70°C. To inoculate a T75 flask, 950 µL 
of growth media was added to a 50 µL aliquot (1:20 dilution) and transferred to a ± 90% 
confluent monolayer of Vero cells. A control flask was inoculated with 1 mL EMEM. The 
flasks were placed in a Gallenkamp Orbital Incubator (60 rpm) for 1 hour at 37°C, 
subsequently were overlayed with 10 mL growth media, and placed back into the 
incubator (40 rpm). Flasks were monitored daily for non-specific cytopathic effects 
(CPE) that involved the cells rounding and lifting off the surface of the flask (Paweska, 
Personal Communication). Flasks showed 90-100% CPE after 5-7 days post-
inoculation and were harvested. The supernatant of approximately 10 mL was poured 
into a sterile 15 mL BD Falcon™ tube (BD Biosciences, San Jose, USA). The tubes 
were centrifuged at 2000 × g for 10 minutes at 4°C in a Beckman-Coulter Avanti® J-





transferred to a new tube and kept at 4°C. The pellet was resuspended in 2.5 mL of 
EMEM and frozen in liquid nitrogen followed by thawing at room temperature. The 
suspension was then subjected to a repeat centrifuge-freeze-thaw cycle. All of the 
supernatants were pooled consecutively and aliquoted into 1 mL volumes. They were 
subsequently stored at -70°C. All work involving the virus was performed according to 
BSL2 safety levels. 
 
3.2.3 AHSV RNA Extraction 
The extraction of viral RNA from the egg yolk and from the cell culture supernatants 
was achieved using TRIzol® LS Reagent (Invitrogen, Carlsbad, USA). Various 
variations to the standard protocol of Invitrogen (Carlsbad, USA) were used to extract 
viral RNA from the egg yolk as the standard protocol  resulted in no RNA being 
extracted (Additional or amended steps for the yolk extraction are shown in italics). 
 
3.2.3.1 Extraction from egg yolk 
3.2.3.1.1 Homogenisation  
250 µL of egg yolk sample and 750 µL of TRIzol® LS Reagent were combined in a 
microcentrifuge tube to achieve a minimum ratio of one part sample to three parts 
TRIzol® LS Reagent. The sample was homogenised by passing several times through 
a Gilson Pipetman® P1000 pipette. The initial yolk sample was diluted 1:1 with DEPC-
water and compared to non-diluted samples (Invitrogen, 2007; Watson, Personal 
Communication). Homogenisation was also achieved using a 21G needle (Watson, 
Personal Communication). 
 
An extra centrifugation step was added after homogenisation to remove any insoluble 
material from the yolk. The homogenised sample was centrifuged at 12,000 × g for 10 
minutes at 4°C. Three phases resulted and all but the top, fatty layer were removed for 
downstream steps (Invitrogen, 2007). 
 
3.2.3.1.2 Phase Separation 
The homogenised samples were incubated for 5 minutes at room temperature (15 to 
30°C). 150 µL of chloroform was added at a ratio of 0.2 mL of chloroform per 1 mL of 





seconds followed by an incubation period of a few minutes at room temperature (15 to 
30°C). The samples were subsequently centrifuged at 12,000 × g for 15 minutes at 4°C 
in an Eppendorf® Microcentrifuge 5415 R. 
 
3.2.3.1.3 RNA Precipitation 
After centrifugation, three layers are apparent: an upper aqueous phase, an interphase 
and a bottom phenol chloroform phase. RNA in the upper aqueous phase was 
removed and transferred to a fresh tube. The RNA was precipitated from the aqueous 
phase by mixing with 375 µL of isopropyl alcohol to achieve a ratio of 0.5 mL of 
isopropyl alcohol per 1 mL of TRIzol® LS Reagent used for the initial homogenization. 
The samples were incubated at room temperature (15 to 25°C) for 10 minutes and 
subsequently centrifuged at no more than 12,000 × g for 10 minutes at 4°C.  
Additionally, pure isopropyl alcohol was compared to a 1:1 mix of isopropyl alcohol and 
1.2 M NaCl (Invitrogen, 2007; Watson, Personal Communication). 
 
3.2.3.1.4 RNA Wash 
The supernatant was poured off and the RNA pellet was washed once with 950 µL 
75% (v/v) ethanol, adding at least 1 mL of 75% ethanol per 1 mL of TRIzol® LS 
Reagent used for the initial homogenization. The sample was mixed by vortexing briefly 
and centrifuged at no more than 7,500 × g for 5 minutes at 4°C. 
 
3.2.3.1.5 Redissolving the RNA 
The supernatant was poured off and the tubes returned to the centrifuge and spun 
down briefly to collect the last drops of ethanol. The tubes were then carefully aspirated 
and the RNA pellet left to air-dry for 5 minutes. The pellet was then dissolved in 40 µL 
of DEPC-treated water and incubated at 55-60°C for 10 minutes. 
 
Standard protocols failed to yield detectable results and it was therefore adjusted to 
include some additional steps: 
 
The additional steps resulted in four different RNA preparations that were compared 
(Table 3.3). In both situations, 4 µL of the extractions with 10 µL of formaldehyde 
loading buffer were run on ethidium bromide (0.5 µg/mL) containing 1.2 % (w/v) 






Table 3.3: Summary of additional procedures in the TRIzol
®
 LS extraction of AHS viral 




 Undiluted yolk as initial sample 
 RNA precipitated with IPA only 
2 
 Undiluted yolk as initial sample 
 RNA precipitated with IPA and 1.2 M NaCl 
3 
 1:1 yolk : water as initial sample 
 RNA precipitated with IPA only 
4 
 1:1 yolk : water as initial sample 
 RNA precipitated with IPA and 1.2 M NaCl 
 
3.2.3.2 Extraction from cell culture 
3.2.3.2.1 1. Homogenisation  
1 mL aliquots for each serotype and control were thawed and transferred to a 15 mL 
Falcon™ tube (BD Biosciences, San Jose, USA). 3 mL of TRIzol® LS was added to 
achieve a 1:3 ratio of sample to reagent. The solution was homogenised by pipetting 
several times.  
 
3.2.3.2.2 Phase Separation 
To achieve the required phase separation, the homogenised samples were incubated 
at room temperature (15-25°C) for at least 60 minutes. 800 µL of chloroform was 
added and shaken vigorously by hand for 15 seconds. The shaken samples were 
incubated again at room temperature for 10-15 minutes and centrifuged at 12,000 × g 






3.2.3.2.3 RNA Precipitation 
The solution separated into a lower red-pink phase, a white opaque interphase and an 
upper clear aqueous phase. RNA remains exclusively in the aqueous phase 
(Invitrogen, 2007). The upper aqueous phase was transferred to a new tube containing 
750 µL of a 1.2 M sodium chloride/0.8 M sodium citrate sterile solution and 750 µL of 
ice-cold isopropyl alcohol. The tubes were inverted several times and incubated at 
room temperature for 10-15 minutes followed by a centrifugation at 12,000 × g for 10 
minutes at 4°C.  
 
3.2.3.2.4 RNA Wash 
The resultant supernatant was discarded and the translucent pellet was washed by 
adding 4 mL of 75% ethanol in DEPC-treated water. The tubes were vortexed for 30 
seconds and centrifuged at 7,500 × g for 5 minutes at 4°C. The supernatant was 
discarded and the pellet and remaining ethanol was aspirated and transferred to a 1.5 
mL micro-centrifuge tube. The tubes were centrifuged at 7,500 × g for 5 minutes at 4°C 
in an Eppendorf® Microcentrifuge 5415 R. The remaining ethanol was carefully 
aspirated and the pellet air-dried for 5 minutes.  
 
3.2.3.2.5 Redissolving the RNA 
The pellet was subsequently re-suspended in 20 µL of DEPC-treated water and 
incubated at 55-60°C for 10 minutes. Absorbance readings were taken on the 




The standard RNA extraction protocol recommended by the TRIzol® manual revealed 
no results, indicating that no viral RNA was extracted from the harvested yolks. 
 
The amended protocol (as indicated by italics above) resulted in the successful TRIzol® 
extraction of RNA from ECE yolk (Figure 3.2). Undiluted egg yolks and the lack of NaCl 
in the precipitation step (Treatments 1 and 3) produced a feint smear towards the 





low molecular weight RNA. The products seen in Figure 3.2 are confirmed to be RNA 






 LS RNA extractions of AHS vaccine inoculated embryonated chicken 
egg yolks using four different treatments. Extractions were performed on 48 hour post 
inoculation egg yolks inoculated with 1:2 dilution of AHS vaccine vial 1 using the 
additional and modified procedures. 2 µL sample + 8 µL formaldehyde-containing loading 
buffer on a 1.2 % (w/v) agarose gel containing 1 µg/µL of ethidium bromide in 0.5× TBE.  
MWM: Fermentas GeneRuler
™
 100 bp Plus DNA ladder. Lane 1: Undiluted yolk, isopropyl 
alcohol precipitation of RNA. Lane 2: Undiluted yolk, isopropyl alcohol and NaCl 
precipitation of RNA. Lane 3: Diluted yolk, isopropyl alcohol precipitation of RNA. Lane 4: 




Figure 3.3: RNase treatment of TRIzol
®
 ECE yolk extractions. TRIzol extracted RNA from 
AHS vaccine vial 1 1:2 dilution inoculated egg yolk showing before and after RNase 
treatments. 2 µL sample + 8 µL formaldehyde-containing loading buffer on a 1.2 % (w/v) 
agarose gel containing 1 µg/µL of ethidium bromide.  
MWM: Fermentas GeneRuler™ 100 bp Plus DNA ladder. Lane 1: RNA before the addition 



















































3.3.2 Vero cell culture 
The nine strains of AHSV were each inoculated into monolayers of Vero cells. The 
cytopathic effects seen were a general rounding of the cells and lifting off the surface of 
the flask. This was visible in all of the inoculations. An example is shown in Figure 3.4 
. 
 
Figure 3.4: AHS inoculated (Serotype 7) Vero cell culture 84 hours post-inoculation. 
Rounded cells have altered refractory properties and appear opaque.  
 
3.4 Discussion 
Two propagation protocols for the AHS virus were evaluated for their relative merits. 
The relatively antiquated ECE protocol required less sophisticated equipment, but was 
laborious and unpredictable. It was compared with a more contemporary cell culture 
system that requires sophisticated equipment, but is more controlled. 
 
Zero mortality in the chicken embryo‟s post inoculation is an indication of the avirulence 
of the AHS vaccine vial 1 and indicates that the vaccine virus can safely be grown in 
chicken embryos. To our knowledge, this is the first report of the inoculation of 
embryonated chicken eggs with a modern, live attenuated vaccine. No literature exists 
outside of the 1950‟s and 1960‟s that refers to growing the modern cell-cultured live 
attenuated vaccine virus in ECE‟s. 
 
The standard procedure offered by TRIzol® manufacturers for the extraction of RNA 






has established itself as an industry standard commercial reagent based on the acid 
guanidinium thiocyanate-phenol-chloroform nucleic acid extraction procedure 
(Chomczynski & Sacchi, 1987). In a direct comparison between TRIzol® and a column-
based technology, Rodriguez-Sanchez et al. (2008a), found that TRIzol® yielded 
consistently more RNA. 
 
Egg yolk is a highly viscous substance and contains many other components and 
extracellular material, which may inhibit the one or more of the steps involved in the 
extraction procedure. A second extraction procedure was devised which contained 
additional steps to counter the nature of the yolk sample. Firstly, the yolk was diluted 
with DEPC-treated water in an effort to reduce the viscosity. Secondly, after addition of 
the required amount of TRIzol®, the mixture was homogenised with a 21G needle that 
exerted greater shearing forces on the cells and generated a homogenous solution. 
The third additional step was to centrifuge the solution before phase separation such 
that a greater amount of the insoluble material could be removed increasing the ratio of 
TRIzol® to the cells. After this centrifugation, four layers resulted: a top white, viscous 
phase; a middle pink phase; a white interphase and a bottom dark pink phase. The top 
layer was reasoned to contain most of the insoluble components due to its viscous 
nature and thus the bottom three layers were removed by aspiration and transferred to 
a new tube and vortexed. The fourth additional step involved creating a 1:1 dilution of 
isopropyl alcohol and 1.2 M NaCl such that the salt could augment the precipitation of 
RNA (Table 3.3). 
 
No RNA was successfully extracted from the egg yolk using the standard protocol. Egg 
yolk contains a number of components that may seriously interfere with the action of 
TRIzol®. The amendment of the TRIzol® protocol (Table 3.3) resulted in RNA 
extractions (Figure 3.2). RNase successfully digested RNA in the egg yolk samples 
(Figure 3.3) to confirm the presence of RNA. 
 
Needle homogenisation and extra centrifugation improved the product of the RNA 
extraction (Figure 3.2). NaCl may, however, result in low molecular weight RNA being 
extracted. (Figure 3.2). The clarity of the gel bands is improved in lanes 2 and 4 where 






The AHS virus has been cultured in Vero cells in a number of studies and the protocol 
is fairly consistent and successful (Paweska et al., 2003; OIE, 2004a; Koekemoer, 
2008; Quan et al., 2008; Rodriguez-Sanchez et al., 2008a; von Teichman & Smit, 
2008; Fernández-Pinero et al., 2009; Guthrie et al., 2009; Paweska, Personal 
Communication). The cultures were ready for harvesting between five and seven days 
post inoculation. Between two and eight days (OIE, 2004a) and between two and four 
days (Paweska et al., 2003) have been reported. TRIzol® LS Regent (Invitrogen, 
Walkersville, USA) is a phenol and guanidine isothiocynate solution based on the RNA 
isolation step developed by Chomczynski and Sacchi (1987) (Invitrogen, 2007). A 2-
step RT-PCR protocol was followed such that a stock of cDNA could be kept. The 
standard protocols of the Quantace SensiMix™ 2-step kit were successfully applied to 
the extraction of AHS viral RNA. Confirmation of the correct size amplicon was 
obtained by 180-182 bp bands visualised on a 1.2% (w/v) agarose gel containing 1 
µg/µL of ethidium bromide in 0.5 × TBE. PCR products were sequenced by Inqaba 
Biotechnical Industries (Pty) Ltd. (Pretoria, South Africa). The control and NTC did not 
produce any product. 
 
3.5 Conclusion 
AHS virus can successfully be grown using Vero cell culture and the RNA extracted 
using TRIzol® LS Reagent. The African horse sickness vaccine virus was also 
successfully propagated in embryonated chicken eggs (ECE) via the yolk sac route. 
Although the intravascular route is recommended for increased yields (Boorman et al., 
1975), it requires a high level of expertise. ECE represents an alternative to cell culture 
techniques but can prove to be complicated due to the nature of the yolk and the 










The African horse sickness virus genome is composed of ten common double-stranded 
RNA segments (Grubman & Lewis, 1992). Only nine serotypes have been discovered 
(Howell, 1962), with two of the segments responsible for the genetic diversity amongst 
the serotypes, namely Segment 2 and 10 (Roy et al., 1994; Venter et al., 2000). 
 
In order to develop an assay that is cost- and time-efficient, the primary goal is to find 
suitable regions across all nine serotypes that are flanked by nearly identical regions, 
but have divergent sequences in between (Figure 4.1) 
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Divergent sequences unique for each serotype 











Figure 4.1: Schematic representation showing the ideal primer design across multiple 
sequences, such as that sought for all of the nine African horse sickness virus serotypes 






Ideally, a single primer pair is used in the final assay. Using more than one primer pair 
in a reaction requires multiple reactions or multiplex PCR and its complications and 
inevitably increases cost factors (Henegariu et al., 1997; Elnifro et al., 2000). 
 
The aim, therefore, when designing primers for this assay, was to select a region that 
was flanked by conserved regions from which primers could be designed, and that 
contains an amplicon region that was divergent among the serotypes, so that they 
would produce significantly different melt curves in the HRM analysis. 
 
The optimal design of a primer will depend on the region to be amplified and the 
flanking regions. However, there exist some common recommendations and 
guidelines. These are outlined as follows (Dieffenbach et al., 1993; Rybicki, 2001): 
 The optimum melting temperature (Tm) should be between 55°C and 65°C, 
although it can be substantially lower or higher, but with consequences for 
specificity and sensitivity. In addition, it must be noted that there are two 
primers per reaction and that the Tm's should be reasonably close to each 
other to aid efficient amplification. 
 The design of primers should avoid any dimersation abilities, viz. the 
primers should not contain complementary regions between themselves 
such that they bind to each other. 
 Individual primers should not contain any complementary regions within 
themselves. This may cause the primers to bind to themselves and form 
„hairpin‟ structures. 
 The target DNA sequence should also be checked to ensure that the primer 
could only bind in one position. 
 The primers should be between 17-28 nucleotide bases in length 
 The composition of the guanidine and cytosine (GC) bases should be 50-
60%  
 The 3‟ end of the primer should end in a guanidine or cytosine. Guanidine 
and cytosine are joined by three hydrogen bonds and are therefore stronger 
than the double hydrogen bonds of an adenine-thymine pairing.  
 A series of three or more Gs or Cs at the 3'-ends of primers should be 






 Complementary 3'-ends of primer pairs should be avoided. This may result 
in primer dimers forming  
 
Many software programs are freely available to design suitable primer pairs. Licensed 
software packages are also available. One of the most commonly used freeware 
programs is Primer3 (Rozen & Skaletsky, 2000). Primer3 is the continuation of a 
software development started in 1991 at the Whitehead Institute and funded by the 
Howard Hughes Medical Institute and the National Institutes of Health. Primer3 
automatically takes into account the above factors to locate the most suitable regions 
for primer binding. 
 
Primer3 is designed to pick a single primer pair for one sequence at a time. As 
mentioned above, the assay depends on the ability to find primers that are common to 
all nine serotypes. Recognising this inadequacy of Primer3, Gadberry et al. (2005) 
designed a web-based application „to find conserved PCR primers across multiple 
species‟. In essence, the program, called Primaclade2 runs a Primer3 analysis on each 
sequence entered and then merges the results.  
 
AHSV sequences are readily available on GenBank. GenBank has developed into one 
of the most valuable tools for bioinformatics. Over 79 million sequences are available 
for over 260,000 organisms. Individual laboratories from all over the world are 
responsible for the majority of sequences submitted (Benson et al., 2009). As such, a 
huge number of sequences are available for identical genomes and can be taken into 
account when designing primers. 
 
The success of the proposed assay is entirely dependant on the design of a primer pair 
and the characteristics of the amplicon. The analysis of Segment 2 and 10 of the 
African horse sickness virus genome begins with the collection and collation of all 
available sequences through GenBank (Burks et al., 1985; Benson et al., 2009). A 
variety of selected sequences are then aligned using the Clustal (Chenna et al., 2003; 
Larkin et al., 2007) program and a cladogram drawn using TreeView (Page, 1996) to 
reveal the extent of sequence divergence. 
 







4.2 Materials and Methods 
In all analyses, both Segment 2 and Segment 10 of the AHS viral genome were 
considered. 
 
4.2.1 Sequence Retrieval 
An analysis of any genomic sequence invariably begins with GenBank. GenBank is a 
service offered by the National Center for Biotechnology Information (NCBI) and hosted 
at http://www.ncbi.nlm.nih.gov. Searching the „Nucleotide‟ database for “African horse 
sickness Segment 2 vp2”, 45 results were recovered. Sequences that only contain the 
coding sequences or partial coding sequences were discarded. 16 sequences were 
found to be complete and contain the full-length genome for Segment 2. When a 
search was performed for „African horse sickness Segment 10 NS3', 23 sequences 
were found and all were relevant for downstream analysis. 
 
4.2.2 Sequence Alignment 
A number of different programs have been designed that enable the alignment of 
multiple sequences using various algorithms. This allows one to compare the identity 
between different sequences. A freeware alignment software is known as Clustal and 
the most recent Microsoft® Windows® interface is known as ClustalX2 (Larkin et al., 
2007). Clustal also allows one to produce various dendrograms based on the alignment 
algorithms (Chenna et al., 2003). Sequences are downloaded from GenBank in FASTA 
format, loaded into Clustal and the alignment formed. Full alignments are given in 
Appendix 1 (sequence Segment 2) and Appendix 2 (sequence Segment 10). By way of 
example and ease of reference, the first 60 bases of AHSV Segment 2 from 16 full-







Figure 4.2: ClustalX2 alignment of 16 sequences of African horse sickness virus 
Segment 2 taken from GenBank. 
 
The asterisks below the sequences (alignment indices) represent identical bases 
across the alignment. The first column contains a unique identifier assigned to the 
sequences. The number after AHSV represents the serotype that that particular 
sequence comes from and the code following the underscore are the unique accession 
numbers assigned to each submitted sequence on the GenBank database.  
 
It is important to note that the entire sequence alignment must be studied for a suitable 
region to be found. Despite there only being nine known serotypes, the sequences 
found on GenBank all represent actual sequenced data of the viral genome. As such, it 
is imperative that all known sequences are used to establish an alignment as opposed 
to just nine (one of each serotype) in order that the most accurate data is used 
concerning the most up-to-date and historical genetic state of the viral genome. In 
terms of published literature, the genomic comparison of more than one serotype is 
rarely performed due to the lack of research surrounding genetic/molecular serotyping. 
 
4.2.3 Dendrogram Visualisation 
A dendrogram enables one to infer any sequence identities and the relationships 
between sequences based on their relative identities and differences. Full-length 
alignments of both Segment 2 and 10 were visualised in a dendrogram using 
TreeView. Following the alignment and selection of suitable primer pair sites, the 
proposed amplicon (containing the primer sites) was subjected to a secondary 
Identifier   Sequences and alignment indices 
AHSV8_DQ868775       GTTTAATTCATCATGGCGTTCGAGTTTGGCATATTACTAACTGAGAAAGTAGAAGGTGAT 
AHSV8_AY163333       GTTTAATTCATCATGGCGTCGGAGTTTGGCATATTACTAACTGAGAAAGTAGAAGGTGAT 
AHSV5_AY163331       GTTTATTTCATCATGGCTTCAGAGTTTGGCGTTCTGTTGACCGATAAAGTTGAAGGCGAT 
AHSV6_DQ868774       GTTAAATTCACCATGGCTTCCGAATTTGGCATTTTGATTTGTGATAAATTAAAGGAAAAC 
AHSV6_NC_005996      GTTAAATTCACCATGGCTTCCGAATTTGGCATTTTGATTTGTGATAAATTGAAGGAAAAT 
AHSV9_DQ868776       GTTTAATTCACCATGGCGTTCGAGTTTGGAATACTTCAGACGGACAAAATTAGAGAGAAT 
AHSV4_EU046574       GTTTAATTCACCATGGCGCCCGAGTTTGGAATATTGATGACAAATGAAAAATTTGACCCA 
AHSV4_DQ868773       GTTTAATTCACCATGGCGTCCGAGTTTGGAATATTGATGACAAATGAAAAATTTGACCCA 
AHSV4_D26570         GTTTAATTCACCATGGCGTCCGAGTTTGGAATATTGTTGACAGATGAAAAATTTGACCCG 
AHSV1_FJ011108       GTTTATTTCAGCATGGCGTCTGAATTTGGAATTCTATTGACCGAGAGAATCTTTGACGAA 
AHSV1_AY163329       GTTTATTTCAGCATGGCGTCTGAATTTGGAATTCTATTGACCGAGAGAATCTTTGACGAA 
AHSV2_AY163332       GTTTATTTCAGCATGGCGTCTGAATTTGGAATACTTTTCACCGAAAAGATCTATGACCAA 
AHSV1_Z26316         GTTTAATTCACCATGGCTTCGGAATTCGGGATCCTATTGACAAATCAAATATATGATCAA 
AHSV3_U01832         GTTTAATTCACCATGGCTTCGGAATTCGGGATCCTATTGACAAATCAAATATATGATCAA 
AHSV3_DQ868772       GTTTAATTCACCATGGCTTCGGAATTCGGGATCTTATTGACAATTCAAATATATGATCAA 
AHSV7_AY163330       GTTTAATTCACTATGGCTTCTGAGTTTGGAATTTTGTACACTGATCAGATCTACGAACAA 





alignment. This alignment was then visualised in a dendrogram for relative sequence 
identities and relationships. The separation of sequences on a dendrogram is likely to 
give an indication of the relative melt profiles after HRM analysis. Dendrograms of the 
full-length sequence were compared such that the ability to separate sequences on a 
short amplicon versus the entire full-length segment could be assessed. 
 
4.2.4 Primer Design 
Both segments were scrupulously analysed for potential primer sites. Using the 
ClustalX alignment files, ideal sites would be regions where there are approximately 20 
asterisks in a row flanking a region of approximately 200 base pairs where the 
asterisks are very erratic across all 16 sequences. In addition to the manual, visual 
inspection of the alignment for suitable primer regions, the alignment files were 
submitted to Primaclade. Simply stated, Primaclade runs Primer3 on each sequence in 
the alignment and produces a consensus sequence. From this consensus sequence, 
possible primer sites are shown. The Primaclade results were compared to the manual, 
visually designed primer pairs. 
 
4.2.5 BLAST 
It is important to confirm the specificity of the chosen primer pair. Primer pairs that are 
not highly specific may lead to incorrect priming on either a different part of the 
segment or genome. Alternatively, it may be possible that they could prime to unrelated 
sequences from different organisms, such as the host cell in which they were cultured. 
To assess their specificity, the Basic Local Alignment Search Tool (BLAST) is used. As 
part of the NCBI‟s compendium of bioinformatic programs, it searches through the 
entire GenBank database for possible matches. 
 
4.2.6 POLAND 
POLAND is a program that calculates the thermal dissociation patterns of dsDNA and 
RNA, in essence, an in silico melt profile with resultant peaks (Steger, 1994). The 
program can be used to predict melt profiles in assay design. The 10-190 bp regions of 







TreeView (Page, 1996) is a freeware program that converts the alignment file from 
Clustal into a dendrogram. Figure 4.3 represents the dendrogram achieved after the 
alignment of full-length sequences of Segment 2 (Appendix 1).  
 
 
Figure 4.3: The dendrogram (TreeView) produced from the full-length sequences of 
Segment 2 of the African horse sickness virus genome. The bar represents 0.1 
substitutions per site. 
 
The dendrogram of Segment 2 reveals very little identity between the sequences and 
distinct groupings are not easily discerned. The alignment of the full length AHSV 
























Figure 4.4: The dendrogram (TreeView) produced from the full-length sequences of 
Segment 10 of the African horse sickness virus genome. The bar represents 0.1 
substitutions per site. 
 
Three distinct groupings exist in the dendrogram in Figure 4.4 as shown by the red 
circles. Figure 4.5 displays the dendrogram achieved after the alignment of the 10-190 
bp region of Segment 10. This was the only region that complied with the conditions of 
being a single primer pair across all nine serotypes. These groupings of the full-length 
Segment 10 (Figure 4.4) dendrogram and the 10-190 bp regions (Figure 4.5) coincide. 
 
 
Figure 4.5: The dendrogram (TreeView) produced from the 10-190 bp region of Segment 
10 of the African horse sickness virus genome amplified by the primer pair AHS Seg10 














































Serotypes 1, 2 and 8 have an identical amplicon and will not be distinguishable using 
the 10-190 bp region of Segment 10. Divergence within serotype 3 is low, while 
Serotype 7 is closely related to serotype 3. Serotype 6 is segregated from the nodes of 
serotype 4 and serotype 9. Serotype 5 exists in a node with one of the serotype 4‟s. 
Three distinct groupings are easily identified, as shown by the circles. 
 
The conditions for the selection of primers for the proposed assay were not met for 
Segment 2. Two primer sites on Segment 10, however, amplify a 180 bp region from 
position 10 to 190 across the 23 known sequences of the nine serotypes (Figure 4.6).  
 
 
AHSV3_AJ007304        GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3_D12479          GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3_AJ007303        GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV7_U60190          GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV7_AJ007306        GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV4_U02712          GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV4_AJ007305        GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV4_Z48734          GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV4_Z48735          GTTTAAATTATCC-TTGTCATGAATCTAGCTACAATCGCCAAGAATTATAGCATGCATAA 
AHSV5_AJ007309        GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGCATGCATAA 
AHSV9_D12480          GTTTAA-TTATCCCTTGTCATGAATCTAGCTGCAATCGCCGAAAATTATAGTATGCATAA 
AHSV9_AJ007308        GTTTAA-TTATCCCTTGTCATGAATCTAGCTGCAATCGCCGAAAATTATAGTATGCATAA 
AHSV6_U26171          GTTTAA-TTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV6_U60189          --TTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAACTACAGTATGCATAA 
AHSVref_AM883173      GTTTAA-TTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV1_U02711          GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV8_AJ007307        GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV2_AFU59279        GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV8_U02713          GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
                        **** ****** ********* *** ***   *** ** * *  ** *     ***** 
 
AHSV3_AJ007304        TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3_D12479          TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3_AJ007303        TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV7_U60190          TGAAACTCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV7_AJ007306        TGGAAATCAGAGAGCAATTGTGCCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV4_U02712          TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCC 
AHSV4_AJ007305        TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCC 
AHSV4_Z48734          TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATGTTGCGAGTGCTCC 
AHSV4_Z48735          TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV5_AJ007309        TGGAGAGTCGGGGACGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV9_D12480          TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV9_AJ007308        TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV6_U26171          TGGAGAGTCGGAGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV6_U60189          TGGAGAGCAAGAGGCGATCGTCCCATATGTGCCGCCACCATACAATTTCGCAAGTGCTCC 
AHSVref_AM883173      TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV1_U02711          TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV8_AJ007307        TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV2_AFU59279        TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV8_U02713          TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 






Figure 4.6: The selection of two primer sites for the African horse sickness virus 
Segment 10 across the Clustal alignment of the 19 selected sequences located on 
GenBank. The primer sites are indicated in red and amplify a 180 bp product from 
position 10 to 190. 
 
The primers, therefore, are as follows and amplify a 180 bp region from position 10-190 
(Table 4.1): 
 
Table 4.1: The selected primers and calculated properties to amplify a 180 bp product 
from position 10-190 of the African horse sickness virus Segment 10 (Bioneer, Daejeon, 
Korea) 
Primer Sequence Length Tm 
AHS Seg10 10-190Fwd ATCCCTTGTCATGARTCTWGCT 22 59.3°C 
AHS Seg10 10-190Rev CTTGACATKGCTTGRTTAAGTATCC 25 57.5°C 
 
 
AHSV3_AJ007304        GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV3_D12479          GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV3_AJ007303        GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV7_U60190          GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV7_AJ007306        GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV4_U02712          GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_AJ007305        GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_Z48734          GACGTTTTCTCAGGGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_Z48735          GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV5_AJ007309        GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV9_D12480          GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV9_AJ007308        GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV6_U26171          GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV6_U60189          GGCGCTTCCTCAGCGTACAAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAGGC 
AHSVref_AM883173      GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV1_U02711          GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV8_AJ007307        GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV2_AFU59279        GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV8_U02713          GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
                      * ** **  *       *  ** ******** ** ******************* ** ** 
 
AHSV3_AJ007304        CATGTCAAGTACAACTGGTGCAAGTCGGGC---- 
AHSV3_D12479          CATGTCAAGTACAACTGGTGCAAGTCGGGC---- 
AHSV3_AJ007303        CATGTCAAGTACAACTGGTGCAAGTCGGGC---- 
AHSV7_U60190          CATGTCAAGTACAACTGGTGCAAGTGGGGC---- 
AHSV7_AJ007306        CATGTCAAGTACAACTGGTGCAAGTGGGGC---- 
AHSV4_U02712          CATGTCAAGTACAACTGGTGCGAGTGGGGC---- 
AHSV4_AJ007305        CATGTCAAGTACAACTGGTGCGAGTGGGGC---- 
AHSV4_Z48734          CATGTCAAATACAACTGGTGCGAGTGGGGC---- 
AHSV4_Z48735          CATGTCAAGTACAACTGGTGCGAGTGGGGCG--- 
AHSV5_AJ007309        CATGTCAAGTACAACTGGTGCGAGTGGGGC---- 
AHSV9_D12480          CATGTCAAGTACAACTGGTGCGAGTGGGGCG--- 
AHSV9_AJ007308        CATGTCAAGTACAACTGGTGCGAGTGGGGCG--- 
AHSV6_U26171          CATGTCAAGTACAACTGGTGCGAGTGGGGCG--- 
AHSV6_U60189          CATGTCAAGTACAACTGGTGCGAGTGGGGCAC-- 
AHSVref_AM883173      AATGTCAAGTTCAGCTGGTGCGAGCGGAGCACTT 
AHSV1_U02711          AATGTCAAGTTCAGCTGGTGCGAGCGGAGCACT- 
AHSV8_AJ007307        AATGTCAAGTTCAGCTGGTGCGAGTGGCGCACT- 
AHSV2_AFU59279        AATGTCAAGTTCAGCTGGTGCGAGTGGCGCACT- 
AHSV8_U02713          AATGTCAAGTTCAGCTGGTGCGAGTGGCGCACT- 





The annealing temperatures (Tm) of each primer were calculated using the OliCalc 
function in pDRAW32. Bioneer calculated the Tm‟s of the primer pair but did not provide 
any conditions or method of calculation for verification. The degeneracies of the primer 
pair require some minor adjustments to the primer pair in order to calculate an accurate 
Tm. The „bases‟ R, W and K may represent one of two bases – R: G/A; W: A/T and K: 
G/T. Since A and T contribute to a lower melting point, they were substituted into the 
primer in order to calculate the Tm. The PCR reaction conditions also affect the Tm, and, 
as such, the following conditions were defined according to the Quantace SensiMix™ 2 
step kit protocol: Primers = 200 nM; NaCl + KCl = 50 mM; MgCl2 = 3 mM; glycerol = 1 
% (w/v); formamide = 0 % (w/v) and DMSO = 0 % (w/v). 
 
The relative position of the primers on Segment 10 of the AHSV genome are shown in 
Figure 4.7 according to the program pDRAW32 (Tippmann, 2004). 
 
 
AHSV Segment 10 Consensus Sequence (767 bp) 
Figure 4.7: Relative positions of AHS Seg10 10-190Fwd (Fwd) and AHS Seg10 10-190Rev 
(Rev) with reference to a consensus sequence of 19 sequences of Segment 10 of the 
African horse sickness virus genome as defined by pDraw32. The numbers represent the 
position of each primer towards the centre of the amplicon. 
 
Therefore, the 180 bp primer selection (AHS Seg10 10-190Fwd and AHS Seg10 10-
190Rev) is theoretically ensured of discriminating between the serotypes 9, 4 and 6; 3 
and 7; and 1, 2 and 8. The significance of the primer selection in amplifying appropriate 
regions of the AHSV genome is that any field/vaccine strains of AHSV in serum will be 
identified to serotype. 
 
A GenBank sequence representative of each serotype was used to determine the 
simulated melt profiles using POLAND (Steger, 1994 ) using the 10-190 bp region of 
Segment 10 (Figure 4.8).  
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AHSV1_U02711     AHSV2_AFU59279 
 
  
AHSV3_D12479     AHSV4_AJ007305 
 
  






Figure 4.8: Simulated melt profiles of the 10-190 bp regions of Segment 10 using 
POLAND. The serotype and GenBank accession number from which the amplicon was 
selected are found under each graph. 
The red and blue lines use the predicted absorbance readings at 260 nm and 280 nm 














Previous phylogenetic studies of the African horse sickness virus have been rather 
limited due to the lack of sequences available (de Sá et al., 1994) or the fact that only 
one sequence per serotype may have been considered (Sailleau et al., 2000). Recent 
research on serotype determination using Segment 2 and Segment 10 has greatly 
increased the database of AHSV serotypes in GenBank and consequently improved 
the integrity of primer selection. 
 
The first segment to be considered when considering serotype specific tests would be 
Segment 2 as it is the primary genome segment responsible for serotype specificity 
(Roy et al., 1994). However, upon visual and in silico analysis of the alignment 
(Appendix 1), no suitable region could be found for primer design. This was confirmed 
by the dendrogram analysis that revealed the large divergence in the serotypes (Figure 
4.3). In addition, Segment 2 is approximately 3205 bp in length, while Segment 10 is 
approximately 756 bp in length (Mertens et al., 2006). In Figures 4.3 to 4.5, the scale 
bar represents 0.1 nucleotide substitutions per site. In other words, following and 
measuring the horizontal branches from one entry to another, a distance ten times the 
length of the bar would represent one substitution. Taking into account the length of the 
horizontal branches, Segment 10 is clearly more conserved than Segment 2. Segment 
10 presented greater opportunities in terms of the alignment and possible primer 
regions and was represented to a much greater degree on GenBank. 
 
Variation in sequences is due to single or multiple base pair substitutions or gaps in 
one or more sequences. For primer selection, conserved regions in more or less 
identical regions should be aligned such that they are reasonably and suitably spaced 
by variable regions. The Clustal programs were developed in 1988 by Des Higgins and 
continue to improve (Chenna et al., 2003). As explained above, asterisks (*) represent 
identical, convergent regions and dashes (-) represent areas where gaps have been 
introduced in order to create a better alignment. In the alignment of Segment 2, no 
suitable regions could be found without introducing a large number of degenerate 
bases in the primer sequence. (Degenerate bases are bases in the primer sequence 
that can be interchanged in order to complete the primer.) Segment 10 provided 
suitable primer regions. The selected Segment 10 primers contained minimal 





represents a G or T.) The length is ideal (Dieffenbach et al., 1993) and the theoretical 
Tm is within one degree of the other. However, different programs will give different Tm's 
based on the particular method and calculation that is used. As a result, AHS Seg10 
10-190Fwd has a Tm of 54°C according to Bioneer and 53.5°C when using the program 
pDRAW32 and ranges from 53.5°C to 58.2°C when individual bases are substituted for 
the degenerate ones calculated using the Tm calculator on pDRAW32. AHS Seg10 10-
190Rev has a Tm of 55.1°C according to Bioneer and 43°C when using the program 
pDRAW32 and ranges from 50.4°C to 55.8°C when individual bases are substituted for 
the degenerate ones calculated using the Tm calculator on pDRAW32. Primer selection 
using Clustal was verified using Primaclade. 
 
In Figure 4.8, the use of POLAND to predict the melt profiles showed that serotypes 1, 
2 and 8, with a common melt profile, were also found in the same grouping in the 
dendrogram (Figure 4.5). The other groupings can also be seen with similarities 
between serotypes 3 and 7 and also serotypes 4, 5, 6, and 9.  
 
Despite the fact that the best possible primer selection for Segment 10 might not be 
able to differentiate the nine serotypes exclusively, melt curves that are uniquely 
associated with each node would prove the ability of HRM to differentiate viral RNA 
that belongs to particular dendrogram groupings from clinical samples. Further 
bioinformatic analysis will investigate the use of probes or two different primer pairs to 
differentiate all nine serotypes uniquely and conclusively in the context of High 
Resolution Melt analysis. 
 
4.5 Conclusion 
The combination of GenBank, ClustalX2, Primaclade, TreeView and BLAST represent 
an ideal suite of programs for bioinformatic analysis and primer design. In addition, 
they are all freely available. Following the inadequacies of Segment 2 for the assay to 
be developed, Segment 10 represented another option. The primers AHS Seg10 10-
190Fwd and AHS Seg10 10-190Rev were chosen to amplify the 10-190 bp region of 
Segment 10 of the AHSV genome for all nine serotypes. Degeneracies were 
unavoidably present, however. Although the dendrogram analysis reveals the 
inadequacies for this primer pair as far as the objectives of the assay are concerned, 





Chapter 5: AMPLIFICATION AND ANALYSIS OF 
EXTRACTED AHS VIRAL RNA 
 
5.1 Introduction 
The development of a rapid assay for the AHS virus is largely dependent on the 
characteristics of the techniques available and their inherent rapidity. Molecular 
diagnostics based on nucleic acid amplification, such as RT-PCR, represent the most 
modern, commonly used procedures to achieve rapid assays for the detection of 
pathogens. Indeed, infectious disease diagnosis has been revolutionised by PCR-
based molecular detection systems (Eaton & White, 2004). 
 
PCR has additional advantages in that it can detect the virus during the early stages of 
viraemia and in samples that have been poorly preserved, unlike viral isolation 
techniques. PCR achieves results in less than 24 hours as opposed to the more 
traditional viral isolation methods where it may take five days and sometimes up to 15 
days for a positive result in less virulent strains (Stone-Marschat et al., 1994; Sailleau 
et al., 1997). 
 
The significance of this research lies within the advantages of PCR combined with High 
Resolution Melt analysis (HRMA) for detecting the AHS virus in the blood or other 
biological sample of infected equids. Noteworthy advantages exist in using PCR and 
HRMA in clinical situations where conventional microbiology is inadequate, time-
consuming or labour-intensive (e.g. cell culture), or difficult and hazardous (Abdalla et 
al., 2002). The rapid nature of PCR also has important consequences for limiting the 
spread of highly contagious pathogens in an epidemic.  
 
High resolution melting (HRM) was introduced in 2002 through the collaborative efforts 
of academia (University of Utah) and industry (Idaho Technology) (Reed et al., 2007). 
A variety of methods have previously been developed to detect DNA sequence 
variation of PCR products. However, these involve extra processing and separation 
steps subsequent to the PCR run, include additional apparatuses and are time-





distinguish unique variants in a homogenous, closed tube procedure performed 
automatically after PCR. HRM requires normal PCR reagents, a fluorescing dsDNA-
binding dye and a short period of closed-tube, post-PCR analysis (Reed & Wittwer, 
2004). Reed et al. (2007) considers HRM the simplest method of determining 
sequence variation and recognises its increasing popularity. 
 
As discussed in Chapter 4, primers were selected according to their ability to amplify a 
portion of Segment 10 that may reveal HRM curves suitable for downstream analysis, 
after performing a standard 2-step RT-PCR. 
 
5.2 Materials and Methods 
5.2.1 Real-time RT-PCR  
In order to confirm that AHS viral RNA was indeed extracted from the ECE yolk and 
cell culture supernatants, a RT-PCR was performed on the extracted RNA samples. 
 
5.2.1.1 Primers 
The primers described in Chapter 4 (AHS Seg10 10-190Fwd and AHS Seg10 10-
190Rev) were used for the amplification reactions. 
 
5.2.1.2 RT-PCR 
The SensiMix™ Two-Step Kit (Quantace: QT305-01) was used in all reactions 
according to the manufacturer‟s instructions, albeit scaled down. Volumes that follow 
are for one reaction. For the reverse-transcription reaction 2 µL of the extracted ECE 
RNA samples or 7 µL of the extracted cell culture RNA suspension was combined with 
2 µL of a 50 µM solution of random hexamers, 1 µL of 10 mM dNTP mix and made up 
to 10 µL with DEPC-treated water if necessary, all on ice. The ECE samples were 
incubated at 95°C for 5 minutes and immediately chilled on ice for 2 minutes. The cell 
culture samples were incubated at 65°C for ten minutes followed by immediately 
freezing the mixture in liquid nitrogen for one minute and thawing on ice (Batten et al., 
2000). The 10 µL containing the RNA template was added to a separate tube 
containing 4 µL of the 5 × reverse transcriptase buffer, 1 µL RNase inhibitor (10 u.µL-1), 





total of 20 µL. The solution was incubated at 37-42°C for 50 minutes followed by 70°C 
for 15 minutes and immediately chilled on ice. All thermal cycling for the reverse-
transcriptase (RT) reactions took place in an Applied Biosystems GeneAmp® 2700. 
 
The amplification reaction was conducted as follows (for one reaction): 1 µL of the 
cDNA template from the RT reaction was combined with 7 µL sterile distilled water, 10 
µL of SensiMix™ dT, 0.4 µL 50x SYBR® Green I solution, 0.8 µL each of 5 µM AHS 
Seg10 10-190Fwd and AHS Seg10 10-190Rev to achieve 20 µL. followed by a brief 
centrifugation. The reactions were carried out in a Corbett Rotor-Gene™ 6000 under 
the following conditions: Hold at 95°C for 10 minutes and 60 cycles of 95°C for 15 
seconds, 50°C for 30 seconds, 72°C for 15 seconds. The ECE samples proceeded with 
a standard melt from 72-95°C. The cell culture samples were subjected to a High 
Resolution Melt immediately afterwards from 72-95°C at 0.1°C rise per step and the 
results analysed using the in-house Corbett Rotor-Gene™ 6000 Series Software 1.7©. 
 
To confirm that the targeted 180 bp region was being amplified, a 1.2 % agarose gel 
containing 1 µg/µL ethidium bromide in 0.5 × TBE was loaded with the amplified 
samples (10 µL of sample was combined with 2 µL of loading buffer) and was run at 
120V for 1 hour. The Fermentas O‟GeneRuler™ 100 bp Plus, ready-to-use molecular 
weight marker (MWM) was used. 
 
5.2.2 Amplicon DNA Sequencing 
Inqaba Biotechnical Industries (Pty) Ltd. (Pretoria, South Africa) sequenced the 
resulting amplicons of the cell culture samples. The amplicons were first cloned into 
pJET1.2/blunt cloning vector and sequenced using standard primers. The returned 
sequences were edited to remove vector sequence and were correctly orientated and 









To confirm that the RNA extracted from the ECE yolks was AHS viral RNA, an RT-PCR 
was performed on the extractions using the primers selected in Chapter 4. The real-
time and melt analysis results are seen in Figure 5.2. The real-time nature of the 
Corbett Rotor-Gene™ 6000 enables one to monitor the accumulation of product (White 
& Potts, 2006) (Figure 5.1). A single, diffuse band was evident with a leading edge of 










Figure 5.1: Real-time RT-PCR and HRM results for the 10-190 bp region of Segment 10 
using the primer pair AHS Seg10 10-190Fwd and AHS Seg10 10-190Rev. Top: 
Fluorescence versus cycle number to determine amplification status of amplicon. 
Middle: Melt curve showing fluorescence versus temperature (°C). Bottom: Melt curve 
derivative versus the temperature. Amplicon amplified using the primers AHS Seg10 10-
190Fwd and AHS Seg10 10-190Rev.  
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 extraction 1 (with no NaCl).  - TRIzol
®
 extraction 2 (with NaCl).  - no 
template control.  
  
Cycle


















































Figure 5.2: PCR products of TRIzol
®
 extracted AHS viral RNA using the primers AHS 
Seg10 10-190Fwd and AHS Seg10 10-190Rev. 2 µL sample + 8 µL formaldehyde-
containing loading buffer on an ethidium bromide containing 1.2 % (w/v) agarose gel.  
MWM: Fermentas GeneRuler™ 100 bp DNA Ladder. Lane 1: TRIzol
®
 extraction 1 (with no 
NaCl). Lane 2: TRIzol
®
 extraction 2 (with NaCl). 
 
Melt peaks were calculated using the Rotor-Gene™ 6000 Series Software 1.7©. The 
melt curves seen in Figure 5.1 (bottom) peak at 83.8°C (  – TRIzol® extraction 1 (with 
no NaCl)) and 83.5°C (  – TRIzol® extraction 2 (with NaCl)). Product sizes in the gel 
and the corresponding peak melt temperature indicate that no improvement in the 
quality of the RNA extraction is achieved by the addition of NaCl to the isopropyl 
alcohol. 
 
Figure 5.3 is the graph of the raw fluorescence data from the PCR of the AHS viral 
RNA extractions from the cell cultures and the primers AHS Seg10 10-190Fwd and 
AHS Seg10 10-190Rev that are designed to amplify a 180 bp product from genome 




























Figure 5.3: Corbett Rotor-Gene™ 6000 software raw data fluorescence curves for the 
amplification of the 10-190 bp region of AHSV Segment 10 using primers AHS Seg10 10-
190Fwd and AHS Seg10 10-190Rev.  
Where  - 1;  - 4;  - 5;  - 6;  - 7;  - 8;  - 9;  - Control;  - NTC. 
 
Figure 5.3 clearly shows the amplification of product from cycle 30 until cycle 43, while 
Serotype 2 and 3 did not amplify. Amplified products were confirmed as being 180 bp 
by running a 1.2% (w/v) agarose gel containing 1 µg/µL ethidium bromide in 0.5 × TBE. 
 
Ultimately, real-time PCR negates the need to run PCR products on gels. However, it 
was necessary in this instance in order to confirm that the correct product was being 
amplified. The primers AHS Seg10 10-190Fwd and AHS Seg10 10-190Rev have not 
been used before and it was necessary to confirm that they are amplifying a product of 
the correct size. All of the bands were sized and found to be 182 bp, which compares 
favourably with the expected size of 180 bp. The control from the cell culture did not 
result in a product, nor did the NTC.  
 
The raw data from each data acquisition step is normalised by the Corbett Rotor-
Gene™ 6000 software (Figure 5.4). The Control and NTC are unable to be suitably 
normalised. 
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Figure 5.4: Normalised HRM curves of the 180 bp product of the targeted region of AHS 
viral genome Segment 10 for each of the serotypes, control and NTC.  
Where  - 1;  - 4;  - 5;  - 6;  - 7;  - 8;  - 9;  - Control;  - NTC. 
 
The derivative of the normalised graph measures the point at which the dissociation of 
the two DNA strands is most rapid – the peak melting temperature (Figure 5.5). A 
number of melt peak similarities/groupings can be distinguished: serotype 7 ( ) and 8 (
); serotypes 6 ( ) and 9 ( ) and serotypes 1 ( ) and 4 ( ).  
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Figure 5.5: Corbett Rotor-Gene™ 6000 software HRM curves of the 180 bp product of the 
targeted region of AHS viral genome Segment 10 for each of the serotypes, control and 
NTC.  
Where  - 1;  - 4;  - 5;  - 6;  - 7;  - 8;  - 9;  - Control;  - NTC. 
 
Using the Corbett Rotor-Gene™ 6000 software, „bins‟ can be defined for a set of melt 
curves. Melt peaks are clearly clustered into two, if not three distinct domains (Figure 
5.6-5.8). In Figures 5.6-5.8, these have been defined as A (Figure 5.6; serotypes 7 and 
8); B (Figure 5.7; serotypes 6 and 9) and C (Figure 5.8; serotypes 1, 4 and 5). Table 
5.1 shows the results of the software‟s capabilities to call samples and place them in 


























Figure 5.6: Corbett Rotor-Gene™ 6000 software HRM curves of serotype 7 and 8 AHSV 
Segment 10 10-190 bp – Group A 
Where:  - 7;  - 8. 
 
 
Figure 5.7: Corbett Rotor-Gene™ 6000 software HRM curves of serotype 6 and 9 AHSV 
Segment 10 10-190 bp – Group B.  
Where  - 6;  - 9.  
 
ºC










































Figure 5.8: Corbett Rotor-Gene™ 6000 software HRM curves of serotype 1, 4 and 5 of 
AHSV Segment 10 10-190 bp – Group C.  
Where  - 1;  - 4;  - 5. 
 
Table 5.1: 10-190 bp amplified AHSV Segment 10 regions of each serotype and their 
automatically assigned bin using Corbett Rotor-Gene
™
 in-house software for the  
segregation of melt curves 
 
Colour Serotype Maximum Peak (°C) Bin 
 1 82.75 (C) 
 4 82.82 (C) 
 5 82.48 (C) 
 6 81.98 (B) 
 7 81.23 (A) 
 8 81.23 (A) 
 9 81.80 (B) 
 
The presence of 180 bp products on an agarose gel cannot be regarded as 
unequivocal proof of the successful amplification of the specified target region. The 
PCR products need to be sequenced in order to confirm with confidence that the 
correct target was amplified. 
 
The resulting sequences (Figure 5.9) were edited to remove the vector sequences. In 
addition, due to some slight aberrations in the cloning, some of the sequences were 
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presumably truncated. Serotypes 7 and 9 contained small deletions in the 3′ terminal 
regions while half of serotype 5 appeared to have been deleted from the 5 ′ terminus 
and was therefore discarded. The sequences were therefore adjusted to take into 
account the deletions of serotypes 7 and 9. Identification of the nine serotypes was 
confirmed in this way. 
 
 
Figure 5.9: Alignment of the AHSV Segment 10 10-190 bp amplicons chosen for 
sequencing showing the 3 base pair deletion in serotypes 6, 9, 4 and 1. 
 
Following ClustalX2 sequence alignment, dendrogram analysis with TreeView 
produced distinct groups (Figure 5.10) for serotypes 7 and 8, serotypes 6 and 9 and 
serotypes 1 and 4, which, although not in a distinct group are more closely related to 
each other than to any of the other serotypes. This is indicative of highly similar 
sequences within each group, distinct from the other groups. These features will also 
define the melt curves after HRM analysis. 
 
AHSV6_Inqaba      ATCCCTTGTCATGAGTCTAGCTAGCATCTCCCAAAGCTATATGTCACATAATGAGAATGA 
AHSV9_Inqaba      ATCCCTTGTCATGAGTCTAGCTAGCATCTCCCAAAGCTATATGTCACATAATGAGAATGA 
AHSV4_Inqaba      ATCCCTTGTCATGAGTCTTGCTAGCATCTCCCAAAGCTATATGTCACATAATGAGAATGA 
AHSV1_Inqaba      ATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTACATGTCACATAATGAGAATGA 
AHSV7_Inqaba      ATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAATGAAACTCA 
AHSV8_Inqaba      ATCCCTTGTCATGAGTCTTGCTACGATCGCCGAAAATTATATGATGCATAATGGAAATCA 
                  ************** *** ****  *** ** ***  ** ***   *******  * * * 
 
AHSV6_Inqaba      AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV9_Inqaba      AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV4_Inqaba      AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV1_Inqaba      AATACCAATTGTACCATACGTTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV7_Inqaba      GAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV8_Inqaba      CAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
                   * * ********** **  **** ** ** ***    ** * *  ****** ******  
 
AHSV6_Inqaba      TGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGAT 
AHSV9_Inqaba      TGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGAT 
AHSV4_Inqaba      TGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGAT 
AHSV1_Inqaba      TGCATCCGCCAGTCAAATGGAGACCATGTCACTTGGGAT 
AHSV7_Inqaba      TGGTCAGGCGGGTGGAATGGAGCCCATGTCGCTTGGGAT 
AHSV8_Inqaba      TGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGAT 






Figure 5.10: Dendrogram of the modified sequenced 180 bp AHSV genome Segment 10 
target. The bar represents 0.1 substitutions per site. 
 
To validate the use of POLAND for the predication of melt profiles, the 180 bp Segment 
10 amplicons that were sequenced (Inqaba Biotechnical Industries (Pty) Ltd.,Pretoria, 
South Africa) were also run through POLAND, retrospectively (Figure 5.11). In vitro and 
in silico, it is clear that serotypes 1, 4, 6 and 9 have a similar melt profile (double peak), 
while serotypes 7 and 8 are similar (single peak). The approximate melt peaks are 




   







Figure 5.11: Predicted melt profiles of the sequenced (Inqaba Biotechnical Industries 
(Pty) Ltd., Pretoria, South Africa) 10-190 bp region amplicons according to POLAND. The 
serotype of each amplicon is found under each graph. The red and blue lines use the 
predicted absorbance readings at 260 nm and 280 nm respectively, to draw the graph 
and represent the change in absorbance over temperature. 
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Table 5.2: Melt peaks of the sequenced 10-190 bp amplicon of Segment 10 for the 
serotypes 1, 4, 6, 7, 8 and 9 according to POLAND 
 
Serotype Melt Peak (°C) 
1 79 and 81 
4 79.5 and 81.5 
6 79.5 and 81.5 
7 81.5 
8 81.5 
9 79.5 and 81.5 
 
Although the melt profiles and peaks do not compare to the actual melt profiles and 




Primers selected in Chapter 4 (i.e. AHS Seg10 10-190Fwd and AHS Seg10 10-
190Rev) were used in RT-PCR on the ECE samples. A broad product was evident on 
the gel, with a leading edge of 182 bp (Figure 5.2). This compares favourably with the 
expected size of 180 bp. Examination of the sequences contained in AHS vaccine vial 
1 (i.e. Serotypes 1, 3 and 4) reveals that serotype 1 contains 3 bases less than 




Figure 5.12: Sequences of serotypes 1, 3 and 4 (contained in AHS vaccine vial 1) showing 
the three base pair difference in serotype 1. AHSVref refers to serotype 1. The 
sequences displayed start with base number 61. 
 
These experiments are the first in a series of investigations into the development of a 
rapid, cost-effective assay for the diagnosis and serotyping of the AHS virus. The 
rapidity and cost effectiveness of the assay will largely depend on the reagents used 
AHSV3_AJ007304        TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3_D12479          TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3_AJ007303        TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV4_U02712          TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCC 
AHSV4_AJ007305        TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCC 
AHSV4_Z48734          TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATGTTGCGAGTGCTCC 
AHSV4_Z48735          TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSVref_AM883173      TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 






and their respective protocols. For this reason, the ideal primer pair was chosen which 
would have the ability to amplify all nine serotypes, but produce a variety of melt 
profiles that would ideally be unique to each serotype. Initially, the chosen primer pair is 
only likely to result in a few common melt profiles. If these groupings in the melt profile 
matched the groupings of a dendrogram of the identical sequences, the proof of 
concept for the proposed assay under development would become a reality. Moreover, 
it would allow researchers to exhaust primer selection strategies in situ, and be 
confident that the primers selected would result in melt profiles that match the 
dendrogram groups. POLAND, as an in silico melt simulator, can be used to verify that 
dendrogram groupings from TreeView coincide with melt groupings in vitro. 
 
A 2-step RT-PCR protocol was followed such that a stock of cDNA could be kept. The 
Quantace SensiMix™ 2-step kit had not been used before for an orbivirus, but the 
reagents are all standard and the reaction could be scaled down. Confirmation of the 
correct size amplicon was obtained by 180-182 bp bands visualised on a 1.2% (w/v) 
agarose gel. PCR products were sequenced by Inqaba Biotechnical Industries (Pty) 
Ltd. (Pretoria, South Africa). The control and NTC did not produce any product. 
 
A comparison of the „bins‟ for AHS serotypes produced by HRMA on the Corbett Rotor-
Gene™ 6000 in Figures 5.6-5.8, to the dendrogram produced by TreeView® (Figure 
5.10) demonstrates that the serotypes correspond to the dendrogram groups (Figure 








Figure 5.13: The three distinct groups of the sequenced AHSV Segment 10 amplicons 
correspond with the serogroups of the HRM melt profiles from the Corbett RotorGene
™
 
6000 for six of the nine analysed AHSV genome Segment 10 sequences. The bar 
represents 0.1 substitutions per site. 
 
However, when the sequenced amplicons are aligned with the GenBank sequences of 
the AHSV Segment 10 10-190 bp regions and the dendrogram drawn, the serotypes do 
not correspond (Figure 5.14). The named serotypes of the reference strains do not 
appear to coincide with the serotypes of the GenBank sequences. However, the 













Figure 5.14: Dendrogram of the sequenced amplicons of the AHSV reference strains 
(obtained from the NICD) and the GenBank sequences for the identical region. The bar 
represents 0.1 substitutions per site. 
 
Group A is situated with GenBank serotypes 3 and 7, group B is situated nearer 
GenBank serotypes 1, 2 and 8, while group C has been split, possibly due to the 
interference of the additional sequences. One possible reason may be viral evolution, 
although this is highly unlikely due to the genetically stable nature of the virus (Howell, 
1962).  
 
Interestingly, one of the features of the 10-190 region of AHSV genome Segment 10 is 








Figure 5.15: 61-120 bp region of the 10-190 bp amplicon of AHSV Segment 10 to illustrate 
the three base pair deletion common to serotypes 1, 2 and 8 of the GenBank sequences 
and serotypes 4, 6 and 9 of the sequenced amplicons. 
 
According to the sequences obtained from GenBank, this deletion belongs to serotypes 
1, 2 and 8. The reference sequences from the NICD, however, show the identical 
deletion in serotypes 4, 6 and 9. Obtaining recent isolates from the Onderstepoort 
Veterinary Institute of all nine serotypes and repeating the same procedure may go 
some way to solving the anomaly. The additional, serotyped, strains of the virus will be 
included in the alignment and dendrogram (Figures 5.9 and 5.10 respectively) to 
determine which serotypes may contain the three base pair deletion to determine the 
source of the anomaly.  
 
5.5 Conclusion 
The primers that were selected after an intensive bioinformatic analysis (Chapter 4) 
successfully amplified the correct amplicons. They can thus be deemed suitable for 
HRM analysis. The primers AHS Seg10 10-190Fwd and AHS Seg10 10-190Rev were 
able to amplify the correct product of the AHS viral genome Segment 10 according to 
the gel analysis and sequencing results. 
 
AHSV7_Inqaba          GAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV7_U60190          GAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV3_AJ007303        GAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV3_AJ007304        GAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV3_D12479          GAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV7_AJ007306        GAGAGCAATTGTGCCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV8_Inqaba          CAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCCGACGCTTGG 
AHSV6_Inqaba          AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV9_Inqaba          AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV4_Inqaba          AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV1_U02711          AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV8_AJ007307        AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV2_AFU59279        AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSVref_AM883173      AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV8_U02713          AAGATCAATTGTACCATACATTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV1_Inqaba          AATACCAATTGTACCATACGTTCCGCCACCGTAT---CATCCGACGGCTCCGGCGCTTGC 
AHSV9_D12480          GGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCCGACGTTTTC 
AHSV9_AJ007308        GGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCCGACGTTTTC 
AHSV4_Z48735          GGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCCGACGTTTTC 
AHSV5_AJ007309        GGGGACGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCCGACGTTTTC 
AHSV6_U26171          GGAGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCCGACGTTTTC 
AHSV4_U02712          GGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCCGACGTTTTC 
AHSV4_AJ007305        GGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCCGACGTTTTC 
AHSV4_Z48734          GGGGGCGATCGTCCCTTATGTGCCACCACCATACAATGTTGCGAGTGCTCCGACGTTTTC 
AHSV6_U60189          AGAGGCGATCGTCCCATATGTGCCGCCACCATACAATTTCGCAAGTGCTCCGGCGCTTCC 





Serogroups were successfully defined in both the dendrogram analysis based on 
actual sequencing of the amplicons and in the High Resolution Melt curve analysis of 
the amplicon. Comparing the serogroups obtained from each method it is clear that 
there is a definite relationship between the dendrogram serogroups and the HRM 
serogroups and the two can be directly compared and equated. This thus constitutes 
the proof of concept for the further development of the proposed rapid, cost-effective 






Chapter 6: CONCLUSION 
 
An accurate and rapid diagnosis of African horse sickness is an important goal for 
researchers and veterinarians alike. Early detection of the virus and identification of 
serotype has immediate benefits that include applying the correct treatment regime for 
the animal, notifying authorities in the case of notifiable diseases and implementing 
suitable control measures to prevent further spread of the disease. The development of 
rapid assay methods to identify AHS serotypes is imperative in the study of the disease 
in order that epidemiological control might augment the more conventional prophylactic 
strategies currently employed. The ability to serotype an AHS outbreak as rapidly as 
possible, combined with the increasing development of monovalent vaccines, makes a 
rapid serotyping assay even more important (Koekemoer et al., 2000). As a result, the 
national equine population can be protected far more effectively against AHS. 
Furthermore, the serotyping and classification of the virus will assist greatly in a rapid 
classification of future outbreaks for taxonomic and epidemiological purposes.  
 
The sero-prevalence of the virus and the vaccination coverage in the South African 
equid population are unknown (Lord et al., 1997a) and remain so to this day.  These 
problems are compounded by the lack of research funding for AHS. Expensive tests 
are required to understand the disease thoroughly and are therefore not performed, 
with many owners unwilling to pay for tests on a dead horse carrying already exorbitant 
veterinary expenses or rural horses that die without ever being reported. Tests to 
determine the serotype are undertaken only at Onderstepoort Veterinary Institute and 
take up to two weeks to achieve a result costing in excess of R1000. All of these 
factors compound the minimal number of epidemiological studies being undertaken 
which lead to often grossly misunderstood aspects of the disease. The assay under 
development will go some way to easing the financial and time constraints of studying 
an outbreak in real time. This has the potential to solve many of the unknowns 
surrounding AHS, particularly and most importantly, the role that each serotype plays in 
outbreaks and the form of the disease contracted by horses. In addition, the strain is 
not usually classified until sometime after the initial outbreak, as no system to rapidly 
classify the virus involved in the outbreak exists. In addition, it will benefit overall 
investigations and our understanding of the clinical disease (Abdalla et al., 2002). The 





microbiology to molecular biology based techniques, such as nucleic acid detection, 
particularly the polymerase chain reaction (PCR). The applicability of PCR is increased 
dramatically with the advent of real-time or quantitative PCR  (Pusterla et al., 2006). 
The system that is being developed is based on DNA amplification and High Resolution 
Melt (HRM) analysis that will detect the AHS virus and serotype it in a single test in a 
few hours and could potentially cost under R50 per sample.  
 
However, no work exists that can be built on to develop this assay. Developing the 
protocol therefore requires essential preliminary investigations that constitute the bulk 
of this research. RT-PCR has previously been used to serotype AHSV (although not on 
clinical samples), but involved primer pairs for each serotype and would be impractical 
for routine field diagnosis (Sailleau et al., 2000). As the first investigation, suitable 
primer pairs were selected after a rigorous bioinformatic analysis of the available AHSV 
Segment 10 sequences available on GenBank. Using ClustalX2 and Primaclade, the 
primers AHS Seg10 10-190Fwd and AHS Seg10 10-190Rev were selected. These 
primers were designed with a view to amplify a 180 bp product across all nine 
serotypes such that the amplicon of each serotype (or serogroup) was divergent. 
Therefore, the divergent regions would theoretically result in unique melt profiles. The 
choice of Segment 10 relied on the fact that it was divergent among the serotypes (with 
Segment 2). Segment 2, although responsible for serotype specificity for the virus, was 
too divergent and no region could be found that matched the criteria for the 
development of this assay. 
 
It is unfortunate to note that due to a lack understanding and support amongst AHS 
researchers in South Africa, it proved almost impossible to obtain reference strains or 
recent isolates of the AHS virus from other workers in AHS in South Africa. 
Embryonated chicken eggs (ECE) represent an ideal environment to grow a virus 
without the need for highly specialised cell culture equipment. ECE were therefore 
inoculated with vaccine virus based on the protocol of Boorman et al. (1975). Despite 
the ease of the inoculation and growing of the virus, viral RNA proved very difficult to 
extract in a pure form from the egg yolk. No literature could be found pertaining to the 
extraction of viral RNA from egg yolk. Vero cells are preferred for the propagation of 






These strains were subjected to a RT-PCR using the primers designed in Chapter 3. 
Seven of the nine serotypes were successfully amplified. Serotypes 2 and 3 did not 
amplify. The reason is not yet known. A 180 bp product was achieved per serotype for 
the remaining serotypes. The RT-PCR was repeated with the same results, but 
requires exhaustive duplication to ensure the integrity of the primers and protocol. The 
PCR products were subsequently cloned and sequenced to confirm the correct target 
was amplified. The amplified sequences were subjected to a bioinformatic analysis 
using ClustalX2 to align them and TreeView to establish the sequence relationships in 
a dendrogram. Three distinct groups become evident. 
 
The primary focus of the proposed assay under development is the use of High 
Resolution Melt (HRM) analysis to serotype the virus. The PCR products were 
subjected to HRM immediately subsequent to the PCR. The in-house software of the 
Corbett Rotor-Gene™ 6000 produces the melt curves. Of the seven serotypes that were 
amplified and melted, three groups of highly similar melt peaks evolved. The 
comparison of the three groups of melt peaks correspond very closely with the three 
groups of the phylogenetic analysis on the sequenced amplicons. This represents proof 
of concept for the assay under development.  
 
However, this work represents only the preliminary investigations of this assay. 
Through the funding of UKZN Innovation (Pty) Ltd. and the provisional patent filed 
through the UKZN Intellectual Property and Patents Office, the assay can now be 
developed to its fullest potential such that a rapid, cost-effective serotyping assay for 
AHS becomes available to the South African endemic market and the international 
non-endemic market. 
 
6.1 Future Work 
The primers selected as part of these preliminary investigations can be improved upon 
for serotype differentiation. The single primer pair used in this dissertation has enabled 
proof of concept to be established. As part of the ongoing process, additional primers 
and multiplexing will be investigated. Different approaches to primer design will 
separate the individual serotypes from their groupings. Future strategies may include 
the use of two primer pairs that divide the nine serotypes into two groups. 





Although Segment 10 was chosen for these preliminary investigations, Segment 2 
cannot be excluded from primer design strategies in the future. RT-PCR and the HRM 
protocols will be optimised in the context of the assay. The real-time aspect of the 
instrumentation used will also allow a quantitative assay to be developed in conjunction 
with a serotyping assay. This will jointly provide researchers and veterinarian alike with 
a level of viraemia that may be related to the serotype of the infecting virus. 
 
Recent isolates of the nine serotypes were recently acquired and these will undergo 
the cell culture and RT-PCR protocols as for the reference strains. These serotyped 
isolates may provide an explanation for the anomaly between the sequenced 
amplicons and the GenBank sequences where the serotypes appear incorrectly 
placed. It is also envisaged that the vaccine virus can be subjected to the same 
treatments such that vaccinated and field strain infected equines may be differentiated. 
 
In keeping with the mandate for a rapid and cost-effective assay, the extraction of viral 
RNA from the blood of infected equines will be pursued. Investigations into various 
other extraction procedures will be conducted and additional methods to purify the virus 
from in vitro and field samples will be examined. Examples include the Whatman FTA® 
cards and magnetic nanoparticles (Chen et al., 2006). 
 
6.2 Prospects 
The work contained in this dissertation comprises preliminary investigations into the 
development of a novel assay to rapidly diagnose and serotype African horse sickness 
using molecular biology techniques. This work has been identified as intellectual 
property and a provisional patent (Application No. 2009/04542) has been filed through 
the Intellectual Property and Technology Transfer Office of the Research Office of the 
University of KwaZulu-Natal (June 2009). Proof of concept, that molecular diagnostics 
can differentiate between AHSV serotypes is provided by this work and provides a 
foundation for optimisation and validation of the assay. A business model such as that 
entered for the UKZN Institutional Phase of the National Innovation Competition 2009 
(2nd place) will see the exciting prospects of this rapid diagnostic assay for influencing 
prophylaxis, early warning systems, and epidemiological modelling and therefore 
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Appendix 1  





AHSV8_DQ868775       GTTTAATTCATCATGGCGTTCGAGTTTGGCATATTACTAACTGAGAAAGTAGAAGGTGAT 
AHSV8_AY163333       GTTTAATTCATCATGGCGTCGGAGTTTGGCATATTACTAACTGAGAAAGTAGAAGGTGAT 
AHSV5_AY163331       GTTTATTTCATCATGGCTTCAGAGTTTGGCGTTCTGTTGACCGATAAAGTTGAAGGCGAT 
AHSV6_DQ868774       GTTAAATTCACCATGGCTTCCGAATTTGGCATTTTGATTTGTGATAAATTAAAGGAAAAC 
AHSV6_NC_005996      GTTAAATTCACCATGGCTTCCGAATTTGGCATTTTGATTTGTGATAAATTGAAGGAAAAT 
AHSV9_DQ868776       GTTTAATTCACCATGGCGTTCGAGTTTGGAATACTTCAGACGGACAAAATTAGAGAGAAT 
AHSV4_EU046574       GTTTAATTCACCATGGCGCCCGAGTTTGGAATATTGATGACAAATGAAAAATTTGACCCA 
AHSV4_DQ868773       GTTTAATTCACCATGGCGTCCGAGTTTGGAATATTGATGACAAATGAAAAATTTGACCCA 
AHSV4_D26570         GTTTAATTCACCATGGCGTCCGAGTTTGGAATATTGTTGACAGATGAAAAATTTGACCCG 
AHSV1_FJ011108       GTTTATTTCAGCATGGCGTCTGAATTTGGAATTCTATTGACCGAGAGAATCTTTGACGAA 
AHSV1_AY163329       GTTTATTTCAGCATGGCGTCTGAATTTGGAATTCTATTGACCGAGAGAATCTTTGACGAA 
AHSV2_AY163332       GTTTATTTCAGCATGGCGTCTGAATTTGGAATACTTTTCACCGAAAAGATCTATGACCAA 
AHSV1_Z26316         GTTTAATTCACCATGGCTTCGGAATTCGGGATCCTATTGACAAATCAAATATATGATCAA 
AHSV3_U01832         GTTTAATTCACCATGGCTTCGGAATTCGGGATCCTATTGACAAATCAAATATATGATCAA 
AHSV3_DQ868772       GTTTAATTCACCATGGCTTCGGAATTCGGGATCTTATTGACAATTCAAATATATGATCAA 
AHSV7_AY163330       GTTTAATTCACTATGGCTTCTGAGTTTGGAATTTTGTACACTGATCAGATCTACGAACAA 
                     *** * ****  *****    ** ** **  *  *                   *      
 
AHSV8_DQ868775       GCACTGGAAAAGACGAATTGTGAAGTGATAATAACGAAAAACGGGAGAGTGAAACATAAA 
AHSV8_AY163333       GCACTGGAAAAGACGAATTGTGAAGTGATAATAACGAAAAACGGGAGAGTGAAACATAAA 
AHSV5_AY163331       GCTTTAGAGAAAACGAATTGTGAAGTAATTCTTACACGAAGTGGTCGCGTACGGCGGAGG 
AHSV6_DQ868774       ACCTTGGAAAAAACGAATTGTGACGTTATTATTACGGGAGTAGGAAAGGTGAGTGTACGC 
AHSV6_NC_005996      ACTTTAGAAAAAACGAATTGTGACGTTATTATTACGGGAGTGGGAAAAGTAGGTGTACAC 
AHSV9_DQ868776       ACACTCGAAAAAACAAATTGTGATGTGATTCTTACGAAAGAAAATAGAGTGCGGATGAAA 
AHSV4_EU046574       AGCATAGAGAAAACCATTTGCGATGTTATAGTTACGAAGAAGGGAAGAGTGAAGCATAAA 
AHSV4_DQ868773       AGCTTAGAGAAAACCATTTGCGATGTTATAGTTACGAAGAAGGGAAGAGTGAAGCATAAA 
AHSV4_D26570         AGTTTAGAGAAGACCATTTGCGATGTTATAGTTACGAAGAAGGGGAGAGTGAAACATAAA 
AHSV1_FJ011108       ACATTGGAAAAAACAAATTGTGATGTTATTATAACCGAGGAGAAGAAAGTAAAACGGAAG 
AHSV1_AY163329       ACATTGGGAAAAACAAATTGTGATGTTATTATAACCGAGGAGAAGAAAGTAAAACGGAAG 
AHSV2_AY163332       ACGTTGGAGAAAACGAATTGTGATGTGATTATCACTGAGGAGAGGAAAGTGAATCGGAGA 
AHSV1_Z26316         ACATATGAGAAAGAGATGTGTGATGTAATTATTACAGCGGAGAATGCAGTTAGAAGAGTT 
AHSV3_U01832         ACATATGAGAAAGAGATGTGTGATGTAATTATTACAGCGGAGAATGCAGTTAGAAGAGTT 
AHSV3_DQ868772       ACATATGAGAAAGAGAAGTGCGATGTAATTATTACAGCGGAAAATGCAGTTAGAAGAGTT 
AHSV7_AY163330       ACATTGGAGAAGACGAGCTGTGACGTGATCGTAACAAAAGAGAATGCTGTAAAGAGGGTC 
                           *  **    *  ** ** ** **  * **             **           
 
AHSV8_DQ868775       GAGGTTGATGGAGTAAAAGGCTATGAGTGGGAATTTACAGACCATAGGCTGGGGCTCTGC 
AHSV8_AY163333       GAGGTTGATGGAGTAAAAGGCTATGAGTGGGAGTTTACAGACCATAGGCTGGGGCTCTGC 
AHSV5_AY163331       GAGGTTGACGGAGTTAAAGGATATGAATGGGAATTTACAGATCATCGATTAGGATTATGT 
AHSV6_DQ868774       GAAGAAGACGGCATATTAGGTTACGAGTGGGAAGAGACTAATCATAGATTGGGATTGTGC 
AHSV6_NC_005996      GAAGAGGACGGTGTGTTAGGATATGAGTGGGAGGAGACTAACTATAGGTTAGGATTGTGC 
AHSV9_DQ868776       GAGGTCGAAGGAGTGAAAGGATATTATTGGGAGGACACCGATCACAGGTTAGGTTTATGT 
AHSV4_EU046574       GAGGTGGATGGCGTATGTGGATACGAGTGGGATGAAACGAATCACCGATTCGGATTGTGT 
AHSV4_DQ868773       GAGGTGGATGGCGTATGTGGATACGAGTGGGATGAAACGAATCACCGATTCGGATTGTGT 
AHSV4_D26570         GAGGTGGATGGCGTGTGTGGATACGAGTGGGATGAAACGAACCACCGATTTGGATTGTGT 
AHSV1_FJ011108       GAGGTCGAGGGAGTGTTGGGTTACGTGTGGGAGGAAACTAACCATAGGTTCGGCTTATGC 
AHSV1_AY163329       GAGGTCGAGGGAGTGTTGGGTTACGTGTGGGAGGAAACTAACCATAGGTTCGGCTTATGC 
AHSV2_AY163332       GAGGTGGAAGGAGTGCGGGGATATGTATGGGAAGAAACAAACCACCGTTTTGGATTATGT 
AHSV1_Z26316         GAGGTTGCGGGAGTACATGGTTATGAGTGGGGTGCGACGAATCATAGGCTTGGGTTGTGT 
AHSV3_U01832         GAGGTTGCGGGAGTACATGGTTATGAGTGGGGTGCGACGAATCATAGGCTTGGGTTGTGT 
AHSV3_DQ868772       GAGGTTGCGGGAGTATATGGTTATGAGTGGGGTGCGACGAATCATAGGCTCGGGTTGTGT 
AHSV7_AY163330       GAAATCGATGGCGTGCTAGGGTATGAGTGGGGCGCAACAAATCACCGATTAGGACTATGC 
                     **    *  **  *    ** **    ****     **  *  *  *  * **  * **  
AHSV8_DQ868775       GAAGAGAGTTATCTGATGAAAATGGCGGAGTATGTGTATACGCAAACAAAATGCGAAGGT 
AHSV8_AY163333       GAAGAGAGTTATCTGATGAAAATGGCGGAGTATGTGTATACGCAAACAAAATGCGAAGGT 
AHSV5_AY163331       GAAATAGAGCATACAATGTCTATGGCGGATTTCTTTTATAATCAAATTAAGTGCGAGGGT 
AHSV6_DQ868774       GAAATAGAAAATACGGTATCAATCAGTGATTTCGTCTATAAGCAAATAAGATGTGAAGGA 
AHSV6_NC_005996      GAAATAGAGAATACGATGTCAATCAGTGATTTTGTTTATAAGCAAATAAGATGTGAGGGA 
AHSV9_DQ868776       GAGGTCGAACATACTGTGTCTGTGAGGGATTTTGTGTATAAACAAACGAAATGTGAAGGA 
AHSV4_EU046574       GAGGTGGAACACGACATGTCTATATCGGAATTTATGTACAATGAGATCAGATGTGAGGGG 
AHSV4_DQ868773       GAGGTGGAACACGACATGTCTATATCGGAATTTATGTACAATGAGATCAGATGTGAGGGG 
AHSV4_D26570         GAGGTGGAACACGATATGTCAATATCGGAGTTTATGTACAATGAGATCAGATGTGAGGGG 
AHSV1_FJ011108       GAAGGAAATTATGATTTGGCATTTTCAGATACGATGTATTGCCAAACAAAGTGCGACGGA 
AHSV1_AY163329       GAAGGAAATTATGATTTGGCATTTTCAGATACGATGTATTGCCAAACAAAGTGCGACGGA 
AHSV2_AY163332       GAGAATTCATTTGACGAAAAAATATCGGAAACCATGTATTGCCAAATTAAGTGTGAAGGT 
AHSV1_Z26316         GAGGTAGAGAACACGAAGTCGATTGGGAGAATGATTTATGAACAGATTCGATGCGAAGGT 
AHSV3_U01832         GAGGTAGAGAACACGAAGTCGATTGGGAGAATGATTTATGAACAGATTCGATGCGAAGGT 
AHSV3_DQ868772       GAGATAGAGAATACGAAGTCGATCGGGAGAATGATTTATGAACAGATTCGATGCGAAGGT 
AHSV7_AY163330       GAAATAGAACACGTAAAGACGATATCTGAGTTCATGTATGAACAAATTAAATGTGAGGGT 
                     **                    *           * **     * *     ** ** **  
 
AHSV8_DQ868775       GCGTATCCGGTGTTTCCGCATTATATTACTGATGTTTTGAAGTATGGTGTCATGGTTGAT 
AHSV8_AY163333       GCGTATCCGGTGTTTCCGCATTATATTACTGATGTTTTGAAGTACGGTGTCATGGTTGAT 
AHSV5_AY163331       GCATATCCGATATTTCCACATTATATTACCGACGTGCTAAAATATGGGAAAATGGTTGAT 
AHSV6_DQ868774       GCGTACCCGATTTTACCGCACTATGTTACGGACGTCATTAAATATGGGATGGTAATCGAT 
AHSV6_NC_005996      GCATACCCCATTTTGCCGCACTATGTTACAGACGTCATTAAATATGGCATGGTAATTCAT 
AHSV9_DQ868776       TCATATCCGGTTGTGCCTTTATACATGATTGATGCAATTAAATATGGACGAATGATTGAC 
AHSV4_EU046574       GCATATCCAATTTTTCCGCGTTATATAATTGATACGTTAAAATACGAGAAATTTATTGAT 
AHSV4_DQ868773       GCATATCCAATTTTTCCGCGTTATATAATTGATACGTTAAAATACGAGAAATTTATTGAT 
AHSV4_D26570         GCATATCCAATTTTTCCACGTTACATAATTGATACGTTGAAATACGAGAAATTTATTGAT 
AHSV1_FJ011108       TCGTATCCAGTATTTCCGCATTATATAATTGATGCTTTAAGATATGGAGTTATGATTGAT 
AHSV1_AY163329       TCGTATCCAGTATTTCCGCATTATATAATTGATGCTTTAAGATATGGAGTTATGATTGAT 
AHSV2_AY163332       GCTTACCCGATCTTTCCACATTATATTGTTGATGCGTTGAGGTATGGTAAGATGATCGAT 
AHSV1_Z26316         GCGTACCCAATTTTTCCGCACTATATAACGGATACTCTAAAATATGGGAAATCAATTGAT 
AHSV3_U01832         GCGTACCCAATTTTTCCGCACTATATAACGGATACTCTAAAATATGGGAAATCAATTGAT 
AHSV3_DQ868772       GCGTACCCAATTTTTCCGCACTATATAACAGATACTTTAAAATATGGGAAATCAATTGAT 
AHSV7_AY163330       GCATATCCGGTGTTCCCTCATTATGTAATCGATGCCTTAAAATATAACAAAGTTATAGAG 
                      * ** **  *  * **    **  *    **     * *  **           *  *  
 
AHSV8_DQ868775       AGGAATGATCACCAAATAAGAGTGGATAGGGATGTGAAAGAGTTAGGAAAGATTTTGATC 
AHSV8_AY163333       AGGAATGATCACCAAATAAGAGTGGATAGGGACGTGAAAGAATTAGGAAAGATTTTGATC 
AHSV5_AY163331       AGAAATGATCACCAAGTTAGAGTTGATAGGGATGTTAAAGAGCTAAGCAAAATATTGATA 
AHSV6_DQ868774       AGAAACGATCATCAGATCCGAGTTGACAGAGATGAAAAAAGTATTGGAAAAATCCAGATT 
AHSV6_NC_005996      AGAAATGATCATCAGATCCGAGTTGACAGAGATGAAAAAAGTATTGGAAAAATCCAGATT 
AHSV9_DQ868776       AGGAACGACCACCAAATTAGAGTAGACAAAGATGATAAAATTCTATCTAAAATACAAGTA 
AHSV4_EU046574       AGGAATGACCATCAAATTAGAGTGGATAGAGATGATAACGAAATGAGGAAAATATTGATA 
AHSV4_DQ868773       AGGAATGACCATCAAATTAGAGTGGATAGAGATGATAACGAAATGAGGAAAATATTGATA 
AHSV4_D26570         AGGAATGATCATCAGATTAGAGTGGACAGAGACGATAATGAAATGAGGAAAATATTGATA 
AHSV1_FJ011108       CGGAATGATAATCAAGTAAGAGTTGATCTAGATGACAAGCGATTAATGAAAATTAAGATT 
AHSV1_AY163329       CGGAATGATAATCAAGTAAGAGTTGATCTAGATGACAAGCGATTAATGAAAATTAAGATT 
AHSV2_AY163332       AGAAATGATAACCAGGTTAGGGTTGATCAGGATGACAAGCGATTGATGAAAATTAAAATT 
AHSV1_Z26316         AGAAATGACAACCAAATAAGGGTGGATAGGGATGATGAACGCGTCCGCAAAATAAAAATT 
AHSV3_U01832         AGAAATGACAACCAAATAAGGGTGGATAGGGATGATGAACGCGTCCGCAAAATAAAAATT 
AHSV3_DQ868772       AGAAATGACAACCAAATAAGGGTGGATAGGGACGACGAACGGCTCCGCAAAATAAAAATC 
AHSV7_AY163330       AGAAATGATAATCAAGTAAGAGTAGATAGAGATGATGAAAGACTACAAAAAATAAAGATC 






AHSV8_DQ868775       CAACCGTACTTTGGAGAGGTGTTCTTTTCACCTGAGTTTTATACATCGACCTTTTTGAAA 
AHSV8_AY163333       CAACCGTACTTTGGAGAGGTGTTCTTTTCACCTGAGTTTTATACATCGACCTTTTTGAAA 
AHSV5_AY163331       CAACCATACTTCGGTGAGGCGTACTTTTCACCAGAATTTTACACCTCAACTTTTTTGAAG 
AHSV6_DQ868774       CAGCCGTATTTCGGCGATATGTATTTCTCCCCCGAGTATTACCCGGCAACTTTCGTTAAA 
AHSV6_NC_005996      CAGCCGTATTTTGGCGATATGTATTTCTCCCCCGAGTACTACCCGGCAACTTTTATTAAA 
AHSV9_DQ868776       CAGCCGTATTTAGGCGACGCTTATTTTTCGCCAGAGTATTACACTGCTACCTTCTTTAAA 
AHSV4_EU046574       CAGCCGTATGCAGGTGAGATGTACTTTTCGCCGGAATGTTATCCGAGCGTTTTTCTTCGG 
AHSV4_DQ868773       CAGCCGTATGCAGGTGAGATGTACTTTTCGCCGGAATGTTATCCGAGCGTTTTTCTTCGG 
AHSV4_D26570         CAGCCGTATGCGGGTGAGATGTATTTTTCGCCAGAATGTTATCCGAGCGTTTTCCTTCGG 
AHSV1_FJ011108       CAGCCGTATTTGGGTGAAATGTATTTTTCGCCGGAGAACTATTCAACTGTATTTTGCAAA 
AHSV1_AY163329       CAGCCGTATTTGGGTGAAATGTATTTTTCGCCGGAGAACTATTCAACTGTATTTTGCAAA 
AHSV2_AY163332       CAGCCGTATATGGGTGAAATGTATTTCTCACCCGAGAGCTATTCTACCGTTTTCTGTAAG 
AHSV1_Z26316         CAGCCGTATTTTGGAGAAATGTACTTTTCACCAGAAAATTATATAACAGTTTTTTGTAAA 
AHSV3_U01832         CAGCCGTATTTTGGAGAAATGTACTTTTCACCAGAAAATTATATAACAGTTTTTTGTAAA 
AHSV3_DQ868772       CAGCCGTATTTTGGAGAAATGTACTTCTCACCAGAAAATTATATAACAGTTTTTTGTAAA 
AHSV7_AY163330       CAACCATATTTTGGAGAAGCGTTCTTCTCGCCGGAGACCTACTCTTCAACTTTTTGCAAA 
                     ** ** **    ** **    *  ** ** ** **    **          **        
AHSV8_DQ868775       AGACAAGCGATTAATAGTGATGTTGAGATGTTGAGGAGATCGATTCCGAAACGGATAAAA 
AHSV8_AY163333       AGACAAGCGATTAATAGTGATGTTGAGATGTTGAGGAGATCGATTCCGAAACGGATAAAA 
AHSV5_AY163331       AGACAGGCGATTCAAATGAATGTTGAGATGCTGAGAGCGTTTGTACCAAAAAGGGTGGCT 
AHSV6_DQ868774       CGTGAGCCTCTGCCAATCTCAGTAGATATGATCAGAGATTATATTGGAGCCAGAATGCGA 
AHSV6_NC_005996      CGTGAGTCTTTACCAATCTCAGTAGATACGATCAGAGGTTATATTGGAGCTAGAATGCGA 
AHSV9_DQ868776       AGAGAACCGCTGCCAATTCATGTGGATATGATTCGGGATTATATCGGAAAACGAAT-TAA 
AHSV4_EU046574       AGGGAAGCGCGAAGTCAAAAGCTTGATCGGATTCGGAATTATATTGGAAAGAGAGTCGAA 
AHSV4_DQ868773       AGGGAAGCGCGAAGTCAAAAGCTTGATCGGATTCGGAATTATATTGGAAAGAGAGTCGAA 
AHSV4_D26570         AGGGAGGCGCGAAGCCAAAAGCTTGATCGAATTCGGAATTACATTGGAAAAAGAGTCGAA 
AHSV1_FJ011108       AGGCAAGCGCTGGCACTTGGAGTTGACGATCTAAGACATTCTGTTGATGTAAGGAATGAG 
AHSV1_AY163329       AGGCAAGCGCTGGCACTTGGAGTTGACGATCTAAGACATTCTGTTGATGTAAGGAATGAG 
AHSV2_AY163332       AGACAAGCAGAGCTCATGTCAATTGAAGATCTAAGGTATCCATTTGATATAAGATGCGAC 
AHSV1_Z26316         AGGCAGGCAATCAGTGGCCAAATTGAGGTTTCTCGTTCAATTATAGGTCGGCGGATGAAG 
AHSV3_U01832         AGGCAGGCAATCAGTGGCCAAATTGAGGTTTCTCGTTCAATTATAGGTCGGCGGATGAAG 
AHSV3_DQ868772       AGGCAGGCAATCAGCGGCCAAATTGAGGTTTCTCGTTCAATTATAGGCCGGCGAATGAAG 
AHSV7_AY163330       AGACAAGCGATTAGAGGGCACGTTGCGAAGATGCGAACGTTTGCAAAGGATAGGATTGAT 
                      *  *  *              * *         *                 *        
 
AHSV8_DQ868775       TACTTTGAAGACCAGATGGAGTTAAGGAAAAGCGTAAACGGAAATTGGATCGGTACGTTA 
AHSV8_AY163333       TACTTTGAAGATCAGATGGAGTTAAGGAAAAGCGTAAATGGAAATTGGATCGGTACGTTA 
AHSV5_AY163331       TTTTATGAAGACGATATGAGGAGGGGCGGTACTATTAACGGGAATTGGATTGGAGCGTTA 
AHSV6_DQ868774       AAGATTGAAGCCAGGGCGGGACGAATTAAGGAGGGTGGTGGAAATTTGTTGGAGTGCGCG 
AHSV6_NC_005996      GGGATTGAAGCTAGGGCTGGGCGAATTAGGGAGGGTGATGGAAACTTGTTAGAATGCGCG 
AHSV9_DQ868776       TTATTTTGAGCGAGAATTAAGTGG--TGGGGTGCGAGATGCAAATTTAGAGATGATAGTT 
AHSV4_EU046574       TTTTATGAAGAGGAGAGTAAGAGAAAAGCAATCCTTGATCAGAATAAGATGTCTAAGGTT 
AHSV4_DQ868773       TTTTATGAAGAGGAGAGTAAGAGAAAAGCAATCCTTGATCAGAATAAGATGTCTAAGGTT 
AHSV4_D26570         TTTTTTGAAGAGGAGAGTGGGAGAAAGGCGATCCTTAATCAGAATAAGATGTCTAAGATT 
AHSV1_FJ011108       TTCGAAGAAACGAATCACCAAACGAAAGGTGTGTTGAATGGAAATAAACAGAGAGCGCTT 
AHSV1_AY163329       TTCGAAGAAACGAATCACCAAACGAAAGGTGTGTTGAATGGAAATAAACAGAGAGCGCTT 
AHSV2_AY163332       TTCGAAGAAACTTCGTTCCAAACGAAATCCTCTTTAGATGGTAAGAAGCTTAGATTATTG 
AHSV1_Z26316         TATGAAGAGAGTGCTGAACAGACGAAGGGAACGATAAACGCAAATAAATATCGATTGTTG 
AHSV3_U01832         TATGAAGAGAGTGCTGAACAGACGAAGGGAACGATAAACGCAAATAAATATCGATTGTTG 
AHSV3_DQ868772       TATGAAGAGAGCGCTGAACAGACGAAGGGAACGATAAACGCAAATAAATATCGATTGTTG 
AHSV7_AY163330       TTTGAAGAGAGTAGCGCACAGACGAAAT--ACG-TCAATGGAAATAAGGTTAAGATTTTA 
                                                               **                 
 
AHSV8_DQ868775       CACAAATGGAAAGAGAGCGTAGATGCGCGTATGTTA-GAGGAGGGAGTGGGAAAGAAAGT 
AHSV8_AY163333       CACAAATGGAAAGAGAGCGTAGATGCGCGTATGTTA-GAGGAGGGAGTGGGAAAGAGAGT 
AHSV5_AY163331       CAGGCGTGGAAGGAAAAAGCGGATTTGCAAATGTCGCGCGAGGGGAATAGTCAAACTAAT 
AHSV6_DQ868774       CGCAGATGGGAAAAAGCGGCATATGAGAGAATTGAG-AATGAAAGAGCAT--TACGGTGT 
AHSV6_NC_005996      CGCAGATGGGAAAAAGCGGCGTATGAGAGGATTGAG-AATGAAAAAGCGT--TGCGGTGC 
AHSV9_DQ868776       GAGAAGTGGAAAGATAATACTTATAAAAGGATTGAA-GGTGAGAAAACGA--CGATGTGC 
AHSV4_EU046574       GAACAATGGAGAGATGCGGTTAATGAAAGGATTGTG-AGTATCGAACCAAAGCGAGGTGA 
AHSV4_DQ868773       GAACAATGGAGAGATGCGGTTAATGAAAGGATTGTG-AGTATCGAACCAAAGCGAGGTGA 
AHSV4_D26570         GAGCAGTGGAGAGATGCGGTTAATGAAAGGATTGTA-AGTGCCGAACCAAAGCGAGGTCA 
AHSV1_FJ011108       GAAGTTTGGAAGGAAATGGCGTATCAACGGATGCGTAAGGAGGGATCGCGGGGTAGATGT 
AHSV1_AY163329       GAAGTTTGGAAGGAAATGGCGCATCAACGGATGCGTAAGGAGGGATCGCGGGGTAGATGT 
AHSV2_AY163332       GAAAAATGGAAACGGGCTTCGCAAGAACGCATGCACGAAGAAAACGACCGTGGAAAGTGT 
AHSV1_Z26316         GAGAAGTGGCGCGATCTGGCCTATGAACAAATTGAAATAGAACGTGATAATGAAAGATGT 
AHSV3_U01832         GAGAAGTGGCGCGATCTGGCCTATGAACAAATTGAAATAGAACGTGATAATGAAAGATGT 
AHSV3_DQ868772       GAGAAGTGGCGTGATCTGGCTTATGAGCAAATTGAAATGGAAGGTAGTAGTGAAAGGTGT 
AHSV7_AY163330       GAGGAGTGGAAGGGGCGGACTGATGCTAGAATGTTGATGGAGGGCCAACAAGAGAAGTGC 
                           ***             *       **                             
AHSV8_DQ868775       GTGTGTAAGCCACGAAACTGATGTGGTATATCAGCTAATGAAAAAGATGCGGTTTGGTCT 
AHSV8_AY163333       GTGTGTAAGCCACGAAACTGACGTGGTATATCAGCTAATGAAAGAGATGCGGTTTGGTCT 
AHSV5_AY163331       -TGCGTTGACCATAATGCGGATGTAATATATCAACACATGAAGAAGTTAAGATTTGGATT 
AHSV6_DQ868774       GTGGTG----CATGAAACAGATCCGACGTATCAAATTCTTAAAAAACTAAGATTTGGATT 
AHSV6_NC_005996      GTGGCA----CATGAAACAGATCCAACGTATCAAATTCTTAAAAAACAAAGATTTGGATT 
AHSV9_DQ868776       GTGAGA----CATGAACCAGACTCAGTGCTACAGATGTTGAAAAAGATGAGGTTTGGGAT 
AHSV4_EU046574       GTGCTATGATCACGGAACCGACATTATCTACCAATTCATAAAAAAGCTGAGATTTGGAAT 
AHSV4_DQ868773       GTGCTATGATCACGGAACCGACATTATCTACCAATTCATAAAAAAGCTGAGATTTGGAAT 
AHSV4_D26570         ATGCTATGATCATGGTACCGACATTATCTACCAATTCATAAAAAAGCTAAGATTCGGAAT 
AHSV1_FJ011108       ATCGGA----CACGATGATGATGTAATGTACCAACTGATAAAGAAATTGAGATATGGGAT 
AHSV1_AY163329       ATCGGA----CACGATGATGATGTAATGTACCAACTGATAAAGAAATTGAGATATGGGAT 
AHSV2_AY163332       GCTGGT----CACGACGAAGATGTGTTGTATCAATTAGTTAAGAAATTAAGGTATGGCCT 
AHSV1_Z26316         TTGACG----CATAACACCGACCCGATTTATCAATTGATAAAAAAGATGAGGTATGGAAT 
AHSV3_U01832         TTGACG----CATAACACCGACCCGATTTATCAATTGATAAAAAAGATGAGGTATGGAAT 
AHSV3_DQ868772       TTGACG----CATAACACTGATCCGATTTATCAATTGATAAAGAAGATGAGGTTTGGAAT 
AHSV7_AY163330       GTTGCA----CATGAGGTTGATCCGATTTACCAATTGATTAAAAAGATGAGATATGGAAT 
                               **       **          **     * **  *     * *  **  * 
 
AHSV8_DQ868775       ATTATACCCCCATTATTATATGCTAAACAATGAGTATGTAGTGAAGAAAGAGAATGTTGA 
AHSV8_AY163333       ATTATACCCCCATTATTATATGCTAAACAATGAGTATGTAGTGAAGAAAGAGAATGTTGA 
AHSV5_AY163331       ACTGTATCCGCATTACTATATGCTCAATCCAGAATATACGGTTGAAGAAAAGAGCAAAGG 
AHSV6_DQ868774       CATTTATCCGCATTATTATGTCTTGAATACTGACTATAATCCAACAACTGTGACTAGAAC 
AHSV6_NC_005996      TGTCTATCCGCATTATTATGTTTTGAATACTAATTATAATCCAACAACGGTGACTAGAAC 
AHSV9_DQ868776       GTTATATCCAAACTACTATATGCTGAATACAGATTATATAGTTACTGAATCAAGTAAGGA 
AHSV4_EU046574       GATGTACCCACACTATTATGTTTTGCATAGTGATTACTGTATTGTACCAAATAAGGGGGG 
AHSV4_DQ868773       GATGTACCCACACTATTATGTTTTGCCTAGTGATTACTGTATTGTACCAAATAAGGGGGG 
AHSV4_D26570         GATGTACCCACATTATTATGTTCTGCATAGTGACTATTGTATTGTACCAAACAAAGGCGG 
AHSV1_FJ011108       GATGTATCCTCATCATTACGCATTGAATGCTCGATATGAGGTTTCAAACCCAAGCGC--- 
AHSV1_AY163329       GATGTATCCTCATCATTACGCATTGAATGCTCGATATGAGGTTTCAAACCCAAGCGC--- 
AHSV2_AY163332       ACTGTATCCACATAGCTATACCCTTAACACGAAATATAAAATTGTCAACCCAAGCGT--- 
AHSV1_Z26316         GATGTATCCAGTGCACTACATGCTAAACGATAGATATAAAGTTGTGCAAGAGCGCGCAGA 
AHSV3_U01832         GATGTATCCAGTGCACTACATGCTAAACGATAGATATAAAGTTGTGCAAGAGCGCGCAGA 
AHSV3_DQ868772       GATGTATCCAGTGCATTACATACTAAACGATAAATACAAGGTCGTACAAGAGCGCGCAGA 
AHSV7_AY163330       GATGTATCCTACGCATTATATGTTGAGCCAGAGATATAGGATTATATCTGAACGTCGAAA 






AHSV8_DQ868775       CGCGTTAATTGGTAGTTGGTTGATCAAGGAGAGATCGAGTGGAAAGGCAGAGTACTCCCA 
AHSV8_AY163333       CGCGTTAATTGGTAGTTGGTTGATCAAGGAGAGATCGAGTGGAAAGGCAGAGTACTCCCA 
AHSV5_AY163331       AGGTTTGATAGCCAACTGGTTAGTGAAAGAGAAGGCGGCGGGACGTGCTGAGAATTCACC 
AHSV6_DQ868774       TTCGCGGATTAATGATTGGTTGCTAAAAGAAAAGACACAAGGAGTTGTGAAGGCCGCTGA 
AHSV6_NC_005996      TTCGCGGATTAATGATTGGTTGCTAAAAGAAAAGACACAAGGAGTTGTGAAGACCGCTGA 
AHSV9_DQ868776       GGCGCCGTTAAATCGATGGTTAGTGAAGGAGAAAACAGTTGGGAAAGTTAAAGCGGCCGA 
AHSV4_EU046574       AACTAGTATTGGATCATGGCATATAAGAAAACGTACTGAGGGTGATGCGAAAGCTTCTGC 
AHSV4_DQ868773       AACTAGTATTGGATCATGGCATATAAGAAAACGTACTGAGGGTGATGCGAAAGTTTCTGC 
AHSV4_D26570         CACAAGTATCGGATCATGGCATATAAGAAAACGTACTGAAGGTGACGCGAAAGCTTCCGC 
AHSV1_FJ011108       GGCACGGATTAAAGATTGGCTGTT---GAAGGTAAGGGTTAATGTAGGGAGGGCACAGGA 
AHSV1_AY163329       GGCACGGATTAAAGATTGGCTGTT---GAAGGTAAGGGTTAATGTAGGGAGGGCACAGGA 
AHSV2_AY163332       TTCACAGATTAAGGACTGGCTGTT---AAAAACAAGGGATGGTATTAGAGAAGAATCTGG 
AHSV1_Z26316         TATGGGGGTTGAAAAGTGGCTTCTTCAAAAAATCGGAAGGGGTACCCAAAGGCGGAAGGC 
AHSV3_U01832         TATGGGGGTTGAAAAGTGGCTTCTTCAAAAAATCGGAAGGGGTACCCAAAGGCGGAAGGC 
AHSV3_DQ868772       TATGGGGATTGAAAAGTGGCTTCTTCAAAAAATCGGAAGGGGTACCCAAAGGCGGAAGGC 
AHSV7_AY163330       AATGGGAATTGAGAAGTGGCTATTGGAGAAAGTTGAAAGGGGAGTACAGAGAGGAGTAGC 
                             *       ***    *     *                               
AHSV8_DQ868775       GATGTATTCAGGGGTGGGACCGCTTAGTGGGTTACGCGAACGTATCGAAAAGGATGAGTT 
AHSV8_AY163333       GATGTATTCAGGGGTAGGACCGCTTAGTGGGTTACGCGAACGTATTGAAAAGGATGAGTT 
AHSV5_AY163331       AATGTATTCGGGGGTCGGACCGCTAAATACATCGCGTGAGCGTATCGAGAGGGATGAGTT 
AHSV6_DQ868774       GGCGTATTCCGATAACGCGGAGTTGAAAACTTTAGCGGAACGAATGGAGGAGGAGGAACT 
AHSV6_NC_005996      GGCGTTTTCCGACAACGCAGAGTTGAAGACTTTAGCGGAACGAATGGAAGAGGAGGAGCT 
AHSV9_DQ868776       AGCTTTTGCGGGTAATTCGTTATTAAAAAGCTTGGCGAGCCGGATGGAGGACGAGGAGTT 
AHSV4_EU046574       TATGTATTCTGGAAAAGGTCCACTGAATGACTTACGAGTTAAAATTGAGCGGGATGATTT 
AHSV4_DQ868773       TATGTATTCTGGAAAAGGTCCACTGAATGACTTACGAGTTAAAATTGAGCGGGATGATTT 
AHSV4_D26570         CATGTATTCTGGAAAGGGTCCGCTGAATGACTTACGAGTTAAAATTGAGCGGGATGATTT 
AHSV1_FJ011108       GAAAGCTGATCAAACAGGCCCGCTCGCCGAGATGGCTAGATCAATTGAAAACGATGAATT 
AHSV1_AY163329       GAAAGCTGATCAAACAGGCCCGCTCGCCGAGATGGCTAGATCAATTGAAAACGATGAATT 
AHSV2_AY163332       AATATCAGATAAGCAGGGACCATTAGCGGAGTTGGTGAGTGCAATCAAAGACGAGGAGCT 
AHSV1_Z26316         TGACGATGGCGATAATGATGCGCTCTTACAGCTAGAAAGAATGATGAGCAGTGAAGAGCT 
AHSV3_U01832         TGACGATGGCGATAATGATGCGCTCTTACAGCTAGAAAGAATGATGAGCAGTGAAGAGCT 
AHSV3_DQ868772       TGACGATGGCGATAATGATACGCTCTTACAGCTAGAAAGAATGATGAGCAGTGAGGAGCT 
AHSV7_AY163330       CGGTGCGAAAGGTAATGAATCGTTAGTACGGTTAGAAAAACTGATGCAGAAAGAAGAGCT 
                                            *                   **       ** **  * 
 
AHSV8_DQ868775       GGACGAAAAAGTTATTCAAGAGATTATCGCCTATGGCTCAAAATTTAGCACATATACAGG 
AHSV8_AY163333       GGATGAAAAAGTTATTCAAGAGATTATTGCCTATGGCTCAAAATTTAGCACATATACAGG 
AHSV5_AY163331       AGATGAAAAAGTTATTCAGGAAATCATTGCTTATGGATCCAAATTTAGCACCTACGCGGG 
AHSV6_DQ868774       GACTGTGGATATCATTCGGGCGGTAATCAGGTATGGGGCCAAATATGCTACGCGCTCGGG 
AHSV6_NC_005996      GACTGAGGATATTATTCGAGCAGTGATCAGGTATGGAGCCAAATACGCTACGCGCTCGGG 
AHSV9_DQ868776       GAGTCGAGAAATAATAATTGCAGTGATCAATTATGGTTCGAAATTTGGAACTAGATCTGG 
AHSV4_EU046574       ATCTCGAGAGACAATTATTCAGATCATTGAGTACGGTAAGAAATTTAATTCATCAGCAGG 
AHSV4_DQ868773       ATCTCGAGAGACAATTATTCAGATCATTGAGTACGGTAAGAAATTTAATTCATCAGCAGG 
AHSV4_D26570         ATCTCGAGAGACGATTATTCAGATTATCGAATACGGTAAAAAATTTAATTCATCTTCAGG 
AHSV1_FJ011108       AAGCCGTCAAGTGGTTGACCAAATTATACAATATGGTGGACAATTTAGTTCATGCTCAGG 
AHSV1_AY163329       AAGCCGTCAAGTGGTTGACCAAATTATACAATATGGTGGACAATTTAGTTCATGCTCAGG 
AHSV2_AY163332       AAGTCGGGGAGTAATTGGGCGGATCGTACAATATGGCTCGCAATTTAGTTCGTGTGCAGG 
AHSV1_Z26316         GGAAAGATCCGTTATTGAGAGCGTCATAAGATTCGGTTCTTTATATAACGCGCACGCGGG 
AHSV3_U01832         GGAAAGATCCGTTATTGAGAGCGTCATAAGATTCGGTTCTTTATATAACGCGCACGCGGG 
AHSV3_DQ868772       AGAAAGACCCGTTATTGAGAGCGTCATAAGATTCGGTTCCTTATATAACGCGCACGCGGG 
AHSV7_AY163330       TGAGAATTCTGTGATCGAGAATGTAATACGCTACGGTTCGCAGTTTAGCACACACGCCGG 
                                   *        *  *    *  **       *      *     * ** 
 
AHSV8_DQ868775       TGCCAAGCAC-GGTGATATATCGCTAAAAGACTTAGTTGAGTATTGTGAAAGTTTAACCA 
AHSV8_AY163333       TACCAAGCGC-GGTGATATATCGCTAAAAAACTTAGTTGAGTATTGTGAAAGTTTGACCA 
AHSV5_AY163331       TAC-ACGCACAGGAGATCTCACTTTGAATGAATTAGTAAAGTATTGCGAAAGTTTAACGA 
AHSV6_DQ868774       TATGCGAGAG-GATACACTGTCACTCCAGGAGTTGGATCGTTATTGCGATTCCCTAACAA 
AHSV6_NC_005996      TATGCGAGAG-GATACACTGTCACTCCAGGAGTTGGATCGTTATTGCGATTCTCTAACAA 
AHSV9_DQ868776       AAAGAAGAAG-GATTTGATGACTATTGATAAGCTTGAAAAATATTGTGATTCGTTGACGA 
AHSV4_EU046574       TGATAAGCAG-GGGAACATTTCAATTGAAAAATTGGTAGAGTATTGTGATTTTTTGACAA 
AHSV4_DQ868773       TGATAAGCAG-GGGAACATTTCAATTGAAAAATTGGTAGAGTATTTTGATTTTTTGACAA 
AHSV4_D26570         TGATAAGCAG-GGGAATATTTCAGTTGATAAATTGGTGGAGTATTGTGACTTCTTGACAA 
AHSV1_FJ011108       CGCACGTGAA-GATGATATTCCGATAAATATTTTGTTGGAGTATTGTGAGTCCTTAACAA 
AHSV1_AY163329       CGCACGTGAA-GATGATATTCCGATAAATATTTTGTTGGAGTATTGTGAGTCCTTAACAA 
AHSV2_AY163332       GGAACGAGAA-GATGATATCCCGATCGAAACATTGATTCGTTACTGCGACTCGCTGACGA 
AHSV1_Z26316         CAAAAAGACA-GGCGACATTCCATTAGAAGTCTTGATTAAATATTGCGATTCGCTTACTA 
AHSV3_U01832         CAAAAAGACA-GGCGACATTCCATTAGAAGTCTTGATTAAATATTGCGATTCGCTTACTA 
AHSV3_DQ868772       CAAGAAGACA-GGCGACATTCCATTAGAAGTCTTGATAAAATATTGCGATTCGCTTACTA 
AHSV7_AY163330       AGAAAAGACT-AATGATATGCCTCTGTCCGTTTTGATAAAATACTGCGAATCATTAACCA 
                                       *  *  *        *       ** *  **     * ** * 
AHSV8_DQ868775       CATTCGTACACAAGAAGAAAAAAGAT---GGTGAGGAGGAAACCGCACGACAGTTTTTTA 
AHSV8_AY163333       CATTCGTACACAAGAAGAAAAAAGAT---GGTGAGGAGGAAACCGCACGACAGTTTTTTA 
AHSV5_AY163331       CTTTTGTTCATAAGAAAAAGAAGGAG---GGAGAGGATGAGACTGCAAGGGAGTTTTTCA 
AHSV6_DQ868774       CTTTTGTTCATAAAAAGAAGAAGGATGAAGGCGATGATGAAACAGCGCGTACGATAATTA 
AHSV6_NC_005996      CTTTTGTTCATAAAAAGAAGAAGGATGAAGGTGATGATGAAACAGCACGTACGATAATTA 
AHSV9_DQ868776       CGTTCGTCCACAAAAAGAAGCGTGACGAAGGTGACGATGAAACAGCTAGGGCTATCATTA 
AHSV4_EU046574       CATTCGTTCATGCGAAGAAGAAAGAAGAGGGTGAGGATGATACTGCTCGACAGGAGATAA 
AHSV4_DQ868773       CATTCGTTCATGCGAAGAAGAAAGAAGAGGGTGAGGATGATACTGCTCGACAGGAGATAA 
AHSV4_D26570         CATTTGTCCACGCGAAGAAGAAAGAAGAGGGTGAAGATGATACCACTCGACAGGAGATAA 
AHSV1_FJ011108       CATTTGTTCACAGAAAGAAGAGAAAGGAGGGGGATGATCTCACTGCACGCAATACCTTTC 
AHSV1_AY163329       CATTTGTTCACAGAAAGAAGAGAAAGGAGGGGGATGATCTCACTGCACGCAATACCTTTC 
AHSV2_AY163332       CATTTGTTCATCGAAAGAAGAGAGAACGAGGCGATGATACCACAGCGCGTGACGTCTTCA 
AHSV1_Z26316         CATTCGTGCATAAAAAGAACAGAGAGGGAGGAGATAATCAGACCGCTCGCGACGAGATTA 
AHSV3_U01832         CATTCGTGCATAAAAAGAACAGAGAGGGAGGAGATAATCAGACCGCTCGCGACGAGATTA 
AHSV3_DQ868772       CATTCGTGCATAAAAAGAACAGAGAGGGAGGAGATAATCAGACCGCTCGCGACGAGATTA 
AHSV7_AY163330       CTTTTGTACATAAAAAGAATCGCGAGGGAGGCGATAATCAGACGGCGCGTGATGAGATTA 
                     * ** ** **    ** **     *    ** **  *    **  *  *        *   
 
AHSV8_DQ868775       AAAACAAGTGGATACAGGGGATGCCCAAGATGAATTTTGAAAGTGAGATGAAGGTATCTC 
AHSV8_AY163333       AAAACAAGTGGATACAGGGGATGCCCAAGATGAATTTTGAAAGTGAGATGAAGGTGTTTC 
AHSV5_AY163331       AAAGTAAATGGATACAAGGTATGCCAAAGATGAACTTTGAAAATGAAATGATTATGTCAA 
AHSV6_DQ868774       GAAATCAGTGGATTAAGGGAATGCCACGAATGGATTTCAAAAAAGAGATGAAAATCACAC 
AHSV6_NC_005996      GAAATCAGTGGATTAAAGGGATGCCTCGAATGGATTTCAAAAAAGAGATGAAAATCACTC 
AHSV9_DQ868776       GAAACCAATGGATTAAGGGGATGCCGAGTATGAATTTGAAAAAAGAAATGAAAGTTTCGC 
AHSV4_EU046574       GAAAAGCATGGGTTAAGGGGATGCCTTATACGGATTTCTCAAAACCGATGAAAATCGCGC 
AHSV4_DQ868773       GAAAAGCATGGGTTAAGGGGATGCCTTATATGGATTTCTCAAAACCGATGAAAATCACGC 
AHSV4_D26570         GAAAAGCATGGGTTAAGAGGATGCCTTATATGGATTTCTCAAAACCGATGAAAATAACGC 
AHSV1_FJ011108       GGCAGGCGCTGATTAAGAGTATGCCAACCATGAATTTCAAGAATCAAATGAAAATGAC-- 
AHSV1_AY163329       GGCAGGCGCTGATTAAGAGTATGCCAACCATGAATTTCAAGAATCAAATGAAAATGAC-- 
AHSV2_AY163332       GAAATGCCTTAGTTGGAAGTATGCCTAAAATGGACTTCAAGAATCAAATGAAGATGGCCA 
AHSV1_Z26316         GGAGGGCAGTGGTAAAGAATATTCCATCGATGAAACAGGAGAATCAGATGAAAGTCACTC 
AHSV3_U01832         GGAGGGCAGTGGTAAAGAATATTCCATCGATGAAACAGGAGAATCAGATGAAAGTCACTC 
AHSV3_DQ868772       GGAGGGCAATGGTAAAGAATATTCCATCGATGAAGCAGGAAAATCAGATGAAAGTCACTC 
AHSV7_AY163330       GAAAAGCTATGGTGCATAATATGCCGACCATGAATCACAACAACCCGATGAAGGTGACGA 






AHSV8_DQ868775       GCGGACCATGGGCTAACATTCAATTCTTCTGGAGCATTGATATGTTTAAAAGAAACAATG 
AHSV8_AY163333       GCGGACCATGGGCTAACATTCAATTCTTCTGGAGCATTGATATGTTTAAAAGAAACAATG 
AHSV5_AY163331       GAAAGTCATGGGCGAATACAAAATTCTTTTGGAGTATTGATATGTTCAAGAGAAATAATG 
AHSV6_DQ868774       GAGGCCCGATTGCGAACTGGTCGTTTTTTATGTCTATAGATGCATTTAAAAGAAACAATA 
AHSV6_NC_005996      GAGGTCCGATTGCGAACTGGTCGTTTTTTATGTCTATAGATGCTTTCAAAAGGAATAATA 
AHSV9_DQ868776       GTGGTCCTATTCAAAATTGGTCGTTTTTCATGTCCCTAGAGATGTTTAAACGTAATAACA 
AHSV4_EU046574       GTGGATTCAACAGAAATATGCTTTTCTTTGCGGCGCTCGATTCATTCAGAAAGAGGAACG 
AHSV4_DQ868773       GTGGATTCAACAGAAATATGCTTTTCCTTGCGGCGCTCGATTCATTCAGAAAGAGGAACG 
AHSV4_D26570         GTCGGTTCAACAAGAATATGCTTTTCTTTGCGGCACTCGATTCATTCAGAAAGAGGAACG 
AHSV1_FJ011108       GAGAGGGTGGGGAAATTATAC-ATTTTTCTCATATATTGATAGATTCAGTCGTATTTATA 
AHSV1_AY163329       GAGAGGGTGGGGAAATTATAC-ATTTTTCTCATATATTGATAGATTCAGTCGTATTTATA 
AHSV2_AY163332       AAGAGGGTGGGGCAACTATACCGTTCTTTTCATACATTGATAGGTTTAGCCGGACTTACA 
AHSV1_Z26316         CTAATATCAGG--AATTTT-CTGTTTTTCGCATATTTAAACGGTTTTAAAAGGAATAATG 
AHSV3_U01832         CTAATATCAGG--AATTTT-CTGTTTTTCGCATATTTAAACGGTTTTAAAAGGAATAATG 
AHSV3_DQ868772       CAAATATCAGG--AATTTT-CTGTTTTTCGCATATTTAAACGGTTTTAAAAGGAATAATG 
AHSV7_AY163330       AGAACTTTAAG--AACTTT-CTCTTTTTCGCGTATTTAGATGGCTTTAAAAGAAATAACG 
                                   *        **  *        *  *    ** *     *   *   
AHSV8_DQ868775       GAGTGGATATAGATCCCAACGGCGAAAACTGGAAAAAATATAAGGCGGAAGTCCAAGAAC 
AHSV8_AY163333       GGGTGGATATAGATCCGAACGGCGAAAATTGGAAAAAATATAAGGCGGAAGTCCAAGAAC 
AHSV5_AY163331       GCGTTGATATTGATCCAAACGGTAAGAATTGGAAAGATTACAAGAAAAAGGTACAAGAGC 
AHSV6_DQ868774       AGGTCGACATTAATCCGAACCACCAAACGTGGAAGGATCATATCAAAGAAGTTACTGATC 
AHSV6_NC_005996      AGGTTGATATTAATCCGAATCACCAGACGTGGAAGGATCACATTAAAGAAGTGACTGATC 
AHSV9_DQ868776       AAGTTGATATTGATCCGAATCATGATACGTGGAAAAATCACGTTAAAGAGATCAGGGAGA 
AHSV4_EU046574       GTGTAGATGTTGATCCGAATAAGGGTAAGTGGAAAGAACATATAAAGGAGGTAACCGAAA 
AHSV4_DQ868773       GTGTAGATGTTGATCCGAATAAGGGTAAGTGGAAAGAACATATAAAGGAGGTAACCGAAA 
AHSV4_D26570         GCGTAGACGTTGATCCAAATAAGAATAAGTGGAAAGAACATATAAAAGAGGTAACCGAAA 
AHSV1_FJ011108       ATATGAATATTGATCCGAATGGTAAGCTTTGGATTGAACATAAACAAACGGTGAGTGAGC 
AHSV1_AY163329       ATATGAATATTGATCCGAATGGTAAGCTTTGGATTGAACATAAACAAACGGTGAGTGAGC 
AHSV2_AY163332       AGATGAATATTGACCCGAATAAGGGTTTATGGAACGAACACAAACAAAAAGTGAAGAAAC 
AHSV1_Z26316         GCGTTGATATCGACCCAAATAATGGTACGTGGAGTAAGCATAAAGCGGAAGTTAAGAAGT 
AHSV3_U01832         GCGTTGATATCGACCCAAATAATGGTACGTGGAGTAAGCATAAAGCGGAAGTTAAGAAGT 
AHSV3_DQ868772       GTGTTGATATCGACCCAAATAATGGTACGTGGAGTAAGCATAAAACGGAAGTTAAGAAGA 
AHSV7_AY163330       GCGTAGATATTAATCCTAACAATTCGACGTGGATCGAGCATAAGAAGAAGATGGCGGAAA 
                        *  *  *  * ** **          ****   *  *           *     *   
 
AHSV8_DQ868775       GTTTGAATGAAGCGCAGAAGAAGAATCGAAATGTTCCTCATTTAATGCTTGTTGATGGAG 
AHSV8_AY163333       GTTTGAATGAAGCGCAGAAGAAGAATGGAGGTGTTCCTCATTTAATGCTTGTTGATGGAG 
AHSV5_AY163331       AGTTGGATGAGGCGCAAAAGAAGAACAATAACGAACCGTATAAAGTAATGGTTGATGGGG 
AHSV6_DQ868774       AAATGAATCGTGCGCAGCAAGGCAACAATAATAAACCTCTAAAGATTCAGATTGATGGAG 
AHSV6_NC_005996      AAATGAATCGTGCGCAACAAGGCAACAATAATAAGCCTCTAAAGGTTCAAATCGATGGTG 
AHSV9_DQ868776       GGATGCAGAAAGAACAGAGCGCGAATTCTAATTCACCCTTAAAGATCCAGGTTGATGGGG 
AHSV4_EU046574       AATTGAAGAAAGCGCAAACCGAAAATGGAGGACAACCATGCCAAGTGTCGATCGATGGAG 
AHSV4_DQ868773       AATTGAAGAAAGCGCTAACCGAAAATGGAGGACAACCATGCCAAGTGTCGATCGATGGAG 
AHSV4_D26570         GATTAAAGAAAGCGCAAAACGAAAATGGAGGACAGCCATGCCAAGTGTCGATCGATGGGG 
AHSV1_FJ011108       AGTTGAAAAAGAAACAAGAGGAGAACCGAGCG---CCTCTAACCGTTCAAATTGATGGGG 
AHSV1_AY163329       AGTTGAAAAAGAAACAAGAGGAGAACCGAGCG---CCTCTAACCGTTCAAATTGATGGGG 
AHSV2_AY163332       AATTAGAAGAAAAACAGGAAGAGAATGGGTCT---CCCATGTCCGTTCAGATCGATGGGG 
AHSV1_Z26316         TTTTGAACGAGGAACAAAAGAAGAATGAAAATAAACCATTAAAGGTGTTGATTGATGGCG 
AHSV3_U01832         TTTTGAACGAGGAACAAAAGAAGAATGAAAATAAACCATTAAAGGTGTTGATTGATGGCG 
AHSV3_DQ868772       TTTTGGACGAGGAACAAAAGAAGAATGAAAACAAACCATTAAAGGTGTTGATTGATGGCG 
AHSV7_AY163330       AGCTAAAGGATGAGCAACAGAAAAACCAAAATCGTCCGATGCTAGTGCCGATTGATGGTG 
                        *  *       *        **          **        *     * ***** * 
 
AHSV8_DQ868775       TGAATATTATGACAGATAAAAAATATGGGACCGTTCAAAATTGGGTTGATTGGGTCGTGA 
AHSV8_AY163333       TGAATATTATGACAGATAAAAAATACGGGACCGTTCAAAATTGGGTTGATTGGGTCGTGA 
AHSV5_AY163331       TTAACATCATGACGAATAAGAAGTACGGATCCGTTGAAAACTGGGTCGATTGGGTTGTAA 
AHSV6_DQ868774       TTAGCATACTCACGAATGAAAAGTATGGTACCGTTGGTCATTGGGTTGATTGGGTTGTTG 
AHSV6_NC_005996      TTAGCATACTCACGAGTGAAAAATATGGTACCGTTGGTCATTGGGTCGATTGGGTTGTTG 
AHSV9_DQ868776       TCAGTTTATCAACCGGTGAATTCTACGGTACGGTTGAACATTGGATAGATTGGGTTGTTG 
AHSV4_EU046574       TAAACGTCTTGACTAACGTAGATTACGGTACGGTTAATCATTGGATAGATTGGGTAACAG 
AHSV4_DQ868773       TAAACGTCTTGACTAACGTAGATTACGGTACGGTTAATCATTGGATAGATTGGGTAACAG 
AHSV4_D26570         TAAACATCTTAACTAACGTGGATTATGGAACGGTTAATCATTGGATCGATTGGGTAACAG 
AHSV1_FJ011108       TGCACATACGTACGGATGAAACCTATGGAACAGTAGATCATTGGGTTGAATGGGTCGTTG 
AHSV1_AY163329       TGCACATACGTACGGATGAAACCTATGGAACAGTAGATCATTGGGTTGAATGGGTCGTTG 
AHSV2_AY163332       TTTATATCCGAACAGATGTGCCGTATGGAACGGTTGATCATTGGGTTGATTGGGTTGTTG 
AHSV1_Z26316         CGTACATATCAACCGATGCTGAGTACGGAACCGTAGCGCATTGGGTGGATTGGGTCGTTG 
AHSV3_U01832         CGTACATATCAACCGATGCTGAGTACGGAACCGTAGCGCATTGGGTGGATTGGGTCGTTG 
AHSV3_DQ868772       CGTACATATCAACTGATGCTGAGTACGGAACCGTAGCGCATTGGGTGGACTGGGTCGTGG 
AHSV7_AY163330       TCTACGTCTCCACTAGTGTTGAGTATGGTACCGTTACACATTGGGTTGATTGGGTCGTTG 
                           *    **          ** **  * **     * *** * ** *****      
AHSV8_DQ868775       ATTATATCATGTTATCGCACGTGAAACGTTTAGTTAAGGATTATAAATTTAAAAGATTGC 
AHSV8_AY163333       ATTATATCATGTTATCGCACGTGAAACGTTTAGTTAAGGATTATAAATTTAAAAAACTGC 
AHSV5_AY163331       ATTATATTATGTTATCGCACGTCAAAAGGCTGGTTAAGGACTATAAATTTAAGAGGCTCA 
AHSV6_DQ868774       ACTTAATTATGTTAGCGCAGGTGAAGATGTTAATAAAAGAATATAAGTTTAAAAGATTGA 
AHSV6_NC_005996      ATTTGATTATGTTGGCGCAGGTGAAAATGTTAATAAAAGAATATAAGTTTAAAAGATTAA 
AHSV9_DQ868776       ATTTAATTATGTTAGCACAGGTGAAACGATTAATCAAGGAGTACAAGTTTGTAAGATTGG 
AHSV4_EU046574       ATATAATTATGGTTGTACAAACTAAACGTTTGGTGAAAGAGTATGCATTTAAAAAACTAA 
AHSV4_DQ868773       ATATAATTATGGTTGTACAAACTAAACGTTTGGTGAAAGAGTATGCATTTAAAAAACTAA 
AHSV4_D26570         ATATGATTATGGTCGTACAGACTAAACGATTAGTAAAAGAGTATGCGTTTAAAAAACTGA 
AHSV1_FJ011108       ACACAATCATGCTTAGAGAGACTGAAAAAATGATTAAGGATTATCGGTTCAAAAAACTTA 
AHSV1_AY163329       ACACAATCATGCTTAGAGAGACTGAAAAAATGATTAAGGATTATCGGTTCAAAAAACTTA 
AHSV2_AY163332       ACACAATCATGCTTAAGGAGACTGACAAAATGATAAAGGATTACGAATTTAAGAAATTAA 
AHSV1_Z26316         ATATCGTAATGATGACTCAAGTTAGCCGCATGATAAAAGAATATAATTTTATTAGATTAA 
AHSV3_U01832         ATATCGTAATGATGACTCAAGTTAGCCGCATGATAAAAGAATATAATTTTATTAGATTAA 
AHSV3_DQ868772       ATATCATAATGACGACTCAAGTTAGCCGCATGATAAAGGAATATAATTTTATTAGATTGA 
AHSV7_AY163330       ATATTATAATGACAACGCAGGTTGAAAGAATGATAAAAGAGTATGATTTTAAACGATTGG 
                     *     * ***       *           *  * ** ** **    **        *   
 
AHSV8_DQ868775       AACCGGATAATTTGATGTCAGGCATGAATAAGCTTGTAGGTGCGTTGAGGTGTTACGCAT 
AHSV8_AY163333       AACCGGATAATTTGATGTCAGGCATGAATAAGCTTGTAGGTGCGTTGAGGTGTTACGCAT 
AHSV5_AY163331       AGCCGGATAATTTGATGTCCGGGATGAATAAGCTAGTCGGCGCACTAAGATGTTATGCGT 
AHSV6_DQ868774       ATAGCCAAAATTTGATGTCGGGTATGAATAAACTGGTCGGTGCACTGAGATGTTATGCTT 
AHSV6_NC_005996      ATAGCCAAAATTTGATGTCGGGTATGAACAAACTGGTTGGTGCGCTGAGATGTTATGCTT 
AHSV9_DQ868776       AAACCTCGAACTTAATGGCGGGAATGAATAAATTAGTTGGAGCCTTGCGCTGCTACGCCT 
AHSV4_EU046574       AGAGCGAAAACTTACTTGCTGGAATGAATAGTTTAGTTGGGGTATTAAGATGTTATATGT 
AHSV4_DQ868773       AGAGCGAAAACTTACTTGCTGGAATGAATAGTTTAGTTGGGGTATTAAGATGTTATATGT 
AHSV4_D26570         AGAGCGAAAACCTACTTGCCGGAATGAATGGTTTAGTTGGGATATTAAGATGTTATATGT 
AHSV1_FJ011108       AGCGTGAGGAGCTGATCTCTGGAATGAATAAATTAGAGGATGGCTTACGATGTATCGTGT 
AHSV1_AY163329       AGCGTGAGGAGCTGATCTCTGGAATGAATAAATTAGAGGATGGCTTACGATGTATCGTGT 
AHSV2_AY163332       AACGTGAAGAATTGATAGCTGGTATGAACAAGTTGGAGGATGGTTTGAGATGCATTGTTT 
AHSV1_Z26316         AAAAGGATCAGCTAATCAGCGGTATGAATAAGTTGGAGGATGGGGTAAAATGCTACGCGT 
AHSV3_U01832         AAAAGGATCAGCTAATCAGCGGTATGAATAAGTTGGAGGATGGGGTAAAATGCTACGCGT 
AHSV3_DQ868772       AAAAGGATCAGCTAATCAGCGGTATGAATAAATTAGAGGATGGGGTAAAATGCTACGCGT 
AHSV7_AY163330       AGAGAAAACAGCTAATTAGTGGTATGAACAAGCTCGAGGATGGAGTTAAATGTTATGCTT 






AHSV8_DQ868775       ATTGCTTAATCCTTGCGTTGTATGATCATTTCGGAGCGGAAATCGAAGGATTTAGGAAGG 
AHSV8_AY163333       ATTGCCTAATCCTTGCGTTGTATGATCATTTCGGAGCGGAAATTGAAGGATTTAGGAAGG 
AHSV5_AY163331       ATTGTTTGATACTCGCGTTATATGATTATTTCGGGGAGGATATCGAAGGGTTTAAGAAAG 
AHSV6_DQ868774       ACTGCTTGATTCTCGCTTTGTATGACTATTATGGTCAAGATATCGAGGGCTTCAAGAAGG 
AHSV6_NC_005996      ACTGCTTGATTCTTGCTTTATATGACTATTATGGTCAAGATATTGAGGGCTTCAAGAAGG 
AHSV9_DQ868776       ATTGCTTGATCTTAGCTCTCTATGATTTTTATGGCGCAGATATTGAAGGTTTTGAGAAGG 
AHSV4_EU046574       ATTGCTTAGCTTTAGCGATCTATGATTTTTATGAAGGGACTATTGATGGTTTTAAGAAAG 
AHSV4_DQ868773       ATTGCTTAGCTTTAGCGATCTATGATTTTTATGAAGGGACTATTGATGGTTTTAAGAAAG 
AHSV4_D26570         ATTGTTTAGCTTTAGCGATTTATGATTTTTATGAAGGAATTATTGATGGTTTTAAGAAAG 
AHSV1_FJ011108       ATTGCTTAATACTTGCTCTATACGATTATTATGAAGGAGATATCGAGGGTTTTAAGAAGG 
AHSV1_AY163329       ATTGCTTAATACTTGCTCTATACGATTATTATGAAGGAGATATCGAGGGTTTTAAGAAGG 
AHSV2_AY163332       ATTGCTTGATTTTAGCGTTATATGATTATTATGGGGCTGAGATTGAGGGATTCAAAAAGG 
AHSV1_Z26316         ATTGTTTGATCCTCGCACTGTACGATTTTCATGGGCGTGACGTAGACGGCTTTGCGCAGG 
AHSV3_U01832         ATTGTTTGATCCTCGCACTGTACGATTTTCATGGGCGTGACGTAGACGGCTTTGCGCAGG 
AHSV3_DQ868772       ATTGTTTGATCCTCGCATTATATGATTTTCATGGGCGTGAACTAGACGGCTTTGCGCAGG 
AHSV7_AY163330       ATTGCTTGATTTTGGCATTGTACGATTATTATGGAGATGCGATCGAGGGTTTCGCGCAAG 
                     * **  *     * **  * ** **   *   *         * ** ** **     * * 
AHSV8_DQ868775       GGACTAACGCAGCTTCGATAGTTGAAACAGTTTCCCAGATGTTTCCAAATTTCAGAAAGG 
AHSV8_AY163333       GGACTAACGCAGCTTCGATAGTTGAAACAGTTTCCCAAATGTTTCCAAATTTCAGAAAGG 
AHSV5_AY163331       GAACGAACGCGGCTTCAATTGTAGAAACAGTGTCCCAAATGTTCCCGCAGTTTAGGAAAG 
AHSV6_DQ868774       GATCAAATTCTTCCGCGATATTAGAGACGGTTATTCAAATGTTTCCGAATTTTAAACAGG 
AHSV6_NC_005996      GATCAAATTCGTCTGCGATATTAGAAACGGTTATTCAGATGTTTCCGAATTTTAAACAGG 
AHSV9_DQ868776       GTTCGAACTCATCCGCGATTGTGGAGACGGTTGTACAGATGTTCCCGAACTTCAAGCAGG 
AHSV4_EU046574       GCTCGAATGCTTCCGCTATCATTGAAACTGTCGCGCAGATGTTTCCGGACTTTCGCAGAG 
AHSV4_DQ868773       GCTCGAATGCTTCCGCTATCATTGAAACTGTCGCGCAGATGTTTCCGGACTTTCGCAGAG 
AHSV4_D26570         GTTCAAACGCTTCCGCTATCATTGAAACCGTCGCGCAGATGTTTCCAGACTTTCGTAGAG 
AHSV1_FJ011108       GGACTATTGCTTCGTCAATAGTTGAGACCGTTTCACAGATGTTTCCAAATTTTCGAAGCG 
AHSV1_AY163329       GGACTATTGCTTCGTCAATAGTTGAGACCGTTTCACAGATGTTTCCAAATTTTCGAAGCG 
AHSV2_AY163332       GGACAAACGCTTCATCTATAGTTGAGACTGTATCACAAATGTTCCCAAACTTCCGTGGAG 
AHSV1_Z26316         GGACGAGAACCGCAGCTATTGTTGAGACCGTCGCGCGAATGTTTCCTGATTTTCGCTCTG 
AHSV3_U01832         GGACGAGAACCGCAGCTATTGTTGAGACCGTCGCGCGAATGTTTCCTGATTTTCGCTCTG 
AHSV3_DQ868772       GAACGAGAACCGCGGCTATTGTCGAGACCGTCGCACGAATGTTTCCCGATTTTCGCTCCG 
AHSV7_AY163330       GAACGCGTGCGGGTTCGATTGTCGAGACAATCTCCCAGATGTTCCCTGAGTTCCGTTCAG 
                     *  *     *     * **  * ** **  *    *  ***** **  * **       * 
 
AHSV8_DQ868775       AAGTTTCGGAAACTTTTGGCATCGATCTCAAAACAAAAGAGATTAAG-CACGAACTTTTC 
AHSV8_AY163333       AGGTTTCGGAAACTTTTGGCATCGATCTCAAAACAAAAGAGATTAAG-CACGAACTTTTC 
AHSV5_AY163331       AAGTTTCAGAGACCTTTGGAATCACTCTGAATACAAAAGACGTCAAA-TATGAGTTGTTT 
AHSV6_DQ868774       AAATTCAAGCTAATTTCGGGATAAATTTGAACATTAAAGATAAAAAA-CAATCGTTATTC 
AHSV6_NC_005996      AAATTCAAGCTAATTTCGGAATAAATTTGAATATTAAAGACAAAAAAACAATCGCTATTC 
AHSV9_DQ868776       AGATTCAAGCTAATTTTGGTATAAATCTAAATATCAAGGATAAAAAA-CAGGCGTTGTTC 
AHSV4_EU046574       AACTTGTCGAAAAATTCGGTATAGATTTAAGGATGAAGGAAATCACG-CGTGAGTTGTTT 
AHSV4_DQ868773       AGCTTGTCGAAAAATTCGGTATAGATTTAAGGATGAAGGAAATCACG-CGTGAGTTGTTT 
AHSV4_D26570         AGCTCGTTGAAAAGTTCGGTATAGATCTAAGGATGAAGGAAATCACG-CGTGAGTTGTTT 
AHSV1_FJ011108       ATATAATAGATAAATTCGGTATTTCTCTGAAAGTTAAAACTGAGGCC-GAAGAATTGTTT 
AHSV1_AY163329       ATATAATAGATAAATTCGGTATTTCTCTGAAAGTTAAAACTGAGGCC-GAAGAATTGTTT 
AHSV2_AY163332       ATATCATCGACAAATTTGGCATACAGCTGAAGGTGAAAAGGGAAGCT-GAGGAGTTGTTC 
AHSV1_Z26316         AGGTTTCGGAAAAATTCGGTATTGATTTAGCGGTGTCAGAGGAATCA-GATGAACTATTC 
AHSV3_U01832         AGGTTTCGGAAAAATTCGGTATTGATTTAGCGGTGTCAGAGGAATCA-GATGAACTATTC 
AHSV3_DQ868772       AGGTTTCGGAAAAATTCGGCATTGATTTAGCGGTGTCAGAGGAATCA-GATGAATTATTC 
AHSV7_AY163330       ACGTAGCGGAAAAGTTTGGTATTAAACTGACTATAAAGGACGAATCA-GAAGAGTTGTTC 
                     *  *    *  *  ** ** **     *                           * **  
 
AHSV8_DQ868775       AAAGCTCAAAATATGAATGTTAAAGCGGCTGATGTTGGAGATTACGGATACAAGTTTCAG 
AHSV8_AY163333       AAAGCTCAAAATATGAATGTTAAAGCGGCTGATGTTGGAGATTACGGATACAAGTTTCAG 
AHSV5_AY163331       ATCGCTAGAGACATGAGTGCGAAAGAGGCTCAGTTCGGTGAGGTTGGGTACAAATTCCAG 
AHSV6_DQ868774       GTTGAGCGAACGATGCATTCGGATTTCTCATCAAATGAAGAGTACGGATATAAATTTGTA 
AHSV6_NC_005996      GTCGAGCGA-CGATGCATTCGGACTTCTCATCGAATGAAGAGTACGGATATAAATTTGTA 
AHSV9_DQ868776       GTCAGGATGGATATGGATTCAGAGTTTAGTGAAGATGAGCAGAAGGGATATATGTTTGAG 
AHSV4_EU046574       GTTGGTAAGAGCATGACGTCAAAATTTATGGAGGAAGGTGAATATGGATATAAGTTCGCC 
AHSV4_DQ868773       GTTGGTAAGAGCATGACGTCAAAATTTATGGAGGAAGGTGAATATGGATATAAGTTCGCC 
AHSV4_D26570         GTCGGTAAGAGCATGACGTCAAAATTTATGGAAGAAGGTGAATATGGATATAAGTTCACC 
AHSV1_FJ011108       CTACCCAAGAATATGAAGTCATCTATGAATGTCGGGGAAGAGAGAGGATACAAGTATAAG 
AHSV1_AY163329       CTACCCAAGAATATGAAGTCATCTATGAATGTCGGGGAAGAGAGAGGATACAAGTATAAG 
AHSV2_AY163332       CTTCCGAAGGATATGGTATCATCTTTTCTAGAGGATGGCGAAGAGGGATATAAATATCAA 
AHSV1_Z26316         GTAAAGAAGACGATGGTCTCGAGTTTCTCTGACTCTGGGGAGATGGGTTACAAATTCATA 
AHSV3_U01832         GTAAAGAAGACGATGGTCTCGAGTTTCTCTGACTCTGGGGAGATGGGTTACAAATTCATA 
AHSV3_DQ868772       GTGAAGAAAACGATGGTTTCGAGTTTCTCTGACTCTGGGGAGATGGGTTATAAATTCATA 
AHSV7_AY163330       GTTCAAAAAGATATGAATTCGGAGTTTTTGGATGAGGGAGAGATGGGCTATAAATTCGTG 
                                 ***                     *   *    ** ** *  *      
AHSV8_DQ868775       TACGGGTGGACTCGAACAGCGGAGCAAGTAATGAGTGATTATGGAGAAATATTGACTGAA 
AHSV8_AY163333       TACGGGTGGACTCGAACAGCGGAGCAGGTAATGAGTGATTACGGAGAAATATTGACTGAA 
AHSV5_AY163331       TATGGGTGGAGAAAAACGGATCAAAAAGTCATGAGCGATTACGCTGACATTTTGAGCGAA 
AHSV6_DQ868774       TTTGGGTGGGCGGCAAGAGGTGAAGAAGTGTTGAGTAATTATGGAGATATTCTCTCAGAT 
AHSV6_NC_005996      TTTGGATGGGCGGCAAGAGGTGAAGAAGTGTTGAGTAATTATGGAGATGTTCTCTCAGAT 
AHSV9_DQ868776       TATGGATGGGCGAAGAGAGAAGAGCAAATATGGTCAAATTATGGTGACATATTAACTGAC 
AHSV4_EU046574       TATGGATGGCGTAGGGATGGCTTCGCGGTGATGGAAGATTACGGAGAAATTTTGACAGAA 
AHSV4_DQ868773       TATGGATGGCGTAGGGATGGCTTCGCGGTGATGGAAGATTACGGAGAAATTTTGACAGAA 
AHSV4_D26570         TATGGGTGGCGTAGGGATGGCTTCGCGGTGATGGAAGATTACGGAGAGATTTTGACAGAG 
AHSV1_FJ011108       TTTGGGTGGAAGGATAATGAGGAGAGAGTGATGAGTGATTACGGGGAAATTTTGACTGAA 
AHSV1_AY163329       TTTGGGTGGAAGGATAATGAGGAGAGAGTGATGAGTGATTACGGGGAAATTTTGACTGAA 
AHSV2_AY163332       TACGGTTGGAAAGATAATGAAGAATTAGTGGCAAGCGATTATGGTGAAATTTTGACTCAG 
AHSV1_Z26316         TTTGGATGGAGGAAAACTGATTTCAAGGTTGAGACTGATTATGGAGAGATAGTTTCTGAT 
AHSV3_U01832         TTTGGATGGAGGAAAACTGATTTCAAGGTTGAGACTGATTATGGAGAGATAGTTTCTGAT 
AHSV3_DQ868772       TTCGGATGGAGGAAAACTGATTTCAAGGTTGAGACTGATTATGGAGAGATAGTTTCTGAC 
AHSV7_AY163330       TTCGGGTGGAAAAATACAGATTTTAAAGTACAGAGCAATTATGGCGAGATCGTTTCAGAG 
                     *  ** ***         *         *        **** *  **  *  *     *  
 
AHSV8_DQ868775       GAAATTGAAACGCTATATCAATCCATTTTAGCAGGCAAAGAATGGGAAAAGGTTTCTGAT 
AHSV8_AY163333       GAAATTGAAACGTTATATCAATCAATTTTAGCAGGCAAAGAATGGGGAAAGGTTTCTGAT 
AHSV5_AY163331       AAGGTTGAAGCATTATATCAAGCACTACTTTCTGGAAGGAAGTGGAGCGATATAGCTGAT 
AHSV6_DQ868774       GAGGTTGAAGAATTATTCACAAAACTTAGGAAGAAAGAGCATTGGGATAAGGTTGTGGAA 
AHSV6_NC_005996      GAGGTTGAAGAATTATTCACGAAACTTAGGAAGAAAGAGCATTGGGATAAGGTTGTGGAA 
AHSV9_DQ868776       TTGGTTGAACAGCTTTATAAGAGCATTATGAATCATGAGGAGTGGGAGAAAATCGTTGAT 
AHSV4_EU046574       AAAGTGGAGGACCTATATAAGGGTGTACTTTTAGGACGAAAGTGGGAGGATGAGGTTGAT 
AHSV4_DQ868773       AAAGTGGAGGACCTATATAAGGGTGTACTTTTAGGACGAAAGTGGGAGGATGAGGTTGAT 
AHSV4_D26570         AAAGTGGAGGATTTATATAAGAGTGTACTTTTAGAGCGAAAGTGGGAAGATGAGGTCGAT 
AHSV1_FJ011108       TCGGTGGAGATCCTATTTAAGAAGCTTCTTAAGGGAGAAAAGTGGAAGATTATCGTTGAT 
AHSV1_AY163329       TCGGTGGAGATCCTATTTAAGAAGCTTCTTAAGGGAGAAAAGTGGAAGATTATCGTTGAT 
AHSV2_AY163332       TCAGTACAAATTCTGTTCGAAGGATTGATGAGAGGGGAGAAGTGGACTTCGATTATAGAT 
AHSV1_Z26316         GAAGTCCATCGGTTATATCAAGCAATTTTGGATGGCAAGGAATGGAGTAAAGAGGTTGAT 
AHSV3_U01832         GAAGTCCATCGGTTATATCAAGCAATTTTGGATGGCAAGGAATGGAGTAAAGAGGTTGAT 
AHSV3_DQ868772       GAAGTTCATCGGTTATATCAAGCAATTTTGGATGGCAAAGAATGGAGTAAAGAGGTTGAT 
AHSV7_AY163330       GAAGTTGAAAGGTTATTCAAAGTGATTTTGGAAGGTAAGGAGTGGTCAAATGAGGTAGAG 






AHSV8_DQ868775       GAAACGGATGTTTATTTTATCGATGATTTATTTTCCTCAACGCCGGACAAGGTATTCAGA 
AHSV8_AY163333       GAAACGGATGTTTATTTCATCGATGATTTATTTTCCTCAACGCCGGACAAGGTATTCAGA 
AHSV5_AY163331       GATACGGAAGAGTATTTTATAGATGATTTGTACGTTAATAAGCCAGATAGGGTCTTTGAG 
AHSV6_DQ868774       GATCCAGAGTCCTATTTCGTAGATGAGCTTTATCAAAAGAATCCAGCGGAAGTATTTTTT 
AHSV6_NC_005996      GATCCAGAATCTTATTTCATAGATGAGCTTTATCAAAAGAATCCGGCGGAAGTGTTTTAT 
AHSV9_DQ868776       GACCCAGAAAAGTATTTCTATGATGATCTTTTTAACGCATCACCAGAGACGGCTTTTATT 
AHSV4_EU046574       GATCCAGAGAGTTATTTTTATGATGATCTTTATACTAATGAGCCCCACAGAGTGTTTCTA 
AHSV4_DQ868773       GATCCAGAGAGTTATTTTTATGATGATCTTTATACTAATGAGCCCCACAGAGTGTTTCTA 
AHSV4_D26570         GATCCAGAGAGCTATTTCTATGATGATCTTTATACCAATGAGCCCCACAGAGTATTTCTA 
AHSV1_FJ011108       GATCCGCAAACTTACTTCGAAGATGACTTGTTCGTTGATCGGGCGAACAAGATTTTCTCT 
AHSV1_AY163329       GATCCGCAAACTTACTTCGAAGATGACTTGTTCGTTGATCGGGCGAACAAGATTTTCTCT 
AHSV2_AY163332       GATCCTCAGTCCTACTTTGAGGATGATATATTTGCGGGAAAAGCTAATAGGATGTTTTTG 
AHSV1_Z26316         GACCCTGAAAAATACTTCGTTGATGATTTATATAATAGATGCCCGGAGTCAATATATGTC 
AHSV3_U01832         GACCCTGAAAAATACTTCGTTGATGATTTATATAATAGATGCCCGGAGTCAATATATGTC 
AHSV3_DQ868772       GATCCAGAAAAATACTTCGTTGATGATTTATATAATAGATGCCCGGAGTCAATATACGTT 
AHSV7_AY163330       GACCCGGAGGATTATTTCGTTGATAACTTGTTTAATAAAACACCGGATGCAGTGTTTGAG 
                     **  *  *    ** **    *** *  * *            *          *      
AHSV8_DQ868775       CGTGTTGGA------CTAGATTCTCAAAATAATATCAAGATTGAGGGTAAAATGAA---- 
AHSV8_AY163333       CGTGTTGGA------CTAGATTCTCAAAATAATATCAAGATTGAGGGTAAAATGAA---- 
AHSV5_AY163331       AGAGCTGGG------TTAGATCCGGAGAGACACATCAAGGTTAAAGGTGTGATGAA---- 
AHSV6_DQ868774       AGTGCAGGT------TATGATACAGATCAAAATGTGGTAATCGATGGAAAAATGAC---- 
AHSV6_NC_005996      AGCGCAGGC------TATGATACAGATCAAAATGTGGTAATCGATGGGAAAATGAC---- 
AHSV9_DQ868776       AGCAAAGGT------TATGATCCTGACAATAATATCGTTATTGAGGGAAAGGTAGG---- 
AHSV4_EU046574       AGCGCAGGA------AAGGATGTGGATAATAATATCACGCTTCGATCGATTTCGCA---- 
AHSV4_DQ868773       AGCGCAGGA------AAGGATGTGGATAATAATATCACGCTTCGATCGATTTCGCA---- 
AHSV4_D26570         AGCGCAGGA------AAGGATGTGGACAATAATATTACACTTCGATCGATTTCGCA---- 
AHSV1_FJ011108       AGGGGTGGACAGACGGTGAATCAGCTGATAAGTATCAAGGTGAATGCGCAATCAAATAAC 
AHSV1_AY163329       AGGGGTGGACAGACGGCGAATCAGCTGATAAGTATCAAGGTGAATGCGCAATCAAATAAC 
AHSV2_AY163332       AGAGGCGGAGAGACGGTTGAACGGCATGTGAAATTGAAGGTTAACGCTCAGACAGAGAAC 
AHSV1_Z26316         AGGAACGGA------GTTGATCCTAATAATAAGATAATGATTAAGAAGCGAGGTTTAGTT 
AHSV3_U01832         AGGAACGGA------GTTGATCCTAATAATAAGATAATGATTAAGAAGCGAGGTTTAGTT 
AHSV3_DQ868772       AGGAACGGA------GTTGATCCTGATAATAAGATAATGATTAAGAAGCGAGGTTTAGTT 
AHSV7_AY163330       AGAGACGGA------ATGGACGGAAGCAACAGGATTATCGTTAAGAATAAAACTACACTT 
                      *    **           *              *     *                    
 
AHSV8_DQ868775       --TGAGTTGACTACATACTTCTCAAAACGTTTTGTTACCTATTGGTATAAAATTACAAAG 
AHSV8_AY163333       --TGAGTTGACTACATACTTCTCAAAACGTTTTGTTACCCATTGGTATAAAATTACAAGG 
AHSV5_AY163331       --TGAGCTGACGACGTACTTCTCAAAACGTTTCATTTCTTATTGGTATAAAATAACTAAG 
AHSV6_DQ868774       --AGAGGGGGTCACGTACTTCTCTAAAAGATTCGTATCGTACTGGTATCGTGTTGAGAAA 
AHSV6_NC_005996      --AGAGGGAGTCACGTACTTCTCTAAAAGATTTGTTTCGTATTGGTATCGTGTTGAGAAA 
AHSV9_DQ868776       --TCAAGATGTTACTTATTTTTCGAAACGGTTTGTATCATATTGGTATCGAGTTCGACAG 
AHSV4_EU046574       --GGCGGAAACCACGTATCTATCGAAGCGTTTCGTATCATATTGGTATAGAATATCACAA 
AHSV4_DQ868773       --GGCGGAAACCACGTATCTATCGAAACGTTTCGTATCATATTGGTATAGAATATCACAA 
AHSV4_D26570         --GGCGGAGACTACGTATTTGTCGAAACGTTTCGTATCGTATTGGTATAGAATATCGCAA 
AHSV1_FJ011108       GTTGAGGGTACGACCTATTTTTCGAAAAGATTTGTTTCTTATTGGTTCAGAATAGAACAT 
AHSV1_AY163329       GTTGAGGGTACGACCTATTTTTCGAAAAGATTTGTTTCTTATTGGTTCAGAATAGAACAT 
AHSV2_AY163332       GTTGAGGGCATCACATACTTTTCAAAAAGATTTGTATCTTATTGGTTCAGAATTGAACGC 
AHSV1_Z26316         GGGGAGAGCCAGCG-CATTTTTCTGCGAGATTTGTCTCATATTGGTATGAATTTCAAAAA 
AHSV3_U01832         GGGGAGAGCCAGCG-CATTTTTCTGCGAGATTTGTCTCATATTGGTATGAATTTCAAAAA 
AHSV3_DQ868772       GGGGAGGGCCAACGGCATTTTTCCGCGAGATTCGTCTCATATTGGTATGAATTTCAAAAA 
AHSV7_AY163330       CGAGAGGGACAACGCCATTTTTCAGCTCGTTTTGTTTCGTATTGGTATACGTTTGAGAAG 
                                     *  * **     * **  *  *  * ****      *        
 
AHSV8_DQ868775       GTGGAGAAGAAAGATTTACTCATTGT-GAATGATATCTACGATGAAAAAAC-GGAA---T 
AHSV8_AY163333       GTGGAGAAGAAAGATTTACTCATTGT-GAATGATATCTACGATGAAAAAACCGGAA---T 
AHSV5_AY163331       GTTGAAGCAAGGAATCTATTGACTTT-AACTGATATAGGGGGGGATGCAAA-AAAG---T 
AHSV6_DQ868774       AT---AACAACGAAG---CATCTCG--AGTTTTTA---AATGAAGAGGGTCGAAAA---G 
AHSV6_NC_005996      AT---AACAACGAAG---CACCTTG--AGTTTTTA---ACTGAAGAGAATCGAAAA---G 
AHSV9_DQ868776       GTTCAGACCTCAAAG---GGTGCTG--AGAGGAGA---TCGATTGAGGATGTCAAA---T 
AHSV4_EU046574       GTTGAAGTAACGAAGGCGCGTAATG--AAGTTCTGGACATGAATGAGAAACAGAAGCCGT 
AHSV4_DQ868773       GTTGAAGTAACGAAGGCGCGTAATG--AAGTTCTGGACATGAATGAGAAACAGAAGCCGT 
AHSV4_D26570         ATTGAAGTGACAAAGGCGCGTAATG--AGGTTCCGGATATGAATGAGAAACAGAAGCCGT 
AHSV1_FJ011108       TTTTCGATTACGACAGC-AAAAAAGCGAACTGACATTCGAGATAAAAAGACTGAA----T 
AHSV1_AY163329       TTTTCGATTACGACAGC-AAAAAAGCGAACTGACATTCGAGATAAAAAGACTGAA----T 
AHSV2_AY163332       ACAACGCACGTAAAGGG-AGGGGGAAGAGTAGATATTCGGGATCGAAAAACAGGG----T 
AHSV1_Z26316         GTTACTATTGAGGCTGAGTTCGAAGCGATTGCACGCACGTGGCGAACATATACAG----T 
AHSV3_U01832         GTTACTATTGAGGCTGAGTTCGAAGCGATTGCACGCACGTGGCGAACATATACAG----T 
AHSV3_DQ868772       GTTACTATTAAGGCTGA-TTCGAAGCGATTGGACGCACGTGGCGAACATACACAG----T 
AHSV7_AY163330       GTGGAGGTTG-GTCGGGCGATGGCGAGAATCGATATTCATGATCGAGAGACCAAG----T 
                                                                                  
AHSV8_DQ868775       ATCAACAGTTTGATCC-GGATGATTTCAAGCCAA-TGGTTATTGGAGAGATGGGTGTTCA 
AHSV8_AY163333       ATCAGCAGTTTTATCCCGGATGATTTCAAGCCAAATGGTTATTGGAGAGATGGGTGTTCA 
AHSV5_AY163331       ATACACAGTTTGATCC-TGATGATTTTAAACCAA-TGGCTGTGGCTGAGCTGGGAGCACA 
AHSV6_DQ868774       TTGCGCAATTTGATTT-CGAGGATTATAAACCGA-TGGCTATTGGAGAGATGGGGATTCA 
AHSV6_NC_005996      TCGCGCAGTTTGATTT-TGAGGATTATAAACCGA-TGGCTATTGGAGAGATGGGGATTCA 
AHSV9_DQ868776       ATAGGGAGTTTGATAT-AGAAAGTTTTAAGCCTT-ACGCGATTGGTGAGATCGGTATTCA 
AHSV4_EU046574       ATTTTGAATTTGAATA-TGATGATTTCAAACCCT-GTTCAATTGGAGAGTTGGGGATCCA 
AHSV4_DQ868773       ATTTTGAATTTGAATA-TGATGATTTCAAACCCT-GTTCAATTGGAGAGTTGGGGATCCA 
AHSV4_D26570         ATTTTGAATTTGAGTA-TGACGATTTTAAGCCTT-GCTCGATTGGAGAGTTGGGGATCCA 
AHSV1_FJ011108       ATAACGAGTTTGACTT-CGAAGACTTCAAGCCGG-CATGTATTGGAGAATTGGGGATACA 
AHSV1_AY163329       ATAACGAGTTTGACTT-CGAAGACTTCAAGCCGG-CATGTATTGGAGAATTGGGGATACA 
AHSV2_AY163332       ACCAGCAGTTCGATGT-AGAAGATTTTAAACCTG-CAAGTGTAGGGGAACTTGGATTTCA 
AHSV1_Z26316         ATCATGAGATAGATGT-TGAAGATTTCAAACCTT-GCGCGATTGCGGAACTTGGATTACA 
AHSV3_U01832         ATCATGAGATAGATGT-TGAAGATTTCAAACCTT-GCGCGATTGCGGAACTTGGATTACA 
AHSV3_DQ868772       ATCATGAGATAGATGT-TGAAGATTTCAAACCCT-GCGCGATTGCGGAACTTGGATTACA 
AHSV7_AY163330       TTTCCGAGTTCGATGT-CGATGACTATAAACCAT-GTTCAGTGGCGGAAATGGGGCTACA 
                           *  *  *     **    *  ** **         * *  **  * **    ** 
 
AHSV8_DQ868775       TGCTTCGACATATATATATCAAAACTTGATTTTAGGTAGAAATAGGGGTGAGCGGATTGT 
AHSV8_AY163333       CGCTTCAACATATATATATCAAAACTTGATTTTAGGTAGAAATAGGGGTGAGCGGATTGT 
AHSV5_AY163331       CGCGTCGACGTATGTTTATCAGAATTTGATTTTAGGGAGGAACAGAGGCGAGAAAATTGG 
AHSV6_DQ868774       TGCATCGACATATAAGTATGAGTCGTTGCTTCTTGGAAAGAATAGAGGGCAAAAAGTGAA 
AHSV6_NC_005996      TGCGTCGACATATAAGTATGAGTCGTTGCTCCTTGGGAAAAATAGAGGGCAAAAAGTGAA 
AHSV9_DQ868776       CGCATCAACTTACAAATATCTGGATCTATTAGCGGGGCGTAATCGCGGAGAGAAAGTGAA 
AHSV4_EU046574       TGCATCCACATATATATATCAGAACCTACTGGTCGGACGTAATAGAGGTGAGGAAATACT 
AHSV4_DQ868773       TGCATCCACATATATATATCAGAACCTACTGGTCGGACGTAATAGAGGTGAGGAAATACT 
AHSV4_D26570         TGCATCGACATACATATATCAGAACCTCCTCGTTGGACGTAATAGGGGCGAGGAGATACT 
AHSV1_FJ011108       CGCGTCGACATATATCTACCAGGATTTGTTGGTCGGGAAGAGCAGAGGGGAACGAGTGAA 
AHSV1_AY163329       CGCGTCGACATATATCTACCAGGATTTGTTGGTCGGGAAGAGCAGAGGGGAACGAGTGAA 
AHSV2_AY163332       CGCGTCAACATATATTTATCAAGATTTACTTGTGGGAGCAAATAGAGGCGAGCGTGTGAA 
AHSV1_Z26316         TTGCTCAACCTATATTTATCAAGATTTGCTCGTTGGCGCGAACAGAGGTGAATATGTGAA 
AHSV3_U01832         TTGCTCAACCTATATTTATCAAGATTTGCTCGTTGGCGCGAACAGAGGTGAATATGTGAA 
AHSV3_DQ868772       TTGCTCAACCTATATTTATCAAGATTTGCTCGTTGGCGCGAACAGAGGTGAATATGTGAA 
AHSV7_AY163330       TTCATCAACTTATATCTATCAAGATTTGTTGATAGGCCCAAATAGGGGAGAGCATGTGAT 






AHSV8_DQ868775       TGATAGCAAGGAGATCGTGTGG-TATGATTTGTCGTTGACCAATTTCGGCCTGGTGCGTT 
AHSV8_AY163333       TGATAGCAAAGAGATCGTGTGG-TATGATTTGTCGTTGACCAATTTCGACCTGGTGCGTT 
AHSV5_AY163331       TGATGCGAAGGAGATCGTTTGG-TATGATTTATCTTTGACTAATTTTGGATGTTCTAGAT 
AHSV6_DQ868774       AGACTCCATTGCTTT-GTGTAACTATGATCTTGCACTTACGAACTTCGAAGTCTCGAGGC 
AHSV6_NC_005996      TGATTCCATCGCTCT-GTGTAACTACGATCTTGCACTTACGAATTTCGGGGTTTCGAGGC 
AHSV9_DQ868776       GGATTCGCAAGCGCTCGTGTGG-TATGATTTCGCTTTAACTAACTACACGCTAGTGCGAC 
AHSV4_EU046574       TGATTCGAAAGAGCTCGTCTGGATG-GATATGTCACTTTTAAATTTTGGAGCGGTCAGAT 
AHSV4_DQ868773       TGATTCGAAAGAGCTCGTCTGGATG-GATATGTCACTTTTAAATTTTGGAGCGGTCAGAT 
AHSV4_D26570         TGATTCGAAGGAGCTTGTCTGGATG-GATATGTCGCTATTAAATTTTGGAGCGGTCAGAC 
AHSV1_FJ011108       AGACGCGAAGGAATTGGTGTGGATG-GATCTTTCGCTGGCGAATTTTGGGTGTTCGCGCT 
AHSV1_AY163329       AGACGCGAAGGAATTGGTGTGGATG-GATCTTTCGCTGGCGAATTTTGGGTGTTCGCGCT 
AHSV2_AY163332       GGACGCGAAAGAGTTAGTGTGGATG-GATTTATCTCTTACCAATTTCGGGTTTGTGCGAA 
AHSV1_Z26316         GGATGCGAAGGAGCTCGTCTGGTTC-GATATCGCTAACACAAACTTCAACATCACGCGTC 
AHSV3_U01832         GGATGCGAAGGAGCTCGTCTGGTTC-GATATCGCTAACACAAACTTCAACATCACGCGTC 
AHSV3_DQ868772       GGATGCGAAGGAGCTCGTTTGGTTC-GATATCGCTAACACAAACTACAACATCACGCGTC 
AHSV7_AY163330       TGATGCAAAAGAATTGGTTTGGTAT-GATATTGCGTTAACAAATTATGGAACAACGCGCT 
                      **       *   * ** *      *** *  *       ** *            *   
AHSV8_DQ868775       CGCAGAATCAATGCTGGATTGGATCAATTTCAAATTTTGAGTTAAGTATGCGATATCACA 
AHSV8_AY163333       CGCAGAATCAATGTTGGATTGGATCAATTTCAAATTTTGAGTTAAGTATGCGATATCACA 
AHSV5_AY163331       CGTTAGATTCTTGTTGGGTGGGGTCAGTTGCTAGATCTGAGCTGAATTTGCGGTTCCACC 
AHSV6_DQ868774       GTCAGGATTGCTGCTGGATCTCATCGTGTAGCGCCATTGAGCTTTCGATGAGAGCCAACA 
AHSV6_NC_005996      GTCAGGACTGTTGCTGGATCTCATCGTGTAGTGCCATTGAGCTTTCGATGAGAGCCAACA 
AHSV9_DQ868776       CACAAGATAGATGTTGGATAATGTCGTGTACTGATTGTGAATACACTTTGAGATTTGCAA 
AHSV4_EU046574       CTCACGATAGGTGCTGGATCTCCTCAAGCGTCGCGATTGAGGTGAATTTACGTCATGCAC 
AHSV4_DQ868773       CTCACGATAGGTGCTGGATCTCCTCAAGCGTCGCGATTGAGGTGAATTTACGTCATGCAC 
AHSV4_D26570         CTCACGATAGGTGTTGGATTTCTTCAAGCGTCGCGATTGAGGTAAATCTACGTCACGCAC 
AHSV1_FJ011108       GCTATGATCGATGTTGGCCAGCTTCCTGCGTTGAAGCGGAGATCTCCTTGAGGTACTATT 
AHSV1_AY163329       GCTATGATCGATGTTGGCCAGCTTCCTGCGTTGAAGCGGAGATCTCCTTGAGGTACTATT 
AHSV2_AY163332       GCTACAATAGATGTTGGATTGCGGCCTTTGTGGAGGCGGAGATTTCGCTCAGATTTTATC 
AHSV1_Z26316         CTTTTGATAGATGCTGGCCTTCTTCTTGCGCGGAGGCTGAGTTATCCTTGAGGTTTCATC 
AHSV3_U01832         CTTTTGATAGATGCTGGCCTTCTTCTTGCGCGGAGGCTGAGTTATCCTTGAGGTTTCATC 
AHSV3_DQ868772       CCTTTGATAGATGCTGGCCTTCTTCTTGCGCGGAGGCTGAGTTATCCTTGAGATTTCATC 
AHSV7_AY163330       ATTTTGATCAGTGTTGGCCATCCTCATGTTCCACCACGGAATTATCAATGAGATATTTTT 
                           *    ** ***       *             **        *  *         
 
AHSV8_DQ868775       TCATAACCGAAATTTTCCAGAGGT---ATAGAGTGGATTCAGCACATAAGTCTTACCACG 
AHSV8_AY163333       TCATAACCGAAATTTTCCAGAGGT---ATAGAGTGGATTCAGCACATAAGTCTTACCACG 
AHSV5_AY163331       TTATATCCGCAATATTTGAACGAT---ATCAGCATGATGCACGACGGAGCTCCTTTTATG 
AHSV6_DQ868774       TCACTATCGCAATTTTTAGGAGA----ATCGAAGACAGAAGATATGAGAGTTTCGCGAAA 
AHSV6_NC_005996      TCATTATCGCTATTTTTAGGAGA----ATCGAAGACAAGAGATATGAGAATTTCGCGAAA 
AHSV9_DQ868776       CGATCACTATGATATTCGAACGTTT--ATCTGAGGAAGCTGATCTTTCT-TATCATGATA 
AHSV4_EU046574       TAATAGTTAGGATTTTTTCACGCTTTGACATGATGTCGGAAAGAGAAACGTTTT-CAACC 
AHSV4_DQ868773       TAATAGTTAGGATTTTTTCACGCTTTGACATGATGTCGGAAAGAGAAACGTTTT-CAACC 
AHSV4_D26570         TGATAGTTAGGATTTTTTCACGCTTTGACATGATGTCGGAGAGAGAAGCGTATT-CAATG 
AHSV1_FJ011108       TAGTCACATCTATTTTCGCTAGAT---ACCTTAACCGTGAAGGATTGAG-CTTTTCAAAG 
AHSV1_AY163329       TAGTCACATCTATTTTCGCTAGAT---ACCTTAACCGTGAAGGATTGAG-CTTTTCAAAG 
AHSV2_AY163332       TCATAACGTCGATCTTTTGTAGAT---ATTTTACTGGCGATAGGAAGAG-TTTCGCTAAG 
AHSV1_Z26316         TGATTACCAAGATCTTCACGAGAT---ATCGA---GGCGAAAGAACTTC-GTTTGTCGAT 
AHSV3_U01832         TGATTACCAAGATCTTCACGAGAT---ATCGA---GGCGAAAGAACTTC-GTTTGTCGAT 
AHSV3_DQ868772       TGATTACCAAGATCTTCACGAGAT---ATCGA---GGCGAAAGAACTTC-GTTTGTCGAT 
AHSV7_AY163330       TGATTACTGAAATCTTTCAGAGAT---ATAGGACTGACGATAGATCATC-TTTTGCGGAT 
                                ** **     *     *                                 
 
AHSV8_DQ868775       AAATTATCAGCGGACTGACTAAGAAAGACGTG----ATTCTTTTCCCTAGTTATAAACAT 
AHSV8_AY163333       AAATTATCAGCGGACTGACTAAGAAAGACGTG----ATTCTTTTCCCTAGTTATAAACAT 
AHSV5_AY163331       AAATTATCTTCGATCTGCCCTCTAAGAAAGAG----AGGATCTTCCCGAGTTACAAACAT 
AHSV6_DQ868774       ATACTATCCGGACTTTCGCAGCAGCAAGACTT------ATACTTTCCTACGTATAAGCAT 
AHSV6_NC_005996      ATATTATCCGGACTCACACAGCAGCAAGACCT------ATATTTCCCTACGTATAAGCAT 
AHSV9_DQ868776       -TCTTATTGAAGGTCCGCGAATATCCGATCCA------ATCATTCGCTTCGTATAAACAT 
AHSV4_EU046574       ATTTTAGAAAAAGTCATGGAGGATGTGAAAGAGTTGAGATTTTTCCCGACATATCGTCAT 
AHSV4_DQ868773       ATTTTAGAAAAAGTCATGGAGGATGTGAAAGAGTTGAGATTTTTCCCGACATATCGTCAT 
AHSV4_D26570         ATTTTGGAAAAAGTCATGGAGGATGTGAAGGAGCTGAGATTTTTCCCAACATATCGCCAT 
AHSV1_FJ011108       ATTTTGATCTCTCTCA--AAGATTTTTCGGATAGATTATGGTTTCCAA-CGTATAAACAT 
AHSV1_AY163329       ATTTTGATCTCTCTCA--AAGATTTTTCGGATAGATTATGGTTTCCAA-CGTATAAACAT 
AHSV2_AY163332       ATACTAGATGGAGTCA--AGTCATTGAAAGAAAGATTATGGTTCCCTA-CCTACAAACAT 
AHSV1_Z26316         ATAATTAATGAGTTGAGTGAGCATGGCTACGTGAAACACAATTTCCCGTCATATAAGCAT 
AHSV3_U01832         ATAATTAATGAGTTGAGTGAGCATGGCTACGTGAAACACAATTTCCCGTCATATAAGCAT 
AHSV3_DQ868772       ATAATTAATGAGTTGAGTGAGCGAGGCTACGTGAAACACAATTTCCCGTCATATAAGCAT 
AHSV7_AY163330       ATCTTGGAGAGGATGCGTAAGAACGGGTATCCCCGTCGCAATTTTCTGACGTATAAACAT 
                         *                                     *        **    *** 
AHSV8_DQ868775       TATTATGTTAGAGTTATACAAGATGTATTTCAAGATTCGCAAAAGGTAGATGTTTTAGAT 
AHSV8_AY163333       TATTATGTTCGAGTTATACAAGATGTATTTCAAGATTCGCAAAAGGTAGATGTTTTAGAT 
AHSV5_AY163331       TATTACGTCGCTTTGCTACAGAATATCTTTAATGATACTCAACGATTAGAGGTAATGGAC 
AHSV6_DQ868774       TATTATCTGTTTGTATTACAAAAGGTGTTACGAGATGAGAGGAGGATAGATCAGAATAGA 
AHSV6_NC_005996      TATTATCTGTTTGTGTTACAAAAGGTATTACGAGATGAGAGGAGGATAGATCTAAATAGA 
AHSV9_DQ868776       TTCTATGTTCGCGTCTTGCAGCACGTTTTTAGAGATAACCAAGAAATCGACGTATTAGAG 
AHSV4_EU046574       TATTATTTGGAAACTCTCCAACGTGTCTTTAACGATGAGAGACGCTTAGAAGTTGATGAC 
AHSV4_DQ868773       TATTATTTGGAAACTCTCCAACGTGTCTTTAACGATGAGAGACGCTTAGAAGTTGATGAC 
AHSV4_D26570         TATTATTTGGAAACTCTCCAACGTGTCTTTAACGATGAGAGACGTTTGGAGGTTGATGAC 
AHSV1_FJ011108       TTTTATGTTGCAGTTGTACAAAAAGTGCTCCGCGATGATAGACGCTTAGATTATGTACTC 
AHSV1_AY163329       TTTTATGTTGCAGTTGTACAAAAAGTGCTCCGCGATGATAGACGCTTAGATTATGTACTC 
AHSV2_AY163332       TACTATGTTGCCGTCATTCAGAAGATTTACTCAGATGATAGGAATCTAGATAGGAATGAA 
AHSV1_Z26316         TATTACCTCTCTGTTATTCAGACGGTTTTTGAGGATCAAAGAGCGATCGATCCGCTTGAC 
AHSV3_U01832         TATTACCTCTCTGTTATTCAGACGGTTTTTGAGGATCAAAGAGCGATCGATCCGCTTGAC 
AHSV3_DQ868772       TATTACCTCTCTGTCATTCAGACGGTTTTTGAGGATCAAAGAGCAATCGATCCGCTTGAC 
AHSV7_AY163330       TATTATGTCGCTGTCATTCAAGAGGTATTTGGTGATCAAAGACCGATCGATGTGTATAGT 
                     *  **  *        * **     *       ***          * **           
 
AHSV8_DQ868775       TTCTGTTTGAGGATTGCCAACCCAGAGACGCGCTTATCCACGCTGCTGAAGATTCAGGGC 
AHSV8_AY163333       TTCTGTTTGAGGATTGCGAACCCTGAGACGCGCTTATCTACGCTGCTGAAGATTCAGGGT 
AHSV5_AY163331       TATTGCGAGAGACTGATGAATCCGGAAACGAGGATGTCAGCCCTCCTATCACTTCAGGGG 
AHSV6_DQ868774       ATGTGCACAGAGCTGTTTGATATACAGAGGCGAAGAGGTATCCTCCTTTCGTTTACCACG 
AHSV6_NC_005996      ATATGCACCGAGTTGTTTGATACACAGAGGCGAAGAGGTATTCTCCTTTCGTTTACCGCG 
AHSV9_DQ868776       TTCTGTACTAGGATGCTCGATCCGAGGACACGTGAAGCGGGGTTAAATAAGTTCTCAAGG 
AHSV4_EU046574       TTTTATATGAGGTTATATGATGTGCAGACAAGGGAGCGGGCACTAAATACTTTCACGGAT 
AHSV4_DQ868773       TTTTATATGAGGTTATATGATGTGCAGACAAGGGAGCAGGCACTAAATACTTTCACGGAT 
AHSV4_D26570         TTTTATATGAAGTTATATAATGTGCAAACAAGGGAGCAGGCACTAAATACTTTCACGGAC 
AHSV1_FJ011108       TTTTGTTCTAGGGTCTCGGCAATCACAACCCGGCGTGCGACGTTAATGGAATTTAGTACC 
AHSV1_AY163329       TTTTGTTCTAGGGTCTCGGCAATCACAACCCGGCGTGCGACGTTAATGGAATTTAGTACC 
AHSV2_AY163332       TTTTGTAATAGAGTCATGAATATCATGACAAGACGGTCAGTACTCAATGAGTTTGAGAGG 
AHSV1_Z26316         TTTTGTGCAATGATTTCACGGAATGAGACGCGAGAGAGCACGCTCAAGGGATTTAGTATG 
AHSV3_U01832         TTTTGTGCAATGATTTCACGGAATGAGACGCGAGAGAGCACGCTCAAGGGATTTAGTATG 
AHSV3_DQ868772       TTTTGTGCAATGATTTCACGGAATGAGACGCGAGAGAGCACGCTCAAGGGATTTAGTATG 
AHSV7_AY163330       TTTTGTACCGATATCTTTAAGAAAGAGAGGCGCCGAGGGGTTTTGAGTATGTTTCCTACC 






AHSV8_DQ868775       TTCAGAGCATGTGTGGAATCTGAGTTCCTTCTCCCAACACTTCATCTGAATTTTTTGATT 
AHSV8_AY163333       TTCAGAGCATGTGTGGAATCTGAGTTCCTTCTCCCAACACTTCACCTGAATTTTTTGATT 
AHSV5_AY163331       TTCAGAAACTGTGTCGAGTCGGAGTTCGTGGCCCCAACGTTGAAGATGAATGCACTTCTT 
AHSV6_DQ868774       TTGAGATTTTGGAACGATTCGGAGTTTCTAGGTGATACGTTAATGATGAATTTTCTACTA 
AHSV6_NC_005996      TTGAGATTTTGGAATGATTCAGAATTTTTGGGTGATGCGTTAATGATGAATTTTCTACAT 
AHSV9_DQ868776       TTTAGACAATGGAGAGAATCGGAATTCTTGATAGATGCTCTTAAAATGAATTTCCTTTTG 
AHSV4_EU046574       TTTCACAGGTGTGTTGAGTCGGAACTGCTCTTACCGACACTTAAACTTAACTTTCTGCTG 
AHSV4_DQ868773       TTTCACAGGTGTGTTGAGTCGGAACTGCTCTTACCGACACTTAAACTTAACTTTCTGCTG 
AHSV4_D26570         TTTCAAAGGTGTGTTCAGTCAGAATTGCTCTTACCAACGCTTAAGCTCAATTTTTTGTTG 
AHSV1_FJ011108       TTTAAACAGATGGTGGGATCAACACGTTTATTGGATACGCTATTCTTAAATTTTCTACTT 
AHSV1_AY163329       TTTAAACAGATGGTGGGATCAACACGTTTATTGGATACGCTATTCTTAAATTTTCTACTT 
AHSV2_AY163332       TTTAGAAGAGCTATTGAGTCGCCAAAGCTGATTGACACTTTGTCGCTTAATTTTCTCCTT 
AHSV1_Z26316         TTTACTGCAATTGTTAAAAGTGAGAGACTGATAGATACCCTGTTCTTGAATTTCTTGTTA 
AHSV3_U01832         TTTACTGCAATTGTTAAAAGTGAGAGACTGATAGATACCCTGTTCTTGAATTTCTTGTTA 
AHSV3_DQ868772       TTTGCTGCAATTGTTAAGAGTGAGAGACTGATAGATACCTTGTTTTTGAATTTCTTGTTA 
AHSV7_AY163330       TTTTCTACCTTAATCAAGAGCGAAAAATTGATCGATGCTTTATTTCTTAATTTCTTCTTG 
                     **                          *        *  *     * **     *     
AHSV8_DQ868775       TGGCTGCTGATTGACATGGAAAATGGGGACATAAATTACTCGAAGAAAAGACTTCCTTTA 
AHSV8_AY163333       TGGTTGCTGATTGACATGGAAAACGGGGACATAAATTACTCGAAGAAAAGGCTTCCTTTA 
AHSV5_AY163331       TGGGTTTTAGCGGATATGGAGAATATTGATATAAACTACTCGAACAAGCGGATGCCGCTG 
AHSV6_DQ868774       TGGGTGGTTTTTGAGATGGAAAACATCGATGTGGATTATGGGAAAAAGTGGCATCCGCTG 
AHSV6_NC_005996      AGGGTGGTTTTCGAGATGGAAAACGTCGATGTGGATTATGGGAAGAAGTGGCATCCGCTA 
AHSV9_DQ868776       TGGGTGGTCTTCGAACTGGAAAATATAGATGTTGATTATAGTAAGAAAAGGCATCCTTTA 
AHSV4_EU046574       TGGATTGTTTTTGAAATGGAAAATGTTGAAGTGAACGCGGCGTACAAGCGTCATCCGCTT 
AHSV4_DQ868773       TGGATTGTTTTTGAAATGGAAAATGTTGAAGTGAACGCGGCGTACAAGCGTCATCCGCTT 
AHSV4_D26570         TGGATCGTTTTTGAGATGGAAAATGTTGAAGTGAATGCAGCGGACAAGCGTCATCCGCTT 
AHSV1_FJ011108       TGGATCATTTTCGAACAGGAGAATATAGATGTTGATTTCGCAAATAAGTGGCATCCTCTA 
AHSV1_AY163329       TGGATCATTTTCGAACAGGAGAATATAGATGTTGATTTCGCAAATAAGTGGCATCCTCTA 
AHSV2_AY163332       TGGATAATTTTCGAACAAGAGAACATAGATGTTAATTTTGCGGATAAGAGGCATCCACTA 
AHSV1_Z26316         TGGATTGTCTTTGAAATGGAGAATGTTGATGTGAGCGCTGCTAATAAGAGACATCCATTA 
AHSV3_U01832         TGGATTGTCTTTGAAATGGAGAATGTTGATGTGAGCGCTGCTAATAAGAGACATCCATTA 
AHSV3_DQ868772       TGGATTGTTTTTGAAATGGAGAATGTTGATGTGAGCGCTGCTAATAAGAGACATCCATTA 
AHSV7_AY163330       TGGGTTGTTTTCGAGATGGAAAACGTTGACGTAAGTTTTGCAAATAAGCGTCATCCTTTA 
                      ** *  *    **    ** **    **  *           * **  *    **  *  
 
AHSV8_DQ868775       TTGATTTCTACGACGAACGGTTTGAGGGTGATGGCGGTCGACGCATTCAATAACATGATT 
AHSV8_AY163333       TTGATTTCTACGACGAAGGGTTTGAGGGTGATGGCGGTCGACGCATTCAATAACTTGATT 
AHSV5_AY163331       TTGTTATCAACTGAGAAGGGCCTACGTGTGATTTCTATTGATATGTTTAACGGAATGCTG 
AHSV6_DQ868774       CTAGTATCGTCAGAAAAGGGGCTTAGAGTGATTGCGGTTGACGTTTTTAATTCAATGATG 
AHSV6_NC_005996      CTAGTATCGTCAGAGAAGGGGCTTAGAGTGATCGCGGTTGATGTTTTTAACTCAATGATG 
AHSV9_DQ868776       CTAATATCTACCGACAAAGGGTTAAGAGTAGTCTCAGTTGATCTTTTTAATTCTATGCTT 
AHSV4_EU046574       TTAATCTCAACTGCCAAAGGGTTAAGGGTTATCGGCGTTGATATTTTCAACTCACAGCTT 
AHSV4_DQ868773       TTAATCTCAACTGCCAAAGGGTTAAGGGTTATCGGCGTTGATATTTTCAACTCACAGCTT 
AHSV4_D26570         TTAATTTCAACTGCCAAAGGATTAGGGGTTATTGGCGTTGACATTTTCAACTCGCAGCTT 
AHSV1_FJ011108       TTAATTTCTACAGAAAAGGGCTTGAGAGTTATTGCGGTTGATGTTTTTAATAGTTCACTT 
AHSV1_AY163329       TTAATTTCTACAGAAAAGGGCTTGAGAGTTATTGCGGTTGATGTTTTTAATAGTTCACTT 
AHSV2_AY163332       TTAATATCAACGACTAAAGGTTTGAGAGTAATCCCGATTGACGTTTTCAATAGTTCACTA 
AHSV1_Z26316         TTAATATCGCATGAAAAAGGATTACGTTTAATTGGCGTAGATTTGTTTAATGGCGCGCTT 
AHSV3_U01832         TTAATATCGCATGAAAAAGGATTACGTTTAATTGGCGTAGATTTGTTTAATGGCGCGCTT 
AHSV3_DQ868772       TTAATATCGCATGAGAAAGGATTACGTTTAATTGGCGTAGATTTGTTCAATGGCGCGCTT 
AHSV7_AY163330       TTGATATCGCACGATAAGGGTTTGCGATTGATTGGTGTAGATTTGTTCAATAGTGCGTTA 
                      *  * **       ** **  *  *  *  *     * **    ** **        *  
 
AHSV8_DQ868775       GCCATGTCTTATAGCGGTTGGCTCCCGTATTTAGAGAGAATATGTCACGAAACAAAGCAG 
AHSV8_AY163333       GCCATGTCTTATAGCGGTTGGCTCCCGTATTTAGAGAGAATATGTCACGAAACAAAGCAG 
AHSV5_AY163331       GGTGTTTCTTATAGCGGCTGGATCCCATACTTAGAGAGGATCTGCAGTGAAGTAAATCTA 
AHSV6_DQ868774       GGAGTATCAACGAGTGGTTGGCTTCCTTATGTTGAACGCATCTGTTCTGAGTCCGATATG 
AHSV6_NC_005996      GGAGTGTCGACAAGTGGCTGGCTTCCTTATGTTGAACGCATTTGTTCCGAGTCTGATATG 
AHSV9_DQ868776       AGCGTTTCCCTGAGTGGGTGGATCCCATATGTTGAAAGAGTGTGTGAACGCTCGGAAGCT 
AHSV4_EU046574       TCGATATCAATGAGCGGATGGATTCCGTATGTCGAACGGATGTGCGCGGAGAGTAAAGTT 
AHSV4_DQ868773       TCGATATCAATGAGCGGATGGATTCCGTATGTCGAACGGATGTGCGCGGAGAGTAAAGTT 
AHSV4_D26570         TCGATATCAATGAGCGGGTGGATTCCGTACGTCGAAAGGATGTGCGCGGAGAGTAAAGTT 
AHSV1_FJ011108       ACGTTATCAACGAGCGGATGGCTGCCATATTTAGAGCGGATTTGCTCTGAGTCCGCGATG 
AHSV1_AY163329       ACGTTATCAACGAGCGGATGGCTGCCATATTTAGAGCGGATTTGCTCTGAGTCCGCGATG 
AHSV2_AY163332       GCTCTTTCTCCAAGTGGTTGGATCCCTTACGTTGAGAGGATATGTGCAGAGGCTAAGGAA 
AHSV1_Z26316         TCGATTTCCACGGGGGGGTGGATTCCGTATCTAGAGAGGATATGTTCAGAGGAGAAAGCT 
AHSV3_U01832         TCGATTTCCACGGGGGGGTGGATTCCGTATCTAGAGAGGATATGTTCAGAGGAGAAAGCT 
AHSV3_DQ868772       TCGATTTCCACGGGGGGGTGGATTCCGTATCTAGAGAGGATATGTTCAGAGGAGAAAGCT 
AHSV7_AY163330       TCCATTTCAATGGGTGGATGGATCCCTTATGTTGAAAGGATATGCCATGCAGATCATGCA 
                         * **     * ** *** * ** **  * **  *  * **                 
AHSV8_DQ868775       CGGACGAGACTCAATGCTGATGAATTAAAATTAAAGAAGTGGTTTCTGAATTACGTTACG 
AHSV8_AY163333       CGGACGAGACTCAATGCTGATGAATTAAAATTAAAGAAGTGGTTTCTGAATTACGTTACG 
AHSV5_AY163331       CAGAGACGCTTAAGAGCGGATGAGCTAAAATTGAGGAAGTGGTTTATCAGCTACTACGCT 
AHSV6_DQ868774       CGCAGACGACTGAATGCGGATGAATTAGAGTTGAAGCGCTGGTTCTTTGATTATTACGCG 
AHSV6_NC_005996      CGCAGGCGATTGAATGCAGATGAACTAGAGTTAAAACGGTGGTTCTTTGACTACTATGCG 
AHSV9_DQ868776       AAAAGAAGATTGAATGCGGATGAATTGAAACTAAAGAACTGGTTTATTGCGTATTATGTC 
AHSV4_EU046574       CAAACAAAATTGACGGCTGATGAGCTGAAATTGAAGAGGTGGTTCATCTCATATTATACG 
AHSV4_DQ868773       CAAACAAAATTGACGGCTGATGAGCTGAAATTGAAGAGGTGGTTCATCTCATATTATACG 
AHSV4_D26570         CAAACAAAATTGACGGCCGATGAACTAAAGTTGAAGAGGTGGTTTATTTCATATTATACG 
AHSV1_FJ011108       GATCGAGCTCTCACCGCTGACGAAATAAATCTTAAACGATGGTTTGTTGATTACTACATG 
AHSV1_AY163329       GATCGAGCTCTCACCGCTGACGAAATAAATCTTAAACGATGGTTTGTTGATTACTACATG 
AHSV2_AY163332       AACCGTACGCTGAGTTCCGATGAATTGAGAATTAAAACCTGGTTCGTAGAGTACTATCTA 
AHSV1_Z26316         CAGAGAAGGTTGAACGCGGATGAACTGAAAATAAAAAGTTGGTTTTTAACGTATTATATG 
AHSV3_U01832         CAGAGAAGGTTGAACGCGGATGAACTGAAAATAAAAAGTTGGTTTTTAACGTATTATATG 
AHSV3_DQ868772       CAGAGAAGGTTGAACGCGGATGAACTTAAAATAAAAAGTTGGTTTTTAACGTATTATATG 
AHSV7_AY163330       GCAAGAAAATTGAATGCGGACGAACTGAAAATAAAGAGGTGGTTTATAGATTATTATATG 
                               * *   * ** **  *     * *     *****  *    **        
 
AHSV8_DQ868775       AAATACGAAGTTGAGAGAAGGGCGGAGCCGCGTATGAGTTTCAAAATGGAGGGCATAACA 
AHSV8_AY163333       AAATACGAAGTTGAAAGAAGGGCGGAGCCGCGTATGAGTTTCAAAATGGAGGGCATAACA 
AHSV5_AY163331       ACCTATGAAGTTGAGAGACGTGCTGAGCCAAGAATGAGTTTTAAAATGGAGGGAATCTCC 
AHSV6_DQ868774       ACATTATTGCTTGAAAGGAGGGGGGAGCCTCGGTTGAGCTTCAAGTATGAAGGATTGACC 
AHSV6_NC_005996      ACATTACCGCTCGAAAGGAGAGGAGAGCCTCGGTTGAGCTTTAAGTATGAAGGATTGACC 
AHSV9_DQ868776       ACTTTGCCTCTGTTAAGGCGTGCGGAACCAAGGATGAGCTTTAAGTATGAGGGAATTACA 
AHSV4_EU046574       ACGTTGAAATTGGACCGCAGAGCGGAGCCACGTATGAGTTTCAAATTTGAGGGGTTGAGT 
AHSV4_DQ868773       ACGTTGAAATTGGACCGCAGAGCGGAGCCACGTATGAGTTTCAAATTTGAGGGGTTGAGT 
AHSV4_D26570         ACGTTGAAGTTGGACCGCAGAGCGGAGCCACGTATGAGTTTCAAATTCGAAGGGTTAAGT 
AHSV1_FJ011108       GAGCTGAAGTTGGAGAGACGAGCGGAACCTCGAATGAGTTTCAAGAGCGAGGCTTTGATC 
AHSV1_AY163329       GAGCTGAAGTTGGAGAGACGAGCGGAACCTCGAATGAGTTTCAAGAGCGAGGCTTTGATC 
AHSV2_AY163332       AATATAAACTTAGAGAGGAGGGCGGAGCCTAGGATGAGTTTCAAGAGTGAAGCGCTGATC 
AHSV1_Z26316         AATCTTTCGTTAGAAAGGAGAGCGGAGCCGCGTATGAGCTTTAAGTTCGAAGGGTTAACC 
AHSV3_U01832         AATCTTTCGTTAGAAAGGAGAGCGGAGCCGCGTATGAGCTTTAAGTTCGAAGGGTTAACC 
AHSV3_DQ868772       AATCTTTCGTTAGAAAGAAGAGCGGAGCCGCGTATGAGCTTTAAGTTCGAAGGATTAACC 
AHSV7_AY163330       GATCTAAGTTTAGATCGACGAGCAGAGCCGAGAATGAGTTTCAAATATGAAGGACTAGCG 






AHSV8_DQ868775       ACGTGGATTGGATCAAACTGCGGTGGGGTTCAGGATTACATCTTACATTTGATACCATCC 
AHSV8_AY163333       ACGTGGATTGGATCAAACTGCGGTGGGGTTCAGGATTACATCTTACATTTGATACCATCC 
AHSV5_AY163331       ACCTGGATTGGTTCAAACTGTGGGGGCGTCCAAGATTACGTGTTACATTTGATTCCTTCA 
AHSV6_DQ868774       ACGTGGATTGGCTCAAATTGTGGAGGAGTGCGCGATTACGTTGTACAATTGCTTCCCATG 
AHSV6_NC_005996      ACGTGGATTGGCTCAAATTGTGGAGGGGTGCGGGATTACGTTGTGCAATTGCTTCCTATG 
AHSV9_DQ868776       ACGTGGATTGGTTCAAATTGCGGGGGGGTACGAGACTATCTGATTCAGATGCTCCCAGCA 
AHSV4_EU046574       ACATGGATCGGTTCGAACTGCGGAGGTGTTAGGGATTACGTAATACAGATGCTTCCTACC 
AHSV4_DQ868773       ACATGGATCGGTTCGAACTGCGGAGGTGTTAGGGATTACGTAATACAGATGCTTCCTACC 
AHSV4_D26570         ACATGGATCGGTTCGAACTGCGGAGGTGTTAGGGATTACGTGATACAGATGCTTCCTACC 
AHSV1_FJ011108       ACGTGGATCGGGTCAAATTGTGGAGGAGTGACCGATTATGTCGTACAACTTCTACCCGTT 
AHSV1_AY163329       ACGTGGATCGGGTCAAATTGTGGAGGAGTGACCGATTATGTCGTACAACTTCTACCCGTT 
AHSV2_AY163332       ACGTGGATCGGATCGAATTGTGGTGGAGTGACTGATTATGTGGTTCAGCTTTTGCCTGTT 
AHSV1_Z26316         ACTTGGATCGGCTCAAATTGTGGTGGAGTTCGCGATTATGTCGTCCAAGCTCTACCGATG 
AHSV3_U01832         ACTTGGATCGGCTCAAATTGTGGTGGAGTTCGCGATTATGTCGTCCAAGCTCTACCGATG 
AHSV3_DQ868772       ACTTGGATTGGCTCAAATTGTGGTGGAGTTCGCGATTATGTCGTCCAAGCTCTACCGATG 
AHSV7_AY163330       ACGTGGGTTGGATCGAACTGCGGTGGTGTTAGAGACTATATTATCCAGGAGTTGCCAATG 
                     ** *** * ** ** ** ** ** ** **    ** **  *  * **     * **     
AHSV8_DQ868775       CGGAAACCGAAGCCTGGATTATTATTTTTGATTTATACAGACGCAGGGGATGTAGATTGG 
AHSV8_AY163333       CGGAAACCAAAACCTGGATTATTATTTTTGATTTATACGGACGCAGGGGATGTAGATTGG 
AHSV5_AY163331       CGAAAACCAAAGCCTGGACTTCTTTTTCTGATATATGCGGATGATGGTGACGTTGACTGG 
AHSV6_DQ868774       CGTAAACCAAAGCCAGGGCTTCTTTGCATCGCTTATGGCGATGACGTCAATGTACAGTGG 
AHSV6_NC_005996      CGCAAATCAAAGCCAGGGCTTCTCTGCATCGCTTACGGTGATGACGTCAATGTACAGTGG 
AHSV9_DQ868776       AGAAAACCGAAACCGGGCGTTTTAATCTTAGCTCATGGTGCGGAGATTAACGTAGCGTGG 
AHSV4_EU046574       AGAAAACCTAAACCGGGAGCTTTGATGGTGGTATACGCGCGGGATTCGAGAATCGAGTGG 
AHSV4_DQ868773       AGAAAACCTAAACCGGGAGCTTTGATGGTGGTATACGCGCGGGATTCGAGAATCGAGTGG 
AHSV4_D26570         AGAAAACCGAAACCGGGAGCCTTGATGGTAGCGTACGCGCGGGATTCGAGAATTGAATGG 
AHSV1_FJ011108       CGAAAGCCGAAACCGGGGTTATTGGTTGTCGTATATTCGGAGGATGGTGGGGAAAAATGG 
AHSV1_AY163329       CGAAAGCCGAAACCGGGGTTATTGGTTCTCGTATATTCGGAGGATGGTGGGGAAAAATGG 
AHSV2_AY163332       CGGAAACCGAAACCGGGCCTGCTAGTGGTTGTTTATTCGGAGGACGGGAGTGGGAAATGG 
AHSV1_Z26316         CGGAAACCAAAGCCTGGTTTATTGATGATAATTTATGGAGACGATGGGGACGCGCGTTGG 
AHSV3_U01832         CGGAAACCAAAGCCTGGTTTATTGATGATAATTTATGGAGACGATGGGGACGCGCGTTGG 
AHSV3_DQ868772       CGGAAACCAAAGCCTGGTTTATTGATGGTAATTTATGGAGACGATGGGGACGCGCGTTGG 
AHSV7_AY163330       CGAAAGCCAAAACCTGGACTTTTAATATTAGTGTATGGAGAAGATGGAGATCCAAAATGG 
                      * **  * ** ** **     *     *     *       *              *** 
 
AHSV8_DQ868775       GTAACACGGATGCTTTACGATGTGTGTCGACTAGAGGGTAGCTTGGGCTTCATTTTAATC 
AHSV8_AY163333       GTAACACGGATGCTTTACGATGTGTGTCGATTAGAGGGTAGCTTGGGCTTCATTTTAATC 
AHSV5_AY163331       GTAGCGAACATGCTATCAGATGTGATTGGTTCGGAGGGTAGTTTAGGATTCATCTTTATT 
AHSV6_DQ868774       GTTGAACATGAGTTAAGGGATTTTTTGACACATGAGGGCTCGCTCGGCTTAGTGGTAATT 
AHSV6_NC_005996      GTTGAACATGAGTTAAGAGATTTTTTGATGCATGAGGGCTCACTCGGCTTAGTGGTAATT 
AHSV9_DQ868776       TTGAACCATGCGCTACGTGATATACTTTCGCTAGAGGGATCGTTAGGGATAATTATTGTG 
AHSV4_EU046574       ATCGAAGCAGAGCTATCACAGTGGCTGCAAATGGAAGGTTCGCTTGGTTTGATCCTCGTT 
AHSV4_DQ868773       ATCGAAGCAGAGCTATCACAGTGGCTGCAAATGGAAGGTTCGCTTGGTTTGATCCTCGTT 
AHSV4_D26570         ATCGAGGCGGAGCTATCACAGTGGCTGCAAATGGAGGGTTCGCTCGGATTGATTCTCGTT 
AHSV1_FJ011108       GCAGAGTGGGCTTTACGTGACTACCTCGAAATTGATGGTAGTTTGGGTTTAGTATTCATT 
AHSV1_AY163329       GCAGAGTGGGCTTTACGTGACTACCTCGAAATTGATGGTAGTTTGGGTTTAGTATTCATT 
AHSV2_AY163332       GCAGAATGGGCGCTACGCGATTTTTTAGACGTTGAAGGTAGCTTAGGATTAATTTTCATA 
AHSV1_Z26316         GTAGAGTGGGCAATGAAGAATTTTACAGCGGTTGATGGATCGTTGGGCTTCATTTATATC 
AHSV3_U01832         GTAGAGTGGGCAATGAAGAATTTTACAGCGGTTGATGGATCGTTGGGCTTCATTTATATC 
AHSV3_DQ868772       GTAGAATGGGCAATGAAGAATTTTACAGCGGTTGACGGATCGTTGGGCTTCATTTATATC 
AHSV7_AY163330       GTTGAGTGGGCGATTAAGGATTTTACTCAAATTGAAGGCTCTCTTGGCTTTATATACATT 
                                  *     *             ** **     * **  *  *     *  
 
AHSV8_DQ868775       GACGACCGAGTTATGGTGAACAAAAGCCAATTGAGGGCACGGATCTTGAAGATTTATAAC 
AHSV8_AY163333       GACGATCGAGTTATGGTGAACAAAAGCCAATTGAGGGCACGGATCTTAAAGATTTATAAC 
AHSV5_AY163331       AATGATCGCACCTTCGTTAATAAGAGCCAGTTGAAAGTTAGAACTTTGAAGATATATAAT 
AHSV6_DQ868774       AGCGGGAAGATGTTAGTTAATAAAAGTAAGTTGAGGGTAAGGAACTTGAAAATTTATAAT 
AHSV6_NC_005996      AGCGGAAAGATGTTAGTTAATAAAAGTAAATTAAGGGTAAGGAACTTGAAAATTTACAAT 
AHSV9_DQ868776       AGTGACGGCTCAGTGGTGAATAAGAGCAAGCTCCGCGTAAGGGATATGAAGATATATAAT 
AHSV4_EU046574       CATGATTCAGGTATAATAAATAAGAGCGTATTGAGAGCGAGAACTCTGAAAATTTACAAT 
AHSV4_DQ868773       CATGATTCAGGTATAATAAATAAGAGCGTATTGAGAGCGAGAACTCTGAAAATTTACAAT 
AHSV4_D26570         CATGATTCCGGTATAATAAATAAAAGTGTATTGAGAGCGAGAACTCTGAAAATTTACAAT 
AHSV1_FJ011108       ACGCGGAAGGCAGTAAAGAATAAGAGTAAACTTGGCGTACGCGATCTGAAAATCTATAAT 
AHSV1_AY163329       ACGCGGAAGGCAGTAAAGAATAAGAGTAAACTTGGCGTACGCGATCTGAAAATCTATAAT 
AHSV2_AY163332       ACACGTAAAACTGTCAAGAATGGGAGCGCATTGGGAGTCCGAGATTTAAAAATCTACAAT 
AHSV1_Z26316         GATAGACATAAGCTGGTTAACAAGAGTGATTTCCGAGTCAGAGAAATGAAAATATATAAC 
AHSV3_U01832         GATAGACATAAGCTGGTTAACAAGAGTGATTTCCGAGTCAGAGAAATGAAAATATATAAC 
AHSV3_DQ868772       GATAGACATAAGTTAGTTAATAAGAGTGATTTCCGAGTCAGAGAAATGAAAATATATAAC 
AHSV7_AY163330       GATCCGATTTCCGTTGTTAATAAGAGTACTTTTCGGACGAGAGAGATGAAGATTTATAAT 
                                  *    **    **     *        *     * ** ** ** **  
AHSV8_DQ868775       AGGGGAAAATTAGATAAATTGATTTTGATTTCAGGGGGGAATTACACTTTCGGGAACAAA 
AHSV8_AY163333       AGGGGAATATTAGATAAATTGATTTTGATTTCAGGGGGGAATTACACTTTCGGGAACAAA 
AHSV5_AY163331       CGAGGTATGTTGGATAGGTTAATACTAATATCTGGAGGAAATTATACTTTTGGGAATAAG 
AHSV6_DQ868774       CGCGGTACGCTTGATTCTTTGTTCTTGATTTCGGGGGGCAGCTATACATTTGGAAATAAG 
AHSV6_NC_005996      CGCGGTACGCTTGATTCTTTATTCTTGATTTCGGGTGGCAACTATACATTTGGAAATAAG 
AHSV9_DQ868776       AGGTGGGAGGTGGACAGATTAATTTTGATTTCGAGTGGCGATTACACATTTGGGAATAAA 
AHSV4_EU046574       AGGGGTTCGATGGATACTTTAATTCTAATTTCGAGTGGAGTTTACACTTTCGGAAATAAA 
AHSV4_DQ868773       AGGGGTTCGATGGATACTTTAATTCTAATTTCGAGTGGAGTTTACACTTTCGGAAATAAA 
AHSV4_D26570         AGAGGTTCGATGGACACTTTAATTCTGATCTCGAGTGGAGTCTATACCTTTGGAAATAAA 
AHSV1_FJ011108       AGAGGGAGAGTTGATAGGTTGATTTTAATTTCGAGCGGTGTTTATACTTTTGGAAATAAG 
AHSV1_AY163329       AGAGGGAGAGTTGATAGGTTGATTTTAATTTCGAGCGGTGTTTATACTTTTGGAAATAAG 
AHSV2_AY163332       CGAGGGAGAGTAGATAGATTAGTTTTAATTTCGAGCGGCGTTTATACTTTTGGGAACAAA 
AHSV1_Z26316         CGAGGACGTTTAGACCGTCTGATATTGATATCTAGTGGTCATTATACATTTGGGAATAAG 
AHSV3_U01832         CGAGGACGTTTAGACCGTCTGATATTGATATCTAGTGGTCATTATACATTTGGGAATAAG 
AHSV3_DQ868772       CGAGGACGTTTAGACCGTCTGATATTGATATCTAGCGGTCATTATACATTTGGGAATAAG 
AHSV7_AY163330       CGAGGAAGGTTAGATAGATTGATTTTGATATCAAGTGGGAATTACACATTCGGTAATAAG 
                      *  *     * **     *  *  * ** **  * **    ** ** ** ** ** **  
 
AHSV8_DQ868775       TTCTTGCTCTCAAAACTACTAGCCAAAACAGAGAAG-TAGCGTGACTGCTACTCATGATG 
AHSV8_AY163333       TTCTTGCTCTCAAAACTACTAGCCAAAACAGAGAAG-TAGCGTGACTGCTACTCATGATG 
AHSV5_AY163331       TTTTTATTATCAAAATTACTCGCCAAGACAGAAAAG-TAGCGTGACTGCTACTCCAGATG 
AHSV6_DQ868774       TTCCTATTATCGAAGCTGATGGCAAAAGCCGAATAG-CGGAGTGACTTCCGCTCATGGTG 
AHSV6_NC_005996      TTCCTATTATCGAAGCTGATGGCAAAAGCTGAATAG-CGGAGTGACTTCCGCTCATGGTG 
AHSV9_DQ868776       TATCTCTTATCGAAACTAATGGCCAAGATCGAACAG-TAGCGTGACTGCTACTCCATGTG 
AHSV4_EU046574       TTCTTGTTGTCGAAGTTACTCGCAAAAACGGAATAG-CAACGTGACTGTTGCTCCATGTG 
AHSV4_DQ868773       TTCTTGTTGTCGAAGTTACTCGCAAAAACAGAATAG-CAACGTGACTGTTGCTCCATGTG 
AHSV4_D26570         TTCTTGTTGTCGAAGTTACTCGCAAAGACGGAATAG-CAACGTGACTGTTGCTCCATGTG 
AHSV1_FJ011108       TTTCTCTTCTCAAAGTTATTGTCGAAGATAGAGTAA-CGGTGTGACAACCGTTCCATGCT 
AHSV1_AY163329       TTTCTCTTCTCAAAGTTATTGTCGAAGATAGAGTAA-CGGTGTGACAACCGTTCCATGCT 
AHSV2_AY163332       TTTTTATTCTCGAAACTACTATCCAAAATAGAGTAA-CGGCGTGACTGCCGTTCTATGCT 
AHSV1_Z26316         TTTCTAATGTCTAAGCTGCTTGCGAAAACTGAATAAGCGGAGTGACTCCCGCTCCATGTG 
AHSV3_U01832         TTTCTAATGTCTAAGCTGCTTGCGAAAACTGAATAAGCGGAGTGACTCCCGCTCCATGTG 
AHSV3_DQ868772       TTTCTGATGTCTAAGCTGCTTGCGAAAACTGAATAAGCGGAGTGACTCCCGCTCCATGTG 
AHSV7_AY163330       TTCTTATTATCCAAACTGTTATCCAAGGCAGAGTAAGCGGTGTGACTACCGCTCCAAGTG 






AHSV8_DQ868775       AAT-ACACTTAC- 
AHSV8_AY163333       AAT-ACACTTAC- 
AHSV5_AY163331       AAT-ACACTTAC- 
AHSV6_DQ868774       ATT-CAACTTACC 
AHSV6_NC_005996      ATT-CAACTTACC 
AHSV9_DQ868776       AAT-ACACTTAC- 
AHSV4_EU046574       AAT-ACACATAC- 
AHSV4_DQ868773       AAT-ACACATAC- 
AHSV4_D26570         AAT-ACACATAC- 
AHSV1_FJ011108       GATCACCCTTAC- 
AHSV1_AY163329       GATCACCCTTAC- 
AHSV2_AY163332       GAATACACATAC- 
AHSV1_Z26316         AATCAACT-TAC- 
AHSV3_U01832         AATCAACT-TAC- 
AHSV3_DQ868772       AATCAACT-TAC- 
AHSV7_AY163330       AATCAGCCGTAC- 













AHSV4_EU046579       GTTTAAATTATCCCTTGTCATGAATCTAGCTACAATCGCCAAGAATTATAGCATGCATAA 
AHSV4_DQ868783       GTTTAAATTATCCCTTGTCATGAATCTAGCTACAATCGCCAAGAATTATAGCATGCATAA 
AHSV5_AJ007309       GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGCATGCATAA 
AHSV6_AHU26171       GTTTAA-TTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV9_D12480         GTTTAA-TTATCCCTTGTCATGAATCTAGCTGCAATCGCCGAAAATTATAGTATGCATAA 
AHSV9_AJ007308       GTTTAA-TTATCCCTTGTCATGAATCTAGCTGCAATCGCCGAAAATTATAGTATGCATAA 
AHSV4_Z48734         GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV4_AJ007305       GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV4_AHU02712       GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV6_DQ868784       GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAGAATTATAGTATGCATAA 
AHSV9_DQ868786       GTTTAAATTATCCCTTGTCATGAATCTAGCTGCAATCGCCAAAAATTATAGCATGCATAA 
AHSV8_DQ868785       GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3_DQ868782       GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3_NC_006009      GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3_D12479         GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3a_AJ007304      GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV3_AJ007303       GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV7_AJ007306       GTTTAAATTATCCCTTGTCATGAGTCTAGCTACGATCGCCGAAAATTATATGATGCATAA 
AHSV1_FJ011116       GTTTAA-TTATCCCT-GTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV1_U02711         GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV8_AJ007307       GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV8_U02713         GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
AHSV2_U59279         GTTTAAATTATCCCTTGTCATGAATCTTGCTAGCATCTCCCAAAGCTATATGTCACATAA 
                     ****** ******** ******* *** ***   *** ** * *  ****     ***** 
 
AHSV4_EU046579       TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV4_DQ868783       TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV5_AJ007309       TGGAGAGTCGGGGACGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV6_AHU26171       TGGAGAGTCGGAGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV9_D12480         TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV9_AJ007308       TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATTTCGCAAGTGCTCC 
AHSV4_Z48734         TGGAGAGTCGGGGGCGATCGTCCCTTATGTGCCACCACCATACAATGTTGCGAGTGCTCC 
AHSV4_AJ007305       TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCC 
AHSV4_AHU02712       TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCGCCATATAATTTCGCGAGCGCTCC 
AHSV6_DQ868784       TGGAGAGTCGGGGGCGATTGTCCCTTATGTGCCACCACCATATAATTTCGCGAGCGCTCC 
AHSV9_DQ868786       TGGAGAGCAGGGGGCGATCGTCCCATATGTGCCGCCACCATACAATTTCGCAAGTGCTCC 
AHSV8_DQ868785       TGGAAATCAGAGGGCAATCGTACCGTATGTTCCGCCCCCTTATACGTATGCAAATGCTCC 
AHSV3_DQ868782       TGGAAATCAGAGGGCAATTGTACCGTATGTTCCGCCCCCTTATACGTATGCAAATGCTCC 
AHSV3_NC_006009      TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3_D12479         TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3a_AJ007304      TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV3_AJ007303       TGGAAATCAGAGAGCAATTGTACCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV7_AJ007306       TGGAAATCAGAGAGCAATTGTGCCGTATGTTCCACCCCCTTATGCGTATGCAAATGCTCC 
AHSV1_FJ011116       TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV1_U02711         TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV8_AJ007307       TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV8_U02713         TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 
AHSV2_U59279         TGAGAATGAAAGATCAATTGTACCATACATTCCGCCACCGTATCATC---CGACGGCTCC 




AHSV4_EU046579       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_DQ868783       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV5_AJ007309       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV6_AHU26171       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV9_D12480         GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV9_AJ007308       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_Z48734         GACGTTTTCTCAGGGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_AJ007305       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV4_AHU02712       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV6_DQ868784       GACGTTTTCTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV9_DQ868786       GGCGTTTACTCAGCGTACGAGTCAAATGGAGTCCGTGTCGCTTGGGATACTTAACCAAGC 
AHSV8_DQ868785       GACGCTTGGTGGTCAAGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAACCAAGC 
AHSV3_DQ868782       GACGCCTGGTGGTCAAGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAACCAAGC 
AHSV3_NC_006009      GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV3_D12479         GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV3a_AJ007304      GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV3_AJ007303       GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV7_AJ007306       GACGCTTGGTGGTCAGGCGGGTGAAATGGAGTCCATGTCGCTTGGGATACTTAATCAAGC 
AHSV1_FJ011116       GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV1_U02711         GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV8_AJ007307       GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV8_U02713         GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
AHSV2_U59279         GGCGCTTGCTGTATCCGCCAGTCAAATGGAGACCATGTCGCTTGGGATACTTAACCAAGC 
                     * **  *  *       *  ** ******** ** ******************* ***** 
 
AHSV4_EU046579       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCATTCGGTGC 
AHSV4_DQ868783       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCATTCGGTGC 
AHSV5_AJ007309       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCGTTCGGTGC 
AHSV6_AHU26171       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCATTCGGTGC 
AHSV9_D12480         CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCGGCATTTGGTGC 
AHSV9_AJ007308       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCGGCATTTGGTGC 
AHSV4_Z48734         CATGTCAAATACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCATTTGGTGC 
AHSV4_AJ007305       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCGTTCGGTGC 
AHSV4_AHU02712       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCGTTCGGTGC 
AHSV6_DQ868784       CATGTCAAGTACAACTGGTGCGAGTGGGGCGCTTAAAGATGAAAAAGCAGCGTTTGGTGC 
AHSV9_DQ868786       CATGTCAAGCACAACTGGTGCGAGTGGGGCACTTAAAGATGAAAAAGCAGCATTTGGTGC 
AHSV8_DQ868785       CATGTCAAGTACAACTGGTGCGAGTGGGGCCCTTAAGGATGAAAAAGCAGCATTTGGTGC 
AHSV3_DQ868782       CATGTCAAGTACAACTGGTGCGAGTGGGGCCCTTAAGGATGAAAAAGCAGCATTTGGTGC 
AHSV3_NC_006009      CATGTCAAGTACAACTGGTGCAAGTCGGGCTCTTAAGGATGAAAAAGCAGCGTTTGGTGC 
AHSV3_D12479         CATGTCAAGTACAACTGGTGCAAGTCGGGCTCTTAAGGATGAAAAAGCAGCGTTTGGTGC 
AHSV3a_AJ007304      CATGTCAAGTACAACTGGTGCAAGTCGGGCTCTTAAGGATGAAAAAGCAGCGTTTGGTGC 
AHSV3_AJ007303       CATGTCAAGTACAACTGGTGCAAGTCGGGCTCTTAAGGATGAAAAAGCAGCGTTTGGTGC 
AHSV7_AJ007306       CATGTCAAGTACAACTGGTGCAAGTGGGGCTCTTAAGGATGAAAAAGCAGCGTTTGGTGC 
AHSV1_FJ011116       AATGTCAAGTTCAGCTGGTGCGAGCGGAGCACTTAAGGATGAAAAGGCAGCGTTTGGAGC 
AHSV1_U02711         AATGTCAAGTTCAGCTGGTGCGAGCGGAGCACTTAAGGATGAAAAGGCAGCGTATGGAGC 
AHSV8_AJ007307       AATGTCAAGTTCAGCTGGTGCGAGTGGCGCACTTAAGGATGAAAAGGCAGCGTTTGGAGC 
AHSV8_U02713         AATGTCAAGTTCAGCTGGTGCGAGTGGCGCACTTAAGGATGAAAAGGCAGCGTTTGGAGC 
AHSV2_U59279         AATGTCAAGTTCAGCTGGTGCGAGTGGCGCACTTAAGGACGAAAAGGCAGCGTTTGGAGC 








AHSV4_EU046579       TATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV4_DQ868783       TATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV5_AJ007309       CATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV6_AHU26171       TATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV9_D12480         CATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV9_AJ007308       CATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV4_Z48734         TATGGCGGAAGCATTACGTGATCCAGAACCCATACGTCAGATTAAAAAGCAGGTGGGTAT 
AHSV4_AJ007305       TATGGCGGAACGATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV4_AHU02712       TATGGCGGAACGATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV6_DQ868784       TATGGCGGAAGCATTGCGTGATCCAGAACCCATACGTCAAATTAAAAAGCAGGTGGGTAT 
AHSV9_DQ868786       GATGGCGGAAGCATTACGTGATCCAGAACCCATACGTCAAATTAAGAAACAGGTAGGCAT 
AHSV8_DQ868785       GATGGCGGAGGCATTACGTGATCCAGAACCAATACGTCAAATTAAGAAAACCGTTGGATT 
AHSV3_DQ868782       GATGGCGGAAGCATTACGTGATCCAGAACCAATACGTCAAATTAAGAAAACCGTTGGATT 
AHSV3_NC_006009      GATGGCGGAAGCATTACGTGATCCAGAACCGATACGTCAAATAAAGAAACATGTTGGATT 
AHSV3_D12479         GATGGCGGAAGCATTACGTGATCCAGAACCGATACGTCAAATAAAGAAACATGTTGGATT 
AHSV3a_AJ007304      GATGGCGGAAGCATTACGTGATCCAGAACCGATACGTCAAATAAAGAAACATGTTGGATT 
AHSV3_AJ007303       GATGGCGGAAGCATTACGTGATCCAGAACCGATACGTCAAATAAAGAAACATGTTGGATT 
AHSV7_AJ007306       GATGGCGGAAGCATTACGTGATCCAGAACCGATACGTCAAATTAAGAAACATGTTGGATT 
AHSV1_FJ011116       GGTGGCAGAGGCGTTGAGAGATCCGGAGCCGATCAGAAAAATTAAGCGACAAGTAGGTAT 
AHSV1_U02711         GGTGGCAGAGGCGTTGAGAGATCCGGAGCCGATCAGAAAAATTAAGCGACAAGTAGGTAT 
AHSV8_AJ007307       GGTGGCGGAGGCGTTGAGAGATCCGGAGCCGATCAGAAAAATTAAGCGACAAGTAGGTAT 
AHSV8_U02713         GGTGGCGGAGGCGTTGAGAGATCCGGAGCCGATCAGAAAAATTAAGCGACAAGTAGGTAT 
AHSV2_U59279         GATGGCAGAGGCGTTGAGAGATCCGGAGCCGATCAGAAAAATTAAGCGACAAGTAGGTAT 
                       **** **    **  * ***** ** ** **  *  * ** **       ** **  * 
 
AHSV4_EU046579       CAGAACTTTAAAGAACCTAAAGATGGAGTTAGCAACAATGCGTCGAAAGAAATCGGCATT 
AHSV4_DQ868783       CAGAACTTTAAAGAACCTAAAGATGGAGTTAGCAACAATGCGTCGAAAGAAATCGGCATT 
AHSV5_AJ007309       CAGAACTTTAAAGAACCTAAAGATGGAGTTAGCAACAATGCGTCGAAAGAAATCGGCATT 
AHSV6_AHU26171       CAGAACTTTAAAGAACCTAAAGATGGAGCTGGCAACAATGCGTCGAAAGAAATCGGCATT 
AHSV9_D12480         CAGAACTTTAAAGAACTTAAAGATGGAGTTAGCAACAATGCGTCGAAAGAAATCGGCATT 
AHSV9_AJ007308       CAGAACTTTAAAGAACTTAAAGATGGAGTTAGCAACAATGCGTCGAAAGAAATCGGCATT 
AHSV4_Z48734         CAGAACTTTAAAAAACTTAAAGATGGAGTTAGTAACAATGCGTCGAAAGAAATCGGCATT 
AHSV4_AJ007305       CAGAACTTTAAAGAACTTGAAGATGGAGTTAGCAACAATGCGTCGAAAAAAGTCGGCATT 
AHSV4_AHU02712       CAGAACTTTAAAGAACTTGAAGATGGAGTTAGCAACAATGCGTCGAAAAAAGTCGGCATT 
AHSV6_DQ868784       CAGAACTTTAAAGAACTTAAAGATGGAGTTAGCGACAATGCGTCGAAAAAAGTCGGCATT 
AHSV9_DQ868786       TAGAACCTTGAAAAATTTGAAGACGGAGCTAACGACTATGCGCCGAAAGAAATCGGCATT 
AHSV8_DQ868785       AAGGACACTTAAGCATTTAAAGATAGAGTTGGCGTCGATGAGACGTAGGTATGCGATATT 
AHSV3_DQ868782       AAGGACGCTTAAGCATTTAAAGATAGAGTTGGCGTCGATGAGACGTAGGTATGCGATATT 
AHSV3_NC_006009      AAGAACGCTCAAGCATTTAAAGATAGAGTTGGCGTCAATGAGACGTAGGTATGCGATACT 
AHSV3_D12479         AAGAACGCTCAAGCATTTAAAGATAGAGTTGGCGTCAATGAGACGTAGGTATGCGATACT 
AHSV3a_AJ007304      AAGAACGCTCAAGCATTTAAAGATAGAGTTGGCGTCAATGAGACGTAGGTATGCGATACT 
AHSV3_AJ007303       AAGAACGCTCAAGCATTTAAAGATAGAGTTGGCGTCAATGAGACGTAGGTATGCGATACT 
AHSV7_AJ007306       AAGAACGCTCAAGCATTTAAAGATAGAGTTGGCGTCAATGAGACGTAGGTATGCGATACT 
AHSV1_FJ011116       CCAAACTCTAAAAACACTGAAAGTTGAATTGAGCGGGATGCGAAGGAAGAAATTGATTTT 
AHSV1_U02711         CCAAACTCTAAAAACACTGAAAGTTGAATTGAGCGGGATGCGAAGGAAGAAATTGATTTT 
AHSV8_AJ007307       CCAAACTCTAAAAACACTGAAAGTTGAATTGAGCGGGATGCGAAGGAAGAAATTGATTTT 
AHSV8_U02713         CCAAACTCTAAAAACACTGAAAGTTGAATTGAGCGGGATGCGAAGGAAGAAATTGATTTT 
AHSV2_U59279         CCAAACTCTAAAAGCATTGAAAGTTGAATTGAGCGGGATGCGAAGGAAGAGATTGATTTT 





AHSV4_EU046579       AAAAATAATGATCTTTATTAGTGGATGCGTAACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV4_DQ868783       AAAAATAATGATCTTTATTAGTGGATGCGTAACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV5_AJ007309       AAAAATAATGATCTTTATTAGTGGATGCGTGACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV6_AHU26171       AAAGATAATGATCTTTATTAGTGGATGCGTAACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV9_D12480         AAAAATAATGATTTTTATTAGTGGGTGCGTGACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV9_AJ007308       AAAAATAATGATTTTTATTAGTGGGTGCGTGACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV4_Z48734         AAAAATAATGATTTTCATCAGTGGGTGCGTGACGTTAGCTACATCGATGGTTGGGGGATT 
AHSV4_AJ007305       AAAAATAACGATTCTTATCAGCGGATGTGTGACGTTAGCAACATCGATGGTCGGGGGGTT 
AHSV4_AHU02712       AAAAATAACGATTCTTATCAGCGGATGTGTGACGTTAGCAACATCGATGGTCGGGGGGTT 
AHSV6_DQ868784       AAAAATAATGATTTTTATCAGCGGATGTGTGACGTTAGCAACATCGATGGTCGGAGGGTT 
AHSV9_DQ868786       GAAAATAACGATTTTTATCAGTGGGTGTGTGACTTTAGCAACCTCAATGGTTGGAGGATT 
AHSV8_DQ868785       ACGAGTAGTCACTTTTATGAGTGGGTGCGTGACAATGGCTACCTCGATGGTGGGCGGGTT 
AHSV3_DQ868782       ACGAGTAGTCATTTTTATGAGTGGGTGCGTGACAATGGCTACCTCGATGGTGGGCGGGTT 
AHSV3_NC_006009      ACGTGTAGTGATCTTTATGAGCGGGTGCGTAACGATGGCTACCTCGATGGCGGGCGGGTT 
AHSV3_D12479         ACGTGTAGTGATCTTTATGAGCGGGTGCGTAACGATGGCTACCTCGATGGCGGGCGGGTT 
AHSV3a_AJ007304      ACGTGTAGTGATCTTAATGAGCGGGTGCGTAACGATGGCTACCTCGATGGCGGGCGGGTT 
AHSV3_AJ007303       ACGTGTAGTGATCTTAATGAGCGGGTGCGTAACGATGGCTACCTCGATGGCGGGCGGGTT 
AHSV7_AJ007306       ACGTGTAGTGATCTTTATGAGCGGGTGCGTAACGATGGCTACCTCGATGGCGGGCGGGTT 
AHSV1_FJ011116       GAAAATAATTATGTTTATTTGCGCAAACGTAACTATGGCTACTTCTCTAGTTGGAGGTAT 
AHSV1_U02711         GAAAATAATTATGTTTATTTGCGCAAACGTAACTATGGCTACTTCTCTAGTTGGAGGTAT 
AHSV8_AJ007307       GAAAATAATTATGTTTATTTGCGCAAACGTAACTATGGCTACTTCTCTAGTTGGAGGTAT 
AHSV8_U02713         GAAAATAATTATGTTTATTTGCGCAAACGTAACTATGGCTACTTCTCTAGTTGGAGGTAT 
AHSV2_U59279         GAAAATAATTATGTTTATTTGCGCAAACGTAACTATGGCTACTTCTCTAGTTGGAGGTAT 
                          **   *   * **  * *     ** **  * ** ** **  * *  ** **  * 
 
AHSV4_EU046579       GAGTATCGTTGACGACGAAATATTAAGAGATT---------ATAAGAACAACGATTGGTT 
AHSV4_DQ868783       GAGTATCGTTGACGACGAAATATTAAGAGATT---------ATAAGAACAACGATTGGTT 
AHSV5_AJ007309       GAGTATCGTTGACGACGAAATATTAGGAGATT---------ATAAGAACAACGATTGGTT 
AHSV6_AHU26171       GAGTATCGTTGATGACGAAATATTAAGAGATT---------ATAAGAACAACGATTGGTT 
AHSV9_D12480         GAGTATTGTTGATGACCAAATATTAGATGATT---------ATAAGAAAAACGATTGGTT 
AHSV9_AJ007308       GAGTATTGTTGATGACCAAATATTAGATGATT---------ATAAGAAAAACGATTGGTT 
AHSV4_Z48734         GAGTATTGTTGATGACGATATATTAGAAAATT---------ATAAGACAAATGATTGGTT 
AHSV4_AJ007305       AAGTATTGTCGATAACGAAATATTTGAAGATT---------ATAAGAAGAACGATTGGTT 
AHSV4_AHU02712       AAGTATTGTCGATAACGAAATATTTGAAGATT---------ATAAGAAGAACGATTGGTT 
AHSV6_DQ868784       AAGTATTGTTGATAACGAAATATTTGAAGATT---------ATAAGAAGAACGATTGGTT 
AHSV9_DQ868786       AAGCATAGTTGATGACCAGATTTGGGGAGAGT---------ATAAAGATAACGATTGGTT 
AHSV8_DQ868785       AACGATTATTGATACAGATATATATAAGGATC---------TTAATAATGATGGATGGCT 
AHSV3_DQ868782       AACGATTATTGATACAGAAATATATAGGGATC---------TTAATAGTGATGGATGGCT 
AHSV3_NC_006009      AACGATTATTGATAATGAAATATATGAAGACC---------TTAGTGGAGATGGTTGGCT 
AHSV3_D12479         AACGATTATTGATAATGAAATATATGAAGACC---------TTAGTGGAGATGGTTGGCT 
AHSV3a_AJ007304      AACGATTATTGATAATGAAATATATGAAGACC---------TTAGTGGAGATGGTTGGCT 
AHSV3_AJ007303       AACGATTATTGATAATGAAATATATGAAGACC---------TTAGTGGAGATGGTTGGCT 
AHSV7_AJ007306       AACGATTATTGATAAAGAAATATATGATGACC---------TTAGTGGAGATGGTTGGCT 
AHSV1_FJ011116       GTCAATCGTTGATGAGGATATTGCTAAGCATTTGGCGTTTGACGGAAAAGGGGATTGGGT 
AHSV1_U02711         GTCAATCGTTGATGAGGATATTGCTAAGCATTTGGCGTTTGACGGAAAAGGGGATTGGGT 
AHSV8_AJ007307       GTCGATCGTTGATGAGGATATTGCTAAGCATTTGGCGTTTGACGGAAAAGGGGATTGGGT 
AHSV8_U02713         GTCGATCGTTGATGAGGATATTGCTAAGCATTTGGCGTTTGACGGAAAAGGGGATTGGGT 
AHSV2_U59279         ATCAATCGTTGATGAGGATATTGCTAAGCATTTGGCGTTTGACGGAAAGGGAGATTGGGT 









AHSV4_EU046579       AATGAAGACTATACATGGGCTGAATTTGTTATGTACTACAGTTTTGTTAGCGGCGGGTAA 
AHSV4_DQ868783       AATGAAGACTATACATGGGCTGAATTTGTTATGTACTACAGTTTTGTTAGCGGCGGGTAA 
AHSV5_AJ007309       AATGAAGACTATACATGGGCTGAATTTGTTATGTACTACAGTTTTGTTAGCGGCGGGTAA 
AHSV6_AHU26171       AATGAAGACTATACATGGGCTGAATTTGTTGTGTACTACAGTTTTGTTAGCGGCGGGTAA 
AHSV9_D12480         GATGAAGACTATACATGGGCTGAATTTGTTATGTACTACAGTTTTGTTAGCTGCGGGTAA 
AHSV9_AJ007308       GATGAAGACTATACATGGGCTGAATTTGTTATGTACTACAGTTTTGTTAGCTGCGGGTAA 
AHSV4_Z48734         AATGAAAACCATACATGGGCTGAATTTGTTATGTACTACAGTTTTGTTAGCGGCGGGCAA 
AHSV4_AJ007305       AATGAAAGCGATACATGGGCTGAATTTGTTATGTACCACAGTTTTGTTGGCGGCGGGTAA 
AHSV4_AHU02712       AATGAAAGCGATACATGGGCTGAATTTGTTATGTACCACAGTTTTGTTGGCGGCGGGTAA 
AHSV6_DQ868784       AATGAAAACGATACATGGGCTGAATTTGTTATGTACCACAGTTTTGTTGGCGGCAGGTAA 
AHSV9_DQ868786       GATAAAAACGATACATGGACTGAACTTATTATGTACAACAGTATTGCTGGCAGCGGGTAA 
AHSV8_DQ868785       GTCGAAGACGGTTCACGGTCTGAATCTGCTGTGCACCACCATGTTGTTAGCAGCGGGAAA 
AHSV3_DQ868782       GTCGAAGACGGTTCACGGTCTGAATCTGCTGTGCACTACCATGTTGTTAGCAGCGGGAAA 
AHSV3_NC_006009      GTCGAAGACGATTCACGGTTTGAATTTGCTGTGTACCACTATGTTGTTAGCGGCTGGAAA 
AHSV3_D12479         GTCGAAGACGATTCACGGTTTGAATTTGCTGTGTACCACTATGTTGTTAGCGGCTGGAAA 
AHSV3a_AJ007304      GTCGAAGACGATTCACGGTTTGAATTTGCTGTGTACCACTATGTTGTTAGCGGCTGGAAA 
AHSV3_AJ007303       GTCGAAGACGATTCACGGTTTGAATTTGCTGTGTACCACTATGTTGTTAGCGGCTGGAAA 
AHSV7_AJ007306       GTCGAAGACGATTCACGGTTTGAATCTGCTGTGTACCACTATGTTGTTAGCGGCTGGAAA 
AHSV1_FJ011116       GTCAAAAACGGTCCATGGTTTAAATTTATTATGTACCACGATGCTGCTGGCAGCGAATAA 
AHSV1_U02711         GTCAAAAACGGTCCATGGTTTAAATTTATTATGTACCACGATGCTGCTGGCAGCGAATAA 
AHSV8_AJ007307       GTCAAAAACGGTCCATGGTTTAAATTTGTTATGTACCACAATGCTGCTAGCAGCGAATAA 
AHSV8_U02713         GTCAAAAACGGTCCATGGTTTAAATTTGTTATGTACCACAATGCTGCTAGCAGCGAATAA 
AHSV2_U59279         GTCAAAAACGGTCCATGGTTTAAATTTGTTATGTACAACGATGCTGTTGGCAGCGAATAA 
                         **  *  * ** **  * **  *  * ** ** **  *  ** * ** **    ** 
 
AHSV4_EU046579       GATTTCCGATAAAATGCAAGAGGAGATTTCACGGACTAAACGTGACATTGCGAAAAGAGA 
AHSV4_DQ868783       GATTTCCGATAAAATGCAAGAGGAGATTTCACGGACTAAACGTGACATTGCGAAAAGAGA 
AHSV5_AJ007309       GATTTCCGATAAAATACAAGAGGAGATTTCACGGACTAAACGTGACATTGCGAAAAGAGA 
AHSV6_AHU26171       GATTTCCGATAAAATACAAGAGGAGATTTCACGGACTAAACGTGACATCGCGAAAAGAGA 
AHSV9_D12480         GATTTCTGATAAAATACAAGAAGAAATTTCACGGACTAAACGTGACATTGCAAAAAGAGA 
AHSV9_AJ007308       GATTTCTGATAAAATACAAGAAGAAATTTCACGGACTAAACGTGACATTGCAAAAAGAGA 
AHSV4_Z48734         GATTTCTGATAAAATACAAGAGGAGATTTCACGGACTAAGCGTGACATTGCAAAAAGAGA 
AHSV4_AJ007305       GATTTCTGATAAAATACAAGAGGAGATTTCACGAACAAAGCGTGATATTGCGAAAAGAGA 
AHSV4_AHU02712       GATTTCTGATAAAATACAAGAGGAGATTTCACGAACAAAGCGTGATATTGCGAAAAGAGA 
AHSV6_DQ868784       GATTTCTGATAAAATCCAAGAGGAGATTTCACGAACAAAGCGTGATATTGCGAAAAGAGA 
AHSV9_DQ868786       GATTTCCGATAAGATTCAAGAAGAAATTTCGCGGACGAAGCGTGACATTGCGAAGAGAGA 
AHSV8_DQ868785       AATATCAGATAAAATACAGGAGGAGATATCACGGACAAAGCGGGATATAGCAAAAAGAGA 
AHSV3_DQ868782       AATATCAGATAAAATACAGGAGGAGATATCACGGACAAAGCGGGATATAGCAAAAAGAGA 
AHSV3_NC_006009      AATATCAGATAAAATACAGGAGGAGATCTCACGCACAAAGCGGGATATAGCGAAGAGAGA 
AHSV3_D12479         AATATCAGATAAAATACAGGAGGAGATCTCACGCACAAAGCGGGATATAGCGAAGAGAGA 
AHSV3a_AJ007304      AATATCAGATAAAATACAGGAGGAGATCTCACGCACAAAGCGGGATATAGCGAAGAGAGA 
AHSV3_AJ007303       AATATCAGATAAAATACAGGAGGAGATCTCACGCACAAAGCGGGATATAGCGAAGAGAGA 
AHSV7_AJ007306       AATATCAGATAAAATACAGGAGGAGATCTCACGTACAAAGCGGGATATAGCGAAGAGAGA 
AHSV1_FJ011116       AATATCGGAAAAGGTGAGAGAAGAGATTGCGAGGACAAAAAGAGACATCGCGAAAAGACA 
AHSV1_U02711         AATATCGGAAAAGGTGAGAGAAGAGATTGCGAGGACAAAAAGAGACATCGCGAAAAGACA 
AHSV8_AJ007307       AATATCGGAAAAAGTGAGAGAAGAGATTGCGAGGACAAAAAGAGACATCGCGAAAAGACA 
AHSV8_U02713         AATATCGGAAAAAGTGAGAGAAGAGATTGCGAGGACAAAAAGAGACATCGCGAAAAGACA 
AHSV2_U59279         AATATCGGAAAAGGTGAGAGAAGAGATTGCGAGGACAAAAAGAGACATCGCGAAAAGACA 





AHSV4_EU046579       GTCTTACGTGTCAGCGGCGAGTATGTCGTGGAGTGGAGATACTGAGATGTCATTACAGGG 
AHSV4_DQ868783       GTCTTACGTGTCAGCGGCGAGTATGTCGTGGAGTGGAGATACTGAGATGTTATTACAGGG 
AHSV5_AJ007309       GTCTTACGTGTCAGCGGCGAGTATGTCGTGGAACGGAGATACTGAGATGTCATTACAGGG 
AHSV6_AHU26171       GTCTTACGTGTCAGCGGCGAGTATGTCGTGGAATGGAGATACTGAGATGTTATTACAGGG 
AHSV9_D12480         GTCTTACGTATCAGCGGCGAGTATGTCGTGGAATGGAGATACTGAGATGTTATTACAGGG 
AHSV9_AJ007308       GTCTTACGTATCAGCGGCGAGTATGTCGTGGAATGGAGATACTGAGATGTTATTACAGGG 
AHSV4_Z48734         GTCTTACGTATCGGCGGCGAGTATGTCGTGGAGTGGAGATACTGAGATATTATTACAAGG 
AHSV4_AJ007305       GTCTTACGTATCTGCGGCGAGTATGTCATGGAATGGAGATACTGAAGTATTATTGCAAGG 
AHSV4_AHU02712       GTCTTACGTATCTGCGGCGAGTATGTCATGGAATGGAGATACTGAAGTATTATTGCAAGG 
AHSV6_DQ868784       GTCTTATGTATCTGCGGCGAGTATGTCATGGAGTGGAGATACTGAAGTATTATTGCAAGG 
AHSV9_DQ868786       GTCTTATGTGTCAGCAGCCAGTATGTCGTGGAGTGGAGATACTGAGATGTTATTACACGG 
AHSV8_DQ868785       ATCATACGTTTCTGCGGCTAGTATGTCATGGAGTGGGGATACGAGCGTTTTGTTAAGAGA 
AHSV3_DQ868782       ATCATACGTTTCTGCGGCTAGTATGTCATGGAGTGGGGATACGAGCGTTTTGTTAAAAGA 
AHSV3_NC_006009      ATCATATGTTTCCGCGGCTAGTATGTCTTGGAGTGGGGATACGAGCGTTCTATTAAAAGA 
AHSV3_D12479         ATCATATGTTTCCGCGGCTAGTATGTCTTGGAGTGGGGATACGAGCGTTCTATTAAAAGA 
AHSV3a_AJ007304      ATCATATGTTTCCGCGGCTAGTATGTCTTGGAGTGGGGATACGAGCGTTCTATTAAAAGA 
AHSV3_AJ007303       ATCATATGTTTCCGCGGCTAGTATGTCTTGGAGTGGGGATACGAGCGTTCTATTAAAAGA 
AHSV7_AJ007306       ATCATATGTCCCCGCGGCTAGTATGTCTTGGAGTGGGGATACGAGCGTTCTATTAAAAGA 
AHSV1_FJ011116       ATCGTACGTATCAGCTGCGACGATGTCTTGGGATGGCGATAGCGTAACTCTATTACGAGA 
AHSV1_U02711         ATCGTACGTATCAGCTGCGACGATGTCTTGGGATGGCGATAGCGTAACTCAATTACGAGA 
AHSV8_AJ007307       ATCGTACGTATCAGCTGCGACGATGTCTTGGGATGGCGATAGCGTAACTCTATTACGAGA 
AHSV8_U02713         ATCGTACGTATCAGCTGCGACGATGTCTTGGGATGGCGATAGCGTAACTCTATTACGAGA 
AHSV2_U59279         ATCGTACGTATCAGCTGCGACGATGTCTTGGGATGGCGATAGCGTAACTCCATTACGAGA 
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AHSV4_EU046579       AATTAAGTATGGCGAGAGCTAGTATGACCTCCACGAGCGGAAAATCCATCGTGTTGGATG 
AHSV4_DQ868783       AATTAAGTATGGCGAGAGCTAGTATGACCTCCACGAGCGGAAAATCCATCGTGTTGGATG 
AHSV5_AJ007309       AATTAAGTATGGCGAGAGCTAGTATGACCTCCACAAGCGGAAAATCCATCGTGTTGGATG 
AHSV6_AHU26171       AATTAAGTATGGCGAGAGCTAGTATGACCTC-GCGAGCGGAAAATCCATCGTGTTGGATG 
AHSV9_D12480         AACTAAGTATGGCGAAAGCTAGTATGACCTCCATGAGCGGAAAATCCATCGTGTTGGATG 
AHSV9_AJ007308       AACTAAGTATGGCGAAAGCTAGTATGACCTCCATGAGCGGAAAATCCATCGTGTTGGATG 
AHSV4_Z48734         AATTAAGTATGGCGAGAGCTAGTATGACCTCCACGAGCTGAAAATCCATCGTGTTGGATG 
AHSV4_AJ007305       AATTAAGTATGGCGATAGCTAGTACGACCTCCACAAGCGGAAAATCCATCGTGTTGGATG 
AHSV4_AHU02712       AATTAAGTATGGCGATAGCTAGTACGACCTCCACAAGCGGAAAATCCATCGTGTTGGATG 
AHSV6_DQ868784       AATTAAGTATGGCGATAGCTAGTACGACCTCCACAAGCGGAAAATCCATCGTGTTGGATG 
AHSV9_DQ868786       AATTAAGTATGGCGAAAGCTAGTATGACCTCCATGAGCGGAAAATCCATCGTGTTGGATG 
AHSV8_DQ868785       AGTGAAATATGGCGATAGCTAGAATGACCTCCATTTGTGGGAGATCCACAGTGTTGGGTG 
AHSV3_DQ868782       AGTGAAATATGGCGATAGCTAGAATGACCTCCATTTGTGGGAGATCCACAGTGTTGGGTG 
AHSV3_NC_006009      GGTAAAATATGGCGACAGCTAGAATGACCTCCATTTGTGGGAGATCCACAGTGTTGGGTG 
AHSV3_D12479         GGTAAAATATGGCGACAGCTAGAATGACCTCCATTTGTGGGAGATCCACAGTGTTGGGTG 
AHSV3a_AJ007304      GGTAAAATATGGCGACAGCTAGAATGACCTCCATTTGTGGGAGATCCACAGTGTTGGGTG 
AHSV3_AJ007303       GGTAAAATATGGCGACAGCTAGAATGACCTCCATTTGTGGGAGATCCACAGTGTTGGGTG 
AHSV7_AJ007306       GGTAAATATTGGCGACAGCTAGAATGACCTCCATTAGTGGGAGATCCACAGTGTTGGGTG 
AHSV1_FJ011116       TGTAAAATATGGAGACTAGCGGATAGACCTCCAAAAGCGGGATTCCACTGGTGTTGCAGT 
AHSV1_U02711         TGTAAAATATGGAGACTAGCGGATAGACCTCCAAAAGCGGGATTCCACTGGTGTTGCAGT 
AHSV8_AJ007307       TGTAAAATGTGGAGACTAGCGGATAGACCTCCAAAAGCGGGATTCCGCTGGTGTTGCAGT 
AHSV8_U02713         TGTAAAATGTGGAGACTAGCGGATAGACCTCCAAAAGCGGGATTCCGCTGGTGTTGCAGT 
AHSV2_U59279         TGTAAAATATGGAGACTAGCGGATAGACCTCCAAAAGCGGGATTCCGCTGGTGTTGCAGT 









AHSV4_EU046579       GATGGAACGCCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV4_DQ868783       GATGGAACGCCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV5_AJ007309       GATGGAACGCCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV6_AHU26171       GATGGAACGCCTAGATCGTCTTCTAGGGAGT-GGGATAACAACTTAC 
AHSV9_D12480         GATGGAACGCCTAGATCGTTTTCTAGGGAGT-GGGATAACAACTTAC 
AHSV9_AJ007308       GATGGAACGCCTAGATCGTTTTCTAGGGAGT-GGGATAACAACTTAC 
AHSV4_Z48734         GATGGAACGCCTAGATCGTTTTCTAGGGAGCCGGGATAACGA----- 
AHSV4_AJ007305       GATGGAACGCCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV4_AHU02712       GATGGAACGCCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV6_DQ868784       GATGGAACGCCTAGATCGTCTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV9_DQ868786       GATGGAACGCCTAGATCGTTTTCTAGGGAGC-GGGATAACGACTTAC 
AHSV8_DQ868785       GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV3_DQ868782       GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV3_NC_006009      GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV3_D12479         GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV3a_AJ007304      GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV3_AJ007303       GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV7_AJ007306       GATCAAACACCTAGATCGTTTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV1_FJ011116       GGATAACCGCCTAGATCGTGTTCTAGGGAGCCGGGATAACAACTTAC 
AHSV1_U02711         GGATAACCGCCTAGATCGTGTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV8_AJ007307       GGATAACCGCCTAGATCGTGTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV8_U02713         GGATAACCGCCTAGATCGTGTTCTAGGGAGCCGGGATAACGACTTAC 
AHSV2_U59279         GGATAACCGCCTAGATCGTGTTCTAGGGAGCCGGGATAACGACTTAC 
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